SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

CASI Pharmaceuticals, Inc. – ‘10-K’ for 12/31/20 – ‘XML’

On:  Tuesday, 3/30/21, at 5:28pm ET   ·   For:  12/31/20   ·   Accession #:  1558370-21-3735   ·   File #:  0-20713

Previous ‘10-K’:  ‘10-K’ on 3/16/20 for 12/31/19   ·   Next:  ‘10-K/A’ on 4/29/21 for 12/31/20   ·   Latest:  ‘10-K’ on 3/28/22 for 12/31/21   ·   26 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/21  CASI Pharmaceuticals, Inc.        10-K       12/31/20  109:13M                                    Toppan Merrill Bridge/FA

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.49M 
 2: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     40K 
 7: EX-10.29    Material Contract                                   HTML     45K 
 8: EX-10.30    Material Contract                                   HTML    283K 
 3: EX-10.4     Material Contract                                   HTML    249K 
 4: EX-10.5     Material Contract                                   HTML    249K 
 5: EX-10.6     Material Contract                                   HTML    240K 
 6: EX-10.8     Material Contract                                   HTML    444K 
 9: EX-21       Subsidiaries List                                   HTML     28K 
10: EX-23.1     Consent of Expert or Counsel                        HTML     28K 
11: EX-31.1     Certification -- §302 - SOA'02                      HTML     32K 
12: EX-31.2     Certification -- §302 - SOA'02                      HTML     32K 
13: EX-32.1     Certification -- §906 - SOA'02                      HTML     30K 
14: EX-32.2     Certification -- §906 - SOA'02                      HTML     30K 
21: R1          Document and Entity Information                     HTML     91K 
22: R2          Condensed Consolidated Balance Sheets               HTML    120K 
23: R3          Condensed Consolidated Balance Sheets               HTML     50K 
                (Parenthetical)                                                  
24: R4          Condensed Consolidated Statements of Operations     HTML    116K 
                and Comprehensive Loss                                           
25: R5          Condensed Consolidated Statements of Stockholders'  HTML     69K 
                Equity                                                           
26: R6          Condensed Consolidated Statements of Cash Flows     HTML    151K 
27: R7          Description of Business                             HTML     72K 
28: R8          Summary of Significant Accounting Policies          HTML     65K 
29: R9          Investment in Equity Securities, at Fair Value and  HTML     80K 
                Long-Term Investments                                            
30: R10         Inventories                                         HTML     40K 
31: R11         Leases                                              HTML     72K 
32: R12         Property, Plant and Equipment                       HTML     50K 
33: R13         Intangible Assets                                   HTML     61K 
34: R14         Assets Held for Sale                                HTML     37K 
35: R15         Grants                                              HTML     30K 
36: R16         Bank Borrowings                                     HTML     30K 
37: R17         Note Payable                                        HTML     31K 
38: R18         Redeemable Noncontrolling Interest                  HTML     51K 
39: R19         Stockholders' Equity                                HTML     59K 
40: R20         Net Loss Per Share                                  HTML     48K 
41: R21         Employee Benefit Plan                               HTML     31K 
42: R22         Stock-Based Compensation                            HTML    155K 
43: R23         Income Taxes                                        HTML     94K 
44: R24         Fair Value Measurements                             HTML     92K 
45: R25         Related Party Transactions                          HTML     38K 
46: R26         Acrotech License Arrangements                       HTML     31K 
47: R27         Commitments and Contingencies                       HTML     33K 
48: R28         Subsequent Events                                   HTML     36K 
49: R29         Summary of Significant Accounting Policies          HTML    118K 
                (Policies)                                                       
50: R30         Investment in Equity Securities, at Fair Value and  HTML     68K 
                Long-Term Investments (Tables)                                   
51: R31         Inventories (Tables)                                HTML     40K 
52: R32         Leases (Tables)                                     HTML     71K 
53: R33         Property, Plant and Equipment (Tables)              HTML     47K 
54: R34         Intangible Assets (Tables)                          HTML     63K 
55: R35         Assets Held for Sale (Tables)                       HTML     35K 
56: R36         Redeemable Noncontrolling Interest (Tables)         HTML     47K 
57: R37         Stockholders' Equity (Tables)                       HTML     47K 
58: R38         Net Loss Per Share (Tables)                         HTML     46K 
59: R39         Stock-Based Compensation (Tables)                   HTML    155K 
60: R40         Income Taxes (Tables)                               HTML     94K 
61: R41         Fair Value Measurements (Tables)                    HTML     90K 
62: R42         Description of Business (Details)                   HTML    186K 
63: R43         Summary of Significant Accounting Policies          HTML     66K 
                (Details)                                                        
64: R44         INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND  HTML     37K 
                LONG-TERM INVESTMENTS - Summary of Investments                   
                (Details)                                                        
65: R45         INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND  HTML     47K 
                LONG-TERM INVESTMENTS - Summary of Long-term                     
                investments (Details)                                            
66: R46         Investment in Equity Securities, at Fair Value and  HTML    116K 
                Long-Term Investments (Details)                                  
67: R47         Inventories (Details)                               HTML     36K 
68: R48         Leases - (Details)                                  HTML     60K 
69: R49         Leases - Right of Use Assets and Liabilities        HTML     40K 
                (Details)                                                        
70: R50         LEASES - Supplemental Cash Flow (Details)           HTML     32K 
71: R51         LEASES - Future Undiscounted Cash Flows (Details)   HTML     46K 
72: R52         Property, Plant and Equipment (Details)             HTML     44K 
73: R53         Property, Plant and Equipment - Additional          HTML     45K 
                Information (Details)                                            
74: R54         INTANGIBLE ASSETS - Net Definite-lived Intangible   HTML     39K 
                Assets (Details)                                                 
75: R55         INTANGIBLE ASSETS - Changes in intangible assets    HTML     35K 
                (Details)                                                        
76: R56         INTANGIBLE ASSETS - Expected Future Amortization    HTML     41K 
                Expense (Details)                                                
77: R57         INTANGIBLE ASSETS - Additional Information          HTML     46K 
                (Details)                                                        
78: R58         ASSETS HELD FOR SALE - Additional Information       HTML     43K 
                (Details)                                                        
79: R59         ASSETS HELD FOR SALE - Components of assets         HTML     37K 
                held-for-sale (Details)                                          
80: R60         Grants (Details)                                    HTML     40K 
81: R61         Bank Borrowings (Details)                           HTML     43K 
82: R62         Note Payable (Details)                              HTML     39K 
83: R63         Redeemable Noncontrolling Interest (Details)        HTML     51K 
84: R64         Redeemable Noncontrolling Interest - Changes in     HTML     40K 
                Redeemable Noncontrolling Interest (Details)                     
85: R65         Stockholders' Equity (Details)                      HTML     84K 
86: R66         Stockholders' Equity - Warrants Activity (Details)  HTML     54K 
87: R67         Net Loss Per Share (Details)                        HTML     31K 
88: R68         Net Loss Per Share - Basic and diluted net loss     HTML     45K 
                per share computation (Details)                                  
89: R69         Employee Benefit Plan (Details)                     HTML     33K 
90: R70         STOCK-BASED COMPENSATION - Compensation Expense     HTML     37K 
                (Details)                                                        
91: R71         STOCK-BASED COMPENSATION - Weighted-Average         HTML     44K 
                Assumptions (Details)                                            
92: R72         STOCK-BASED COMPENSATION - Options Outstanding      HTML     93K 
                (Details)                                                        
93: R73         STOCK-BASED COMPENSATION - Stock Option             HTML     63K 
                Outstanding (Details)                                            
94: R74         Stock-Based Compensation (Details)                  HTML     73K 
95: R75         INCOME TAXES - Loss Before Income Taxes (Details)   HTML     36K 
96: R76         INCOME TAXES - Deferred Income Tax Assets And       HTML     43K 
                Liabilities (Details)                                            
97: R77         INCOME TAXES - Reconciliation Of The Provision For  HTML     49K 
                Income Taxes (Details)                                           
98: R78         INCOME TAXES - Gross Unrecognized Tax Benefits      HTML     34K 
                (Details)                                                        
99: R79         Income Taxes (Details)                              HTML     40K 
100: R80         FAIR VALUE MEASUREMENTS - Financial and             HTML     47K  
                Non-Financial Assets and Liabilities (Details)                   
101: R81         FAIR VALUE MEASUREMENTS - Quantitative Information  HTML     39K  
                about Level 3 Fair Value Measurements (Details)                  
102: R82         Fair Value Measurements (Details)                   HTML     48K  
103: R83         Related Party Transactions (Details)                HTML     72K  
104: R84         Commitments and Contingencies (Details)             HTML     42K  
105: R85         Subsequent Events (Details)                         HTML     79K  
107: XML         IDEA XML File -- Filing Summary                      XML    189K  
20: XML         XBRL Instance -- casi-20201231x10k_htm               XML   2.24M 
106: EXCEL       IDEA Workbook of Financial Reports                  XLSX    136K  
16: EX-101.CAL  XBRL Calculations -- casi-20201231_cal               XML    198K 
17: EX-101.DEF  XBRL Definitions -- casi-20201231_def                XML    811K 
18: EX-101.LAB  XBRL Labels -- casi-20201231_lab                     XML   1.47M 
19: EX-101.PRE  XBRL Presentations -- casi-20201231_pre              XML   1.31M 
15: EX-101.SCH  XBRL Schema -- casi-20201231                         XSD    233K 
108: JSON        XBRL Instance as JSON Data -- MetaLinks              465±   702K  
109: ZIP         XBRL Zipped Folder -- 0001558370-21-003735-xbrl      Zip    660K

‘XML’   —   XBRL Instance — casi-20201231x10k_htm

This Document is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:casi="http://www.entremed.com/20201231" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:href="casi-20201231.xsd" xlink:type="simple"/>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_n8E96oQwBkSgs0z7diWOIQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputRiskFreeInterestRateMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_4qf8IQUT3E20OqBsMiMhBA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputPriceVolatilityMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentLeasedToOtherPartyMember_ynW65pwr1U-NW4BqvIvEFg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:EquipmentLeasedToOtherPartyMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_7_24_2020_To_7_24_2020_srt_TitleOfIndividualAxis_srt_PresidentMember_6oA-J-UMbEaAx1aHuqxLTQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:PresidentMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-07-24 </startDate>
<endDate> 2020-07-24 </endDate>
</period>
</context>
<context id="Duration_7_24_2020_To_7_24_2020_casi_InvestmentsContractCounterpartyAxis_casi_EtpGlobalFundLpMember_Qnqcw3TT60KYVrNPPxFOcA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:EtpGlobalFundLpMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-07-24 </startDate>
<endDate> 2020-07-24 </endDate>
</period>
</context>
<context id="Duration_7_24_2020_To_7_24_2020_srt_TitleOfIndividualAxis_casi_BoardOfDirectorsChairmanAndChiefExecutiveOfficerMember_2a-h6TSJDkKk_4Tdp0nT0w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> casi:BoardOfDirectorsChairmanAndChiefExecutiveOfficerMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-07-24 </startDate>
<endDate> 2020-07-24 </endDate>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_SZppL-HxnkeSRbfcJFngcQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aJRR-E8ZokW_bhR9AbaoVw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0lW_GWG8UEqJN4q0M1MYng">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aBOEG7xMi0uzQi15BKVVUA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_w5zJosFugU293jyf1aObwA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kFT36rjDSkKNER6SX1b8rA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2U42mnIOp02K0fazELv7fg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_h3-0NAK9Z0mz2AXbUBvUlg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_h7AbZfVPi0KLEXVIcGf2yQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PPxklFVxW0-XGwmnZgPOxA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMBo-r9IZk62VY__A2XDLQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PIobnPqO1E-UYo1iBTa15Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YtFsVj02rkmkMAyyUgI0IA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aq6dyGNJ0UqFkXfLsv0A2g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i3su9UE7w0i61_jHP_SDkw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zBWx11Wy60i0joMyW4w0ZA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fjUBs4x_eEma0c3Hl5peKA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h-9QH2tGWUqbCNzSM986lw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-12-31 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeTwoMember_AXo4Bu7yeEuIiC49yDETsw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> casi:RangeTwoMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeThreeMember_isBWHts9jEy7FMfInj8KWg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> casi:RangeThreeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeOneMember_jz-DLgUYvkea5mzhIVS8vQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> casi:RangeOneMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFourMember_aXWWbqTDPE6E4RElYazC6w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> casi:RangeFourMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFiveMember_766M2vim9Eq48qlcX4EQpQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> casi:RangeFiveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeTwoMember_fSS5z4uSU06hy24wGORyxg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> casi:RangeTwoMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeThreeMember_0X-YDMCZQUuLCmzP98c9CA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> casi:RangeThreeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeOneMember_U3C-XK9iPU6d4Mb42TVotQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> casi:RangeOneMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFourMember_OSvGz7C22EK6BN2w9Fyv-g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> casi:RangeFourMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFiveMember_wuGB45EeWUy7VxJsr6PHTA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> casi:RangeFiveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="Duration_4_1_2019_To_4_30_2019_srt_TitleOfIndividualAxis_casi_ExecutiveChairmanMember_us-gaap_AwardTypeAxis_casi_PerformanceBasedOptionMember_mc9xaL__jkWZVm7ErigaVw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> casi:ExecutiveChairmanMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> casi:PerformanceBasedOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-04-01 </startDate>
<endDate> 2019-04-30 </endDate>
</period>
</context>
<context id="As_Of_3_31_2018_srt_TitleOfIndividualAxis_casi_ExecutiveChairmanMember_us-gaap_AwardTypeAxis_casi_PerformanceBasedOptionMember_8h5yyrni5ku0vijspvPyqw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> casi:ExecutiveChairmanMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> casi:PerformanceBasedOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-03-31 </instant>
</period>
</context>
<context id="As_Of_3_31_2018_srt_TitleOfIndividualAxis_casi_ExecutiveChairmanMember_r_Ljw9-FZEqemo-QQC7_uw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> casi:ExecutiveChairmanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-03-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_E4cfEhslmEqaqXUgTa95tg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2018_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_p17H9TH6Pk6g6X_CEvrwfg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-12-31 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_C_0f2_vSWk2_tFzDxKI0oA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_casi_LongTermIncentivePlan2011Member_rQz5n9k1oUenlUMHQu4ONA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> casi:LongTermIncentivePlan2011Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_6_30_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_casi_LongTermIncentivePlan2011Member_MgY7WQoBlEe7EJlEbYc6cw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> casi:LongTermIncentivePlan2011Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-06-30 </instant>
</period>
</context>
<context id="As_Of_6_30_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_casi_LongTermIncentivePlan2011Member_EICsSx9sp02x6dRKfvkihA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> casi:LongTermIncentivePlan2011Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-06-30 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_XEWtwtpWKU2N8kq6l8bDMg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:SellingAndMarketingExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ktMKlU3VbEO9iPe_PWX9wA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_dumWQGmGeEC_i91cVfcahQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T8yRv0QFxkaYXnAorqVF8Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_eVNKWi8d5EW7yAP4nS5k_g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_GuokangPharmaceuticalsCoLtdMember_ejTdGKSUFEGUZsdgeE5rSg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:GuokangPharmaceuticalsCoLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_GuokangPharmaceuticalsCoLtdMember_fZsl75EJ5kGTspLFOYTRCA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:GuokangPharmaceuticalsCoLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_casi_EVOMELAMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_TvgWYLCS-EmKadKELzLe8g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> casi:EVOMELAMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:SpectrumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_casi_EVOMELAMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_uUR2cfDBL0CuT6877Yyc3g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> casi:EVOMELAMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:SpectrumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="As_Of_12_31_2018_srt_ProductOrServiceAxis_casi_EVOMELAMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_Y8Xhm8SazU6Djq-ZzFHZ0g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> casi:EVOMELAMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:SpectrumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-12-31 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_casi_FurnitureAndEquipmentMember_ENQSzV72ekm0CuvWkMjdRg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> casi:FurnitureAndEquipmentMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_casi_FurnitureAndEquipmentMember_qSQ_8HCuskOkOfUj96vdIA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> casi:FurnitureAndEquipmentMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_0esdaLs8n0679GyzfMH_9A">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_ohbJmyu-WkOXhEgYfW8_vg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsNonrecurringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="Duration_11_7_2021_To_11_7_2021_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2ieeOhbi2kC-vNgbWmoAww">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> casi:ChinaCiticBankCorporationLimitedMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-11-07 </startDate>
<endDate> 2021-11-07 </endDate>
</period>
</context>
<context id="Duration_2_3_2021_To_2_3_2021_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3OV_uj7nQUeF6LjQRXSEAw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> casi:ChinaCiticBankCorporationLimitedMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-02-03 </startDate>
<endDate> 2021-02-03 </endDate>
</period>
</context>
<context id="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_W4eyun0Gp0mlsMHffm3HDQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-26 </startDate>
<endDate> 2021-03-26 </endDate>
</period>
</context>
<context id="Duration_3_26_2021_To_3_26_2021_ktqqJoYxs0CevRHoPfKp5g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<startDate> 2021-03-26 </startDate>
<endDate> 2021-03-26 </endDate>
</period>
</context>
<context id="Duration_7_24_2020_To_7_24_2020_ihrUHlk_VUqYlRnsRY2Bkw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<startDate> 2020-07-24 </startDate>
<endDate> 2020-07-24 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_casi_JuventasCellTherapyLtdMember_MCcbO8_0-kCT1l5Yw081aw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_HczeXupWC029Mz1AoKJcFQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_casi_BlackBeltTxLimitedMember_VS4mLhYQkEK-24qXg_iocg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:BlackBeltTxLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_casi_BioinventInternationalAbMember_uDKy_-S9-ESVayoQKVnGEg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_casi_JuventasCellTherapyLtdMember_SUoa4o6J8UW4Bo7q6VoBSA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_casi_BlackBeltTxLimitedMember_N1DkVcLcfU6EGh4lrjqwXQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:BlackBeltTxLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_casi_BioinventInternationalAbMember_YqQgtqDDpUC-sOnD3uMw7g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_3_31_2019_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_BYNc2K7eUkKwF2lKu3KRMw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-03-31 </endDate>
</period>
</context>
<context id="Duration_9_29_2020_To_9_29_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_PutOptionMember_ZX6XI1FrG0WsJokPrMOrpw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis"> us-gaap:PutOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-09-29 </startDate>
<endDate> 2020-09-29 </endDate>
</period>
</context>
<context id="Duration_6_1_2019_To_6_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_KYklM8q9p0SUd0FzRmImXw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-06-01 </startDate>
<endDate> 2019-06-30 </endDate>
</period>
</context>
<context id="Duration_4_1_2019_To_4_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_Fq9W1J_0B0W3fxLZRghNLg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BlackBeltTxLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-04-01 </startDate>
<endDate> 2019-04-30 </endDate>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_bhXg5qk6QU6mkt_SVdxqhQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:ForeignCountryMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_9VK1qleIH0eKTZhq9GInBQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:DomesticCountryMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_RWh-RP3-R0iFwQZ8pCtu1Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis"> us-gaap:OtherLiabilitiesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_8XJ-VCcwakKprpoLtzi8kw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis"> us-gaap:AccountsPayableAndAccruedLiabilitiesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_CN_uCPV6GlxvECLOcBrt3KrIg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:CN </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_PkStkoceF0e7jELXRQvUsw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis"> us-gaap:OtherLiabilitiesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_1qDyHgjkSkScg3XBvS_eNA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis"> us-gaap:AccountsPayableAndAccruedLiabilitiesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_MCe69bbxj02l1rXtQX7Xbw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis"> us-gaap:AccountingStandardsUpdate201602Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-01-01 </instant>
</period>
</context>
<context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_dTedlgmNdUCWA_VCw7YlqQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:BiocheckInc.Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_Z0SeyPstdkmDCloI1Gk3og">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:BiocheckInc.Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_1_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_MJOVgO3c8kyvCYvnCsQarw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:BiocheckInc.Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-01-31 </endDate>
</period>
</context>
<context id="Duration_7_1_2019_To_7_1_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_JuventasCellTherapyLtdMember_94l2cxCc4UiyeonD5c7v1Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-07-01 </startDate>
<endDate> 2019-07-01 </endDate>
</period>
</context>
<context id="Duration_6_1_2019_To_6_30_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_lJ1ywRFD2EiAOQLrvRKjMA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:BiocheckInc.Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-06-01 </startDate>
<endDate> 2019-06-30 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_c80qokpBP0aQFWTdXRvZ8w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:BiocheckInc.Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_JuventasCellTherapyLtdMember_2ZY7ASMV40aQ7OayhfEwcQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="As_Of_11_3_2020_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_I2VI4HrT3keKtvZbfnRZoA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> casi:ChinaCiticBankCorporationLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-11-03 </instant>
</period>
</context>
<context id="As_Of_4_27_2020_QoUNjSU7SEmhu8IjmUa8GA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<instant> 2020-04-27 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_CN_us-gaap_LeaseContractualTermAxis_casi_ResearchAndDevelopmentFacilityLeaseMember_H5UVztDX6USVVT9wJ01ZYA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:CN </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis"> casi:ResearchAndDevelopmentFacilityLeaseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_CN_us-gaap_LeaseContractualTermAxis_casi_OfficeSpaceLeaseMember_uCOjljswCEi3J-a7ki01yw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:CN </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis"> casi:OfficeSpaceLeaseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_7_1_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_JuventasCellTherapyLtdMember_F_-BCLgjvUy82LzmDiQyTw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-07-01 </instant>
</period>
</context>
<context id="As_Of_6_30_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_g7mShfaPTUiOxv4vMu5DqA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:BiocheckInc.Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-06-30 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_JuventasCellTherapyLtdMember_A4z5U9Prh0Cl6vHsWQwbPQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_MaxcyteIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eVM7R57doUmjvZ6eEPxSdQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:MaxcyteIncMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_j-S5AVLOs0Ge_cTfFPPGEA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel3Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsRecurringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NDecUyJtSU6AmNXpdhMMxA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsRecurringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nrp8PsrLdEGJKj6Whl5zvA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsRecurringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__qtdhHzhcUWblgAuWNIs-g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementJune2020Member_VYuk8JHoUUSqygYQ-DwJvg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> casi:LoanAgreementJune2020Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementAugust2020Member_oq_BBhDaIkmyqxDKGkgojg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> casi:LoanAgreementAugust2020Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_tisilmNFMkG5-CGrMXeKgg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> casi:ChinaCiticBankCorporationLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_2_1_2020_To_2_29_2020_4bJnhMZQ9k6dW7cnRMxw3Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<startDate> 2020-02-01 </startDate>
<endDate> 2020-02-29 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember_G_aMSXOd2EqTf_hSi4fATw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:OtherIntangibleAssetsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_CloudComputingArrangementMember_sh84kcuUvkaRoEGq1g-YsA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> casi:CloudComputingArrangementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_epqcBoht20abZ3M1ndr6rQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> casi:AbbreviatedNewDrugApplicationsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="As_Of_2_29_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_us-gaap_TypeOfArrangementAxis_casi_ChartwellRxSciencesLlcMember_RHtSUlatJUGV_OgD-R5pSQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> casi:AbbreviatedNewDrugApplicationsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> casi:ChartwellRxSciencesLlcMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-02-29 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember__pSyNYoukEidePcebzjm_w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:OtherIntangibleAssetsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_43-3WISlG0ayISQ9cDD6KA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> casi:AbbreviatedNewDrugApplicationsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_FairValueByAssetClassAxis_casi_AssetsHeldForSaleNotPartOfDisposalGroupMember_tRbj_qPHtEahbIxDPt7lFQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis"> casi:AssetsHeldForSaleNotPartOfDisposalGroupMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Mnr_9uqx_kuKq1MlMD3I_g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsNonrecurringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wFvJ_UnaCEy70JZGiqlGhQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsRecurringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FOGLCtLtX0W7vhAYtY48Tw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:OppenheimerAndCo.IncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-24 </instant>
</period>
</context>
<context id="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_m6l7tJZXbESjwZOx5NIjhA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:OppenheimerAndCo.IncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-24 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_FinancialInstrumentAxis_us-gaap_PutOptionMember_7VN6hUMvYUu48nv0jred5w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis"> us-gaap:PutOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_fBKf4Egy40unCyw8gaVITA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis"> us-gaap:EquitySecuritiesMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_kUV7crttSEabXMBT5Xm0eg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis"> us-gaap:EquitySecuritiesMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BlackBeltTxLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_9_29_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_MarketApproachValuationTechniqueMember_dpL9Vj2wlkqRA9BE5CcICQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel3Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsNonrecurringMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis"> us-gaap:MarketApproachValuationTechniqueMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-09-29 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_FinancialInstrumentAxis_us-gaap_PutOptionMember_eOGOIIHry0y8FUmrgm1dRg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis"> us-gaap:PutOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_L19nzOTRm0aWhhnCVxTl6g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis"> us-gaap:EquitySecuritiesMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_8rO34GsaZE-z80jXhic9jQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis"> us-gaap:EquitySecuritiesMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BlackBeltTxLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_MaxcyteIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__IeYP4vqGky5MvkjFQwrsQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:MaxcyteIncMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fZPPvi-QO0WpNkW17udjPg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_FinancialInstrumentAxis_casi_InvestmentsInEquityWarrantsMember_H_94ekLjB0i-85gMQzLVFQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis"> casi:InvestmentsInEquityWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_MaxcyteIncMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_v0T2gbZM-EuXjhritfArfQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:MaxcyteIncMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_oNqeeSSFfEOVlCSI5Kmzrw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_9_29_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_0291pJlo6EugGh_XSP-pTw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-09-29 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_MaxcyteIncMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_C5hxQ1huVUacBZp6zWAt3w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:MaxcyteIncMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_EmergingTechnologyPartnersLLCMember_uXDEWmJ6m0qAVRYQ0UGZ-Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:EmergingTechnologyPartnersLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_PutOptionMember_DGJnZYRQPUixdwZ_FFoEQw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis"> us-gaap:PutOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_8XITJn-_fE-O31gS2WKzSA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis"> us-gaap:CallOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_WoRB8h-TokKoYkiKFGziHw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:SpectrumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_9_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_mHBLAO5l9U2V98sujFDEug">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-09-30 </instant>
</period>
</context>
<context id="As_Of_6_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_zCmsA8hwp0im2PhSRcM0gQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-06-30 </instant>
</period>
</context>
<context id="As_Of_4_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_G4YIlnuvuk64KuwL1D_g0Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BlackBeltTxLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-04-30 </instant>
</period>
</context>
<context id="As_Of_3_31_2019_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_9hPCAcLin0-Jul_tK4viEQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis"> us-gaap:CallOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-03-31 </instant>
</period>
</context>
<context id="Duration_4_27_2020_To_4_27_2020_us-gaap_LineOfCreditFacilityAxis_casi_MTBankMember_DX0xioOoykqBh9iAG3tKYQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> casi:MTBankMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-04-27 </startDate>
<endDate> 2020-04-27 </endDate>
</period>
</context>
<context id="As_Of_11_7_2021_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CutzzCQ8EkG_GH0imLe7UQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> casi:ChinaCiticBankCorporationLimitedMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-11-07 </instant>
</period>
</context>
<context id="As_Of_2_3_2021_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4-xaoyvvokiPt4Qcp-WTww">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> casi:ChinaCiticBankCorporationLimitedMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-02-03 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_s_05U-xn10KXMgGcwjhKCw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> casi:ChinaCiticBankCorporationLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_4_29_2020_us-gaap_LineOfCreditFacilityAxis_casi_MTBankMember_0nZMYOICtUaAGKqjNb_aHA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> casi:MTBankMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-04-29 </instant>
</period>
</context>
<context id="As_Of_12_31_2018_Qx1IVz1wIUe3rkaVNstInA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<instant> 2018-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_dei_LegalEntityAxis_casi_CasiChinaMember_71qQbn-EyECwAn9lEEMaIg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> casi:CasiChinaMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_I1fcxHe9skaWq8RXBH0G3Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BlackBeltTxLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_KJ985i4PHkO4b0jbK6cM1g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="As_Of_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_kjsYxa-Bz0eaH9B0KN-7bw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-11-30 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_20Bl-uHQakKIxHD-KsfnTA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_casi_OptionsMember_C2Tr0pDxQUGtmZ9DJrjCdQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> casi:OptionsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_3Y8tjRmooE6126cW6DY2FA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_casi_OptionsMember_e00VDPx4NUODzSfPbm57qA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> casi:OptionsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_ChinaResourcesGuokangPharmaceuticalsCo.Ltd.Member_Y0DxXxW0Jku9xDP0ovUk6w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:ChinaResourcesGuokangPharmaceuticalsCo.Ltd.Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_ChinaResourcesGuokangPharmaceuticalsCo.Ltd.Member_Ubi5dcaUuUG6ZZP8_hZHNA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:ChinaResourcesGuokangPharmaceuticalsCo.Ltd.Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_eQLemJk6F0WbMAniqK5XdQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:SpectrumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="As_Of_3_26_2021_83yz3hCG60iRKCdDsudRwA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<instant> 2021-03-26 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_fd2NxIMso0qDmLK3pGbFiw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="Duration_3_1_2021_To_3_31_2021_casi_InvestmentsContractCounterpartyAxis_casi_CleaveTherapeuticsIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0v_ILorLUUKRQvssDQlmUw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:CleaveTherapeuticsIncMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="Duration_11_1_2020_To_11_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_WiVJTV4LD0-xqH_HvMbUqA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-11-01 </startDate>
<endDate> 2020-11-30 </endDate>
</period>
</context>
<context id="Duration_4_1_2019_To_4_30_2019_srt_CounterpartyNameAxis_casi_BlackBeltTherapeuticsLimitedMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicenseAgreementTermsMember_QQy-_m59uEmyClAtafXP_A">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:BlackBeltTherapeuticsLimitedMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> us-gaap:LicenseAgreementTermsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-04-01 </startDate>
<endDate> 2019-04-30 </endDate>
</period>
</context>
<context id="Duration_4_1_2019_To_4_30_2019_srt_CounterpartyNameAxis_casi_BlackBeltTherapeuticsLimitedMember_GmGeAS7djE-GDT5nQW_znw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:BlackBeltTherapeuticsLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-04-01 </startDate>
<endDate> 2019-04-30 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_11q5ArWy6kaLcVKbNhif2w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:PharmathenGlobalBvMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_3spZIRCGiUmHPyyMxl3SFA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTXlXOguF0WRCe03oj2yVw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sVsrchdFGUmAmLH3wuyN7A">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember__NxDDjX1fk62PxcK16t5OQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_EooCdr7S7UW9iW2nRmw1uQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9v4eOavRwUGUQp4vvD_aJA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nWCyZcE68kGUN85-TCFT-g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_j-hxpPIRw0SoL7Ys8QOo5g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_4_1_2019_To_4_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_casi_PerformanceBasedOptionMember_om11DpwZb0WH7U8GVWznOQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> casi:PerformanceBasedOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-04-01 </startDate>
<endDate> 2019-04-30 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_LBZNo3Q_F02YKbhbmUqy2Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_FDAXWmiR7UGiK3T94vDFwQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_5_1_2019_To_5_31_2019_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_PqAaNOusu0yGkv02KBsb3Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-05-01 </startDate>
<endDate> 2019-05-31 </endDate>
</period>
</context>
<context id="Duration_3_24_2021_To_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f6dLbzT0Y0-fGMZpVgN2rw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:OppenheimerAndCo.IncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-24 </startDate>
<endDate> 2021-03-24 </endDate>
</period>
</context>
<context id="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_casi_OpenMarketSaleAgreementMember_9cdIM2RDtUGEXRgyHqm0kw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> casi:OpenMarketSaleAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="As_Of_11_20_2020_E8azgY6PLEaD6_ypT2LlDQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<instant> 2020-11-20 </instant>
</period>
</context>
<context id="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_FPImBeVQ6ECFNmosNPG3jQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-04-01 </startDate>
<endDate> 2020-04-30 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_V0P7PHHzRE2gkPiJuJmjuQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_11_1_2020_To_11_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_srt_RangeAxis_srt_MaximumMember_lvxrE5RiIU-OIjfVH_l5Ww">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-11-01 </startDate>
<endDate> 2020-11-30 </endDate>
</period>
</context>
<context id="Duration_3_1_2018_To_3_31_2018_srt_TitleOfIndividualAxis_casi_ExecutiveChairmanMember_us-gaap_AwardTypeAxis_casi_PerformanceBasedOptionMember_5fDUkVDRlk-o3h5saWY3CQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> casi:ExecutiveChairmanMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> casi:PerformanceBasedOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2018-03-01 </startDate>
<endDate> 2018-03-31 </endDate>
</period>
</context>
<context id="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mLDF7BJ3akakLuxfMK7juA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:OppenheimerAndCo.IncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> us-gaap:InvestorMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-24 </instant>
</period>
</context>
<context id="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_srt_TitleOfIndividualAxis_casi_BoardOfDirectorsChairmanAndChiefExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_O2Fp4rasTECUr6UjLSJjfQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> casi:OppenheimerAndCo.IncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> casi:BoardOfDirectorsChairmanAndChiefExecutiveOfficerMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-24 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_y_UDporeOk2GvbA3fWsFdg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="Duration_10_1_2020_To_10_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_l4nV_VQrlEyRIzncxfJ4yQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-10-01 </startDate>
<endDate> 2020-10-31 </endDate>
</period>
</context>
<context id="Duration_10_1_2020_To_12_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_NUAraEzblEODqs8qOYfH3g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis"> casi:AbbreviatedNewDrugApplicationsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-10-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_7_1_2020_To_7_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_AQWaElCDiEOyldG0TKpKaw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis"> casi:AbbreviatedNewDrugApplicationsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-07-01 </startDate>
<endDate> 2020-07-31 </endDate>
</period>
</context>
<context id="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_XPJAlt51aUKS4_V2bDdnJA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_WkfBlGbnmUS5NuDaWNcn0A">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BlackBeltTxLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_Qqp3IKhp4EiuKj2iNZ3R_A">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_10_29_2019_To_10_29_2019_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_UCAuvvHB60ai4ZsxJQRFRA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:PharmathenGlobalBvMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-10-29 </startDate>
<endDate> 2019-10-29 </endDate>
</period>
</context>
<context id="Duration_3_1_2019_To_3_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_GuokangPharmaceuticalsCoLtdMember__PbLeb60hEau-iz8Am8RXA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:GuokangPharmaceuticalsCoLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-03-01 </startDate>
<endDate> 2019-03-31 </endDate>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9VLLZcGICUSzanFc4ARWfA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsRecurringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="Duration_1_1_2019_To_1_1_2019_SbE1vx3xVkeWIt2v6rjU6A">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-01-01 </endDate>
</period>
</context>
<context id="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5Adb8TPeIUuuXeqaxk1Mvw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_casi_OpenMarketSaleAgreementMember_UROplnlJhkWYsb5nLzfnLw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> casi:OpenMarketSaleAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_casi_OpenMarketSaleAgreementMember_laWb5-D2bU6hrpgr2H0Idg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> casi:OpenMarketSaleAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2018_To_12_31_2018_us-gaap_SubsidiarySaleOfStockAxis_casi_SalesAgreementMember_zhfoW35Ni02jmkMmd0foBA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> casi:SalesAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2018-01-01 </startDate>
<endDate> 2018-12-31 </endDate>
</period>
</context>
<context id="As_Of_7_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_KiL3CVBteEW1dcXh5JnEug">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BlackBeltTxLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-07-31 </instant>
</period>
</context>
<context id="Duration_9_29_2020_To_9_29_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_rUjsP-x6pU6mClOZZsbgOQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-09-29 </startDate>
<endDate> 2020-09-29 </endDate>
</period>
</context>
<context id="Duration_7_19_2019_To_7_19_2019_us-gaap_TypeOfArrangementAxis_casi_OpenMarketSaleAgreementMember_nTT1_EMOkEuoIeZHBhIf2Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> casi:OpenMarketSaleAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-07-19 </startDate>
<endDate> 2019-07-19 </endDate>
</period>
</context>
<context id="Duration_7_19_2019_To_7_19_2019_us-gaap_TypeOfArrangementAxis_casi_AmendmentToOpenSaleAgreementMember_f1DIgMboVkqVRCefOa9-0w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> casi:AmendmentToOpenSaleAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-07-19 </startDate>
<endDate> 2019-07-19 </endDate>
</period>
</context>
<context id="Duration_8_1_2020_To_8_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementAugust2020Member_7cvAc7MSxEqhWTLNRIuAxQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> casi:LoanAgreementAugust2020Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-08-01 </startDate>
<endDate> 2020-08-31 </endDate>
</period>
</context>
<context id="Duration_6_1_2020_To_6_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementJune2020Member_Pb62VgCchUyWlIkip9HV8A">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> casi:LoanAgreementJune2020Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-06-01 </startDate>
<endDate> 2020-06-30 </endDate>
</period>
</context>
<context id="Duration_7_1_2020_To_7_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_xYdiaNxtwUylPiiorEew3A">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BlackBeltTxLimitedMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-07-01 </startDate>
<endDate> 2020-07-31 </endDate>
</period>
</context>
<context id="Duration_9_1_2020_To_9_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_nJ9U7Pnbj067zCKADaCrpg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:JuventasCellTherapyLtdMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-09-01 </startDate>
<endDate> 2020-09-30 </endDate>
</period>
</context>
<context id="Duration_10_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_CN_us-gaap_LeaseContractualTermAxis_casi_OfficeSpaceLeaseMember_PQTnsPp6mEOIDggZtPgIQQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:CN </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis"> casi:OfficeSpaceLeaseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-10-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_CN_us-gaap_LeaseContractualTermAxis_casi_ResearchAndDevelopmentFacilityLeaseMember_qJBJAyCzrUqZVLhbrgzA9g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:CN </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis"> casi:ResearchAndDevelopmentFacilityLeaseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_CN_us-gaap_LeaseContractualTermAxis_casi_OfficeSpaceLeaseMember_BZws6bnsN0mMRwpA5vsoJA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:CN </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis"> casi:OfficeSpaceLeaseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lBPlUswpVUGDYjz54-i3Tw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel3Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsRecurringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_oEffp5rJ5EOhLowH14qfHA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsRecurringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jwd5pOG3-ke1GFqFizM3_Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsRecurringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bhHRbIu-z0WM2EpLhHYUOg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsRecurringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_3_31_2021_casi_InvestmentsContractCounterpartyAxis_casi_CleaveTherapeuticsIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_x6JKr8mi90iz9vrSPXy4xw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:CleaveTherapeuticsIncMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="As_Of_12_26_2018_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_w7ApvLwYaUSAQ5DRQbgUKw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-12-26 </instant>
</period>
</context>
<context id="As_Of_2_28_2019_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_eDnJ6ICqy0SfiOTl5H3aEg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-02-28 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_RXB7SHbTW0OVSdz6WUn3bA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis"> casi:AbbreviatedNewDrugApplicationsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="As_Of_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_srt_RangeAxis_srt_MaximumMember_xrQKFAqNhECS5dDZvqPzIg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-11-30 </instant>
</period>
</context>
<context id="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="Duration_11_1_2019_To_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_dYsiMUDgcEaYApPduIKx9Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-11-01 </startDate>
<endDate> 2019-11-30 </endDate>
</period>
</context>
<context id="As_Of_6_30_2020_24wLKU2tYEGtsPPwep1fFw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<instant> 2020-06-30 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentLeasedToOtherPartyMember_Ty8_PndE_EaI4ks32NxmNQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:EquipmentLeasedToOtherPartyMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="Duration_9_29_2020_To_9_29_2020_srt_RangeAxis_srt_MedianMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_MarketApproachValuationTechniqueMember_0NVrfv0jlU6sH7i1LqgFjw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MedianMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel3Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsNonrecurringMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis"> us-gaap:MarketApproachValuationTechniqueMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-09-29 </startDate>
<endDate> 2020-09-29 </endDate>
</period>
</context>
<context id="Duration_9_29_2020_To_9_29_2020_srt_RangeAxis_srt_ArithmeticAverageMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_MarketApproachValuationTechniqueMember_-A6lzXG_GkGIg64-1pBm8Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:ArithmeticAverageMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel3Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis"> us-gaap:FairValueMeasurementsNonrecurringMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis"> us-gaap:MarketApproachValuationTechniqueMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-09-29 </startDate>
<endDate> 2020-09-29 </endDate>
</period>
</context>
<context id="As_Of_10_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_IUudb4TwOk2ozeSRncvThQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:BioinventInternationalAbMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-10-31 </instant>
</period>
</context>
<context id="As_Of_8_27_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_hXZDZBgK3EqZJeFfmlyPRw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-08-27 </instant>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_smYZdRh4o0mSgr634rIWaw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> casi:CASIWuxiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="As_Of_12_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_p8_bCiWIGUqizVMxzZ5O5Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis"> casi:AbbreviatedNewDrugApplicationsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="As_Of_7_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_x33t8c8cE0WXqLTQUKDi1g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis"> casi:AbbreviatedNewDrugApplicationsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-07-31 </instant>
</period>
</context>
<context id="As_Of_12_31_2019_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_3RFfkjq4JkqbR9wdYfWdug">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis"> casi:AbbreviatedNewDrugApplicationsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_cL1Z9OiRlE2fr4NzaW5PTQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> casi:SpectrumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_2_1_2020_To_2_29_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_us-gaap_TypeOfArrangementAxis_casi_ChartwellRxSciencesLlcMember_8yegX2qWFUWs6FfHTkZS4w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> casi:AbbreviatedNewDrugApplicationsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> casi:ChartwellRxSciencesLlcMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-02-01 </startDate>
<endDate> 2020-02-29 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_kc-NooqXmE2NjmxJx3QuNA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:PharmathenGlobalBvMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_srt_RangeAxis_srt_MaximumMember_LuPsA4ND1UaU3cQe63-_WA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="casi:InvestmentsContractCounterpartyAxis"> casi:PharmathenGlobalBvMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000895051 </identifier>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<unit id="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA">
<measure> shares </measure>
</unit>
<unit id="Unit_Standard_subsidiary_mJH4TjT7ikaUUEtVaN0L7g">
<measure> casi:subsidiary </measure>
</unit>
<unit id="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg">
<divide>
<unitNumerator>
<measure> iso4217:USD </measure>
</unitNumerator>
<unitDenominator>
<measure> shares </measure>
</unitDenominator>
</divide>
</unit>
<unit id="Unit_Standard_sqm_5nOihD7L7kmLecswPxNXyA">
<measure> utr:sqm </measure>
</unit>
<unit id="Unit_Standard_segment_F6mrK1_Rg0OWuMCKw-6xVg">
<measure> casi:segment </measure>
</unit>
<unit id="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ">
<measure> iso4217:USD </measure>
</unit>
<unit id="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg">
<measure> iso4217:EUR </measure>
</unit>
<unit id="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw">
<measure> iso4217:CNY </measure>
</unit>
<unit id="Unit_Standard_SEK_HamDqLO41U2OnRnGDD3WNw">
<measure> iso4217:SEK </measure>
</unit>
<unit id="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w">
<measure> pure </measure>
</unit>
<unit id="Unit_Standard_lease_lPgwyBdVyEynXNo_4iSlQg">
<measure> casi:lease </measure>
</unit>
<unit id="Unit_Standard_Milestone__O5I2ENfv0G4abijkh4HOA">
<measure> casi:Milestone </measure>
</unit>
<unit id="Unit_Standard_person_f5DA5054Ykmk0LWf8_a9Cg">
<measure> casi:person </measure>
</unit>
<unit id="Unit_Standard_item_flJTMRpAMk2GmooQY-riJQ">
<measure> casi:item </measure>
</unit>
<us-gaap:CommitmentsAndContingencies contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" id="Hidden_74Y_eHKn9UafoApEbwA2xw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" id="Hidden_8PlD0GJ1rU6aROh6AQOpWg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" id="Hidden_zhrr--IXX0-dYwYVn6JgZg"> P6Y8M16D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" id="Hidden_Z0Bm1zY6XUy9-pvqfpFEHA"> P6Y8M16D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" id="Hidden_oZ7b0hzxPEmmvVmJ8xqw7Q"> P5Y2M1D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<dei:EntityCentralIndexKey contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_DuF6OY6J1USSsnS7E79iWA_2_1"> 0000895051 </dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_erCu46hidkuT05szecmCSA_3_1"> --12-31 </dei:CurrentFiscalYearEndDate>
<dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_BGjSfrsYaEqX9FssDteI3g_4_1"> 2020 </dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_1uamGNH990ClafofgG1z6A_5_1"> FY </dei:DocumentFiscalPeriodFocus>
<dei:AmendmentFlag contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_f0-x5fh7_k-XX-dBd7riiA_6_1"> false </dei:AmendmentFlag>
<us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="0" id="Hidden_b0_EP5rT5EOWBn2X5k8YkQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Hidden_BOkC1uhIG0aZ_unnLRvlYg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_8XJ-VCcwakKprpoLtzi8kw" id="Hidden_VP2HSlCBzke7mrrpg8iwKg"> us-gaap:AccruedLiabilitiesCurrent </us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
<us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_RWh-RP3-R0iFwQZ8pCtu1Q" id="Hidden_sbQuffdDGk-anSqhdPChlA"> us-gaap:OtherLiabilitiesNoncurrent </us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
<us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" id="Hidden_ofosIaxQlEKKZFtF1U43EQ"> us-gaap:AccruedLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent </us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
<us-gaap:NonfinancialLiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9VLLZcGICUSzanFc4ARWfA" decimals="0" id="Hidden_MtmDB6AWoUuLyVNTpAAm0Q" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
<us-gaap:NonfinancialLiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bhHRbIu-z0WM2EpLhHYUOg" decimals="0" id="Hidden_LTzvl0o9aUS8-UEDaWRHMQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_casi_FurnitureAndEquipmentMember_ENQSzV72ekm0CuvWkMjdRg" id="Hidden_mBCIWDY5tEq4f381jaHwFw"> P3Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<casi:SecuritiesLockUpPeriod contextRef="Duration_3_24_2021_To_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f6dLbzT0Y0-fGMZpVgN2rw" id="Hidden_BB9kfPn1KEuNbL6aMwD11Q"> P90D </casi:SecuritiesLockUpPeriod>
<casi:SecuritiesLockUpPeriod contextRef="Duration_3_24_2021_To_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f6dLbzT0Y0-fGMZpVgN2rw" id="Hidden_bZKv5zLq0EK2tTW94z-Ysg"> P90D </casi:SecuritiesLockUpPeriod>
<casi:SecuritiesLockUpPeriod contextRef="Duration_3_24_2021_To_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f6dLbzT0Y0-fGMZpVgN2rw" id="Hidden_XEr4M1yPWEqkn00183lPug"> P90D </casi:SecuritiesLockUpPeriod>
<dei:DocumentType contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_WqyEDvQhZES4A6LNm104Pw"> 10-K </dei:DocumentType>
<dei:DocumentAnnualReport contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_Jv6gnVr_EUKx1S3-XlGqgg"> true </dei:DocumentAnnualReport>
<dei:DocumentPeriodEndDate contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_ZNhps6mKeEizIMxQ6ePzRA"> 2020-12-31 </dei:DocumentPeriodEndDate>
<dei:DocumentTransitionReport contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_oRmTxMCvi0i4RI_cYf3RNA"> false </dei:DocumentTransitionReport>
<dei:EntityFileNumber contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_C9J2Xy8r8UGkDAn-PSO63Q"> 0-20713 </dei:EntityFileNumber>
<dei:EntityRegistrantName contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_N3ilJ0fdH0akM_au7JbXXw"> CASI PHARMACEUTICALS, INC. </dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_V2VKbu_ZU0qjkggUuy6KwA_1_0"> DE </dei:EntityIncorporationStateCountryCode>
<dei:EntityTaxIdentificationNumber contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_i-68RSNZuUSW3VGhfjq3LA_1_2"> 58-1959440 </dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1 contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_9_2ejk0jfkie4EvwbI4q1g"> 9620 Medical Center Drive </dei:EntityAddressAddressLine1>
<dei:EntityAddressAddressLine2 contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_S9ahc09Tc0iawc1XS49rHg"> Suite 300 </dei:EntityAddressAddressLine2>
<dei:EntityAddressCityOrTown contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_KC5tR2WOc0m1j21qJnEKcA"> Rockville </dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_WR-gQsG12Ui1pM8u_aICuA"> MD </dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_tLJor1T_C0yw_7YfHDB3Ng_4_2"> 20850 </dei:EntityAddressPostalZipCode>
<dei:CityAreaCode contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_xGJRxkJzhEiuklaL9Fs-ig"> 240 </dei:CityAreaCode>
<dei:LocalPhoneNumber contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_OZMoxHsWfUK5O-AFk4fIyQ"> 864-2600 </dei:LocalPhoneNumber>
<dei:Security12bTitle contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_HJnKrRUsSkm51xAmI7oiJA_0_0"> Common Stock, $0.01 par value </dei:Security12bTitle>
<dei:SecurityExchangeName contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_ozAqwXyTy0StF_kgaBufFA_0_4"> NASDAQ </dei:SecurityExchangeName>
<dei:TradingSymbol contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_PF-yZm-cSEegi54P1cbqNA_1_2"> CASI </dei:TradingSymbol>
<dei:EntityWellKnownSeasonedIssuer contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_tQTv6wrgTUSiPp2uqP8c1w"> No </dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_lNq3krw9R0GYNiqk-jNTGA"> No </dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_BCKknGqTH0OLZUpezz5P4Q"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr__ro0TO2rkkKDVNWy5MnxrQ"> Yes </dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_I7j3sbUcbUKJCdOoOBG20w"> Non-accelerated Filer </dei:EntityFilerCategory>
<dei:EntitySmallBusiness contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_eas9Tt2K2ky4H5BJbw35Xw"> true </dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_M3fDhDbDy0ujtbcusi8tVg"> false </dei:EntityEmergingGrowthCompany>
<dei:IcfrAuditorAttestationFlag contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_yxiNAExknkGoFc8PV5U4Qg"> false </dei:IcfrAuditorAttestationFlag>
<dei:EntityShellCompany contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_n0v15qVq70W2_X9yaRbj_g"> false </dei:EntityShellCompany>
<dei:EntityPublicFloat contextRef="As_Of_6_30_2020_24wLKU2tYEGtsPPwep1fFw" decimals="0" id="Narr__-bTkC1iTUibMQhJcBODiw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 183834503 </dei:EntityPublicFloat>
<dei:EntityCommonStockSharesOutstanding contextRef="As_Of_3_26_2021_83yz3hCG60iRKCdDsudRwA" decimals="0" id="Narr_3LBwaNMfN02jg1_-IIve6g" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 139797487 </dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_cpKtAh62nUKT9odDA3Vpig_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 57064000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_StwGg1seH0aio9Lj6M2BwQ_5_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 53621000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:ShortTermInvestments contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_VSQWD0lpok6KYyolMVYUDw_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 9309000 </us-gaap:ShortTermInvestments>
<us-gaap:ShortTermInvestments contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_fyNDzD8NqE6hxqL8sBakdQ_6_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 625000 </us-gaap:ShortTermInvestments>
<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Narr_5W9npIEEfkiFEGXiHW3fLg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Narr_2sIePLJ7ckyA-2H2hzV1nQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_HaKWNuRjTkygc19A1xSs5g_7_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4645000 </us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_V4ih_OZqQEePftr2yZFBDg_7_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1293000 </us-gaap:AccountsReceivableNetCurrent>
<us-gaap:InventoryNet contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_dOR4vCJmXk6RQYB4CA50ZA_8_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1356000 </us-gaap:InventoryNet>
<us-gaap:InventoryNet contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_5qJpF2TpW0CjwarDlANTow_8_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4542000 </us-gaap:InventoryNet>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_2leKqc12Kke5qam0tWYk2g_9_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1651000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_saPmeuAFTEyWGO03NZMOsg_9_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1420000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_jFqH7NH7ykGvZJQ3_eg3QA_10_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
<us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_C_HEkzNCokuwVMJtWD0f-g_10_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3221000 </us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
<us-gaap:AssetsCurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_BXsDEuYbJ0SvJrS8_bhIMw_11_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 74025000 </us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_PeRXcr4R002bIC8j-eML9A_11_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 64722000 </us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_QdR-0ABug0GYBMpHi080Ag_13_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2062000 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_rsGd44cSIkSXJAibefgPrg_13_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 985000 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_jpF329mEGkCtFAxOx5lcyA_14_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 13210000 </us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_kDsDrXz6HEmn85HnOgd4Ng_14_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 13674000 </us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:LongTermInvestments contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_23syL26EfUK8b1T39fG24w_15_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 29442000 </us-gaap:LongTermInvestments>
<us-gaap:LongTermInvestments contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_xTmg7LtQI0K_2j7xF9ZUpQ_15_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 14038000 </us-gaap:LongTermInvestments>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_aNlgzS2FLE-xf_DinVff3w_16_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 8696000 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_xuw9aw2x3EmAD1lio9k8fA_16_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 8708000 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_1zMvuOv6y06s-bBhmXK0vw_17_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 299000 </us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_jOm3lfZue0-nUNIBzxmJZQ_17_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 504000 </us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_1Ag9QeUqjEqaOUiMQOVlOA_18_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 127734000 </us-gaap:Assets>
<us-gaap:Assets contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_HoUCWY_YGkeh4g2fgy35Dg_18_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 102631000 </us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_X75VT8Iuikamx7M1K-y6SQ_22_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3669000 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_qdNi3glxI0KhN8w5MYGe1A_22_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5113000 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_zHj83GjYUkScxP2HfsPA4g_23_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3015000 </us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_twKtM82ed0us60PLPxXWvg_23_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2834000 </us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
<us-gaap:ShortTermBorrowings contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_FmjilwDV-UyKdN6UrBseng_24_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 826000 </us-gaap:ShortTermBorrowings>
<us-gaap:ShortTermBorrowings contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_gTkp6ZY-qEKn4eJmpsmJUQ_24_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:ShortTermBorrowings>
<us-gaap:NotesPayableCurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_vmUDm4uMUUyPeRGQ2pHbmw_25_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 466000 </us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_BxO2LAOu7UyM5vhLIZLfvA_25_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NotesPayableCurrent>
<us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_cbGG8na6bESZQ9at_OpqZQ_26_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7976000 </us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_CC_hx7a22EOhL8V2c_cjqw_26_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7947000 </us-gaap:LiabilitiesCurrent>
<us-gaap:DeferredIncome contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_4SrIIZUROUaydXoL9w6_LQ_28_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2351000 </us-gaap:DeferredIncome>
<us-gaap:DeferredIncome contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_64cXBVL3rUqe3igtw6DoJw_28_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:DeferredIncome>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_s4XFWcnjH0mKFkpflg9QmQ_29_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 13834000 </us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_IJ6McH1HTket0uaURMMgIA_29_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1019000 </us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:Liabilities contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_t4VOamrcoEuKBDuxHBVUaQ_30_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 24161000 </us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_ZAbelNDlcEq2zocheF_bAQ_30_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 8966000 </us-gaap:Liabilities>
<us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_HGJqL2yxEUibmPdUnYuoLQ_34_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 22033000 </us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue>
<us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_TWs8NlXWqkGbaidDhkGx6g_34_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 20670000 </us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="2" id="Narr_jW5jUqYobkar_AGT0nRLsw" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.00 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="2" id="Narr_WEUiX6rp3Eai8dqhbgPrGg" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.00 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="0" id="Narr_g4ran4QX7ke7zGCus86-Lg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Narr_cOzFWR77Gk6c3ozuUjHB3g" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="0" id="Narr_twiO3iHTmkai2B2QuoIDNw" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Narr_X65V3nKGM0WiwXvZfh7cHQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockValue contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_xGnltQY2DUWu8CvE6Ltupw_37_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_VCQC9rbCukyLbsTcy06JMg_37_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:PreferredStockValue>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="INF" id="Narr_FWHCflnGL0C1MYSIkSPGMg" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 0.01 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="INF" id="Narr_d25MyGUpgEij1PAetLCsXQ" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 0.01 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="INF" id="Narr_tSox06lY00uSCCAw6alhjw" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 250000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="INF" id="Narr_IjtWq3tzpkKTOL1Pxe7Xgg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 250000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Narr_EmJUOPoAME-dh_qYjuvXzw" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 124023374 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="0" id="Narr_ogqfWXkquEuIWPgbrhA5TQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 97851243 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Narr_h3WPDclyY0KoeooAPBT9bA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 123943829 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="0" id="Narr_T3o1TfPo1U6_e6Rn9F6yyA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 97771698 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockValue contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_xC16veUa_UucDjnb_XTBwQ_42_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1240000 </us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_BLeCalRWqUWx5syqmXTbPg_42_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 979000 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_kloYOIv7IUSN03jOORFpJw_43_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 658246000 </us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_sJf3HNm5yUKI3JmZRNPZ4A_43_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 606686000 </us-gaap:AdditionalPaidInCapital>
<us-gaap:TreasuryStockShares contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="0" id="Narr_DZW9EDLXjE6BPmSlsVt4tA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 79545 </us-gaap:TreasuryStockShares>
<us-gaap:TreasuryStockShares contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Narr_MZhFG9btRkWLYEqvXOpxBA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 79545 </us-gaap:TreasuryStockShares>
<us-gaap:TreasuryStockValue contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_de9Lw1-S90uzshQ3kOQw0Q_44_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 8034000 </us-gaap:TreasuryStockValue>
<us-gaap:TreasuryStockValue contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_j4qqBHXuP0aXp4u0B0_MwA_44_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 8034000 </us-gaap:TreasuryStockValue>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_CUaFouZITkWIBcWH8OFkdw_45_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 589000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_s_hllqWFq0Of3zMquVLDZA_45_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -2728000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_xsw_S4y6Sk-Iww_F--3lQA_46_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -570501000 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_A6hLJA-noky7yX1YAcGZkg_46_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -523908000 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_2ynz64plO0KXR3YHSDasbw_47_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 81540000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_xOSgQKL69kqM9myCCxAIQg_47_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 72995000 </us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_OGV4aLJEmECHepJqGFf9xg_48_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 127734000 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_WihcyDohQ0O02FaBc_ArSg_48_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 102631000 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_yjphMJ0oNU-K1KCZG6O5SQ_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 15001000 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_JTyE-KOjHUyfOJ8YnSYbVA_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4063000 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:LeaseIncome contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_3Xus-XVjOUGf712l2EnWsQ_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 140000 </us-gaap:LeaseIncome>
<us-gaap:LeaseIncome contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_xprB1qlLDUOjFBI3Yj_HxQ_5_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 68000 </us-gaap:LeaseIncome>
<us-gaap:Revenues contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_8BhMFmIpikumgQiRR_bngQ_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 15141000 </us-gaap:Revenues>
<us-gaap:Revenues contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_-iMoCfoKgkmXnJndFA5cPg_6_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4131000 </us-gaap:Revenues>
<us-gaap:CostOfGoodsAndServicesSold contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_0eAi975cZ0S0ufJL6uunuw_9_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 9508000 </us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_FU6d2pWJb0G5UCem4o-HGg_9_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3935000 </us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_-8Pej9WEPUiEB1Az9nDdBg_10_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 11470000 </us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_t0wQU6p-Yk-lY7sCW2BVVw_10_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 9340000 </us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_gtDcQUHZ40mfngYxHMxCzQ_11_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 19661000 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_u39MlLQD0ES49x_icOrwhg_11_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 27336000 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:SellingAndMarketingExpense contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_PpS203A9CEK8CY2kxfx_uQ_12_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7815000 </us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_sQHjk07MBU64S4xcV_tHjQ_12_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3103000 </us-gaap:SellingAndMarketingExpense>
<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_nVfMQdA9H0e4_Xdlrf-kfg_13_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1152000 </us-gaap:GainLossOnDispositionOfIntangibleAssets>
<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_7AfCKpJuu0-MILyakVLD6w_13_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -408000 </us-gaap:GainLossOnDispositionOfIntangibleAssets>
<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_UpASOFOLz06SGbiKHuaP1Q_14_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1537000 </us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_FzJd5zrCY0yL6vM9vtKdIw_14_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_AyOho9bS00yIMYRoXrJzkw_15_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 17828000 </us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_uHnoif3yH0uvlp89dvn9RQ_15_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6967000 </us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:CostsAndExpenses contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_DohcKTFxIEGSfb1GTOhW1w_16_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 66667000 </us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_aEcg3Y7dv0mAKWnMX3_3IA_16_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 51089000 </us-gaap:CostsAndExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_d2G_7iFMskW06xT41BhilQ_18_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -51526000 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_S3yKwns5gkKJ6af2eyX3DQ_18_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -46958000 </us-gaap:OperatingIncomeLoss>
<us-gaap:InterestIncomeExpenseNet contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_fmnqczcCZUKHbdoY_DVsFw_20_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 866000 </us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_fxwJtvXSu0yNcZma8_8KrQ_20_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1062000 </us-gaap:InterestIncomeExpenseNet>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_lhFfqnkMkkKOuNSL61YPWw_21_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1255000 </us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_2a-ZgJWb3EW5yclcQH24ag_21_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 817000 </us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_6UNOaVyuhUKrl9qNfDHLog_22_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4322000 </us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
<us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_jVz7RANXREapxhtcPdsKdg_22_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -288000 </us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
<us-gaap:OtherNonoperatingIncome contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_MV7HMTFqXUi53Ww4nxhvwA_23_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 82000 </us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_5i80sbbGTUy7CKRqbP9vaw_23_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5000 </us-gaap:OtherNonoperatingIncome>
<us-gaap:ProfitLoss contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_BKAEnbe9aUOzeh15RlOPfw_24_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -47511000 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_7UdOvSgktk-mufytyb4Txw_24_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -45362000 </us-gaap:ProfitLoss>
<us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_vIsdswyRf0amQUQ3IXdG7w_25_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -918000 </us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_5nGv8CyWvE21JtWF73cjNA_25_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -395000 </us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
<casi:RedeemableNoncontrollingInterestAccretionToRedemptionValueAdjustment contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_PRlug6lHAkWgYIeyUp24VA_26_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1694000 </casi:RedeemableNoncontrollingInterestAccretionToRedemptionValueAdjustment>
<casi:RedeemableNoncontrollingInterestAccretionToRedemptionValueAdjustment contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_AX00FZaZO0agZIUs9sfOQA_26_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1065000 </casi:RedeemableNoncontrollingInterestAccretionToRedemptionValueAdjustment>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_j5lr9SMkZkmtHt-yyWkVTA_27_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -48287000 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_J53IRGDgSE6IfkGdFu0Tjw_27_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -46032000 </us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="2" id="Tc_gTFTUVAH10O60pFaBoPJag_29_3" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> -0.44 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="2" id="Tc_5mHruIl4n026ompwrsEuKg_29_6" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> -0.48 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_ELEyEahaA0eyXQFMjfKirw_30_3" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 110452000 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_MUdiHeE5CUOLH6ceOKTOpw_30_6" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 95948000 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:ProfitLoss contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_O3BcGFWiIE6XWeUp9gaeRA_33_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -47511000 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_Aw_wBXkB7UiW4AWkSQInWA_33_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -45362000 </us-gaap:ProfitLoss>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_UB18BFhIQ0qvlfX8_TBHaw_34_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3904000 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_yIggwVMHi0a62A3yOvnWGg_34_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1501000 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_8G5ax6-eTEe4kVjeDx-x9w_35_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -43607000 </us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_rE92FFA4x0OHdJbmWFnGuw_35_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -46863000 </us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_waY1ZgMoek-zTzSjek6Nag_36_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -331000 </us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_C281gLGbjkSxnBiybl3_Cg_36_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -395000 </us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_uDR8T263j0Gqc8G720Fldg_37_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -43276000 </us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_Va1OGOJzmkW4-R7ci2uD9g_37_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -46468000 </us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:SharesOutstanding contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fjUBs4x_eEma0c3Hl5peKA" decimals="0" id="Tc_kkKs-cV6AEKLuCjsp7K6XQ_5_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fjUBs4x_eEma0c3Hl5peKA" decimals="-3" id="Tc_Jzc_Hn1pYEKJJcrV25PeEg_5_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h-9QH2tGWUqbCNzSM986lw" decimals="INF" id="Tc_mf6lvCGAHkOnwVtM5Gj2nA_5_7" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 95287268 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h-9QH2tGWUqbCNzSM986lw" decimals="-3" id="Tc_qOAfMQ3T_EOKSePZbOo-ew_5_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 954000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMBo-r9IZk62VY__A2XDLQ" decimals="-3" id="Tc_XrENh1U_LEChNAWf5XLdlA_5_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 596712000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_h7AbZfVPi0KLEXVIcGf2yQ" decimals="-3" id="Tc_XdSlHU7saUCWHLMfIfC1Tg_5_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -8034000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PIobnPqO1E-UYo1iBTa15Q" decimals="-3" id="Tc_yC5LskkkM0O46Wa8MvIPJQ_5_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1227000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PPxklFVxW0-XGwmnZgPOxA" decimals="-3" id="Tc_DW7iXRCojkmQU6Fo5ONoGw_5_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -478941000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_Qx1IVz1wIUe3rkaVNstInA" decimals="-3" id="Tc_RS1_P8tLpEGLO9jij68g4Q_5_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 109464000 </us-gaap:StockholdersEquity>
<casi:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="0" id="Tc_rvE6l2_OokS0bh1jp-54EA_6_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </casi:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc__XliWNE6TU2-CF5bZv81BQ_6_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="INF" id="Tc_QPTc6qAXOUCzn_dT8toO6w_6_7" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 2425526 </casi:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc_QO9RYx6rgkibMxAO780_KA_6_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 24000 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nWCyZcE68kGUN85-TCFT-g" decimals="-3" id="Tc_Z06A7OXFtk-ZTU5yf4xMTg_6_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4105000 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_EooCdr7S7UW9iW2nRmw1uQ" decimals="-3" id="Tc_DId7kzuBKEq5peIRcSUQSQ_6_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_j-hxpPIRw0SoL7Ys8QOo5g" decimals="-3" id="Tc_TDAIFlkRVUSi-5zIHBO3xw_6_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9v4eOavRwUGUQp4vvD_aJA" decimals="-3" id="Tc_0bJqPUdao0CWOMR0g4DVZw_6_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_kCpMaxNVTUG7kVkeb6XgxA_6_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4129000 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_fiq2aUeJOUWOJxHn35tZjg_7_2" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_tuHCq4AIxEGLJfCQycit3w_7_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc_GZJdo6HymEm_AfxmRjeDGw_7_7" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc_hRljeMDnDECQstz8sjUVXw_7_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nWCyZcE68kGUN85-TCFT-g" decimals="-3" id="Tc_Cu6AN_JDVkK-a60vN20hcA_7_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -367000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_EooCdr7S7UW9iW2nRmw1uQ" decimals="-3" id="Tc_gy_80hYLkU-qgzR4sCRRRA_7_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_j-hxpPIRw0SoL7Ys8QOo5g" decimals="-3" id="Tc_2Jb3buJKE0WwTqHXwXs8BA_7_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9v4eOavRwUGUQp4vvD_aJA" decimals="-3" id="Tc_KexEevSRW0G2EReoovwXHA_7_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_abFL36WtzkWCLQmv26A6XQ_7_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -367000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<casi:StockIssuedDuringPeriodSharesCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_a3hj8nu6CkmHQdS4SFEPWA_8_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </casi:StockIssuedDuringPeriodSharesCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_udzr96SqK06Qg2CG_knp1w_8_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodSharesCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="INF" id="Tc_LEFUcQcqDUOm-hK0-KB-rA_8_7" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 58904 </casi:StockIssuedDuringPeriodSharesCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc_2K0KrSk3XEWDAXPJupF6BA_8_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1000 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nWCyZcE68kGUN85-TCFT-g" decimals="-3" id="Tc_GMlKmCeu606LHCMCXEuoIA_8_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 181000 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_EooCdr7S7UW9iW2nRmw1uQ" decimals="-3" id="Tc_Rb2lUD3AqEqz2_6kfZi_pw_8_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_j-hxpPIRw0SoL7Ys8QOo5g" decimals="-3" id="Tc_kMZ2o6dKLEuf48fupLvCsA_8_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9v4eOavRwUGUQp4vvD_aJA" decimals="-3" id="Tc_u-WKmK-HCUeILurX2oIotA_8_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_YDjyP5NfbU6qRgYhw7KbKg_8_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 182000 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_gZ0N3F646kC0PwGwY3EEew_9_2" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_piWqjlCBLkij9sttuYO_wQ_9_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc_aacKvt-0TEafwnOrWaaDDg_9_7" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc__s4vbisDVE-7HUuYGS07lA_9_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nWCyZcE68kGUN85-TCFT-g" decimals="-3" id="Tc_dV4Blu_6IE6L7imOW3424g_9_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 190000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_EooCdr7S7UW9iW2nRmw1uQ" decimals="-3" id="Tc_P_9z3MuEYUmdbP5vegCbfQ_9_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_j-hxpPIRw0SoL7Ys8QOo5g" decimals="-3" id="Tc_yOFBhx84jU2z_OHeB5twvQ_9_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9v4eOavRwUGUQp4vvD_aJA" decimals="-3" id="Tc_IZe-lNNRaEmAKMxnQNV39Q_9_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_PhPHJ2HwDUmbhDY8Ovk4RQ_9_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 190000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_QlG9qKofuEyWkXTBCq_PdQ_10_2" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_qmuZSNxJCECBmyC9YjZlag_10_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc_aUayl6iL4EiM3yjiWGZZvw_10_7" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc_NB-JGH9keEmqu69V1YulLQ_10_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nWCyZcE68kGUN85-TCFT-g" decimals="-3" id="Tc_b88WC8m8PE6jnkIrCoK6yA_10_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7310000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_EooCdr7S7UW9iW2nRmw1uQ" decimals="-3" id="Tc_TUrxNLsOH0mFF9tfu5yp5Q_10_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_j-hxpPIRw0SoL7Ys8QOo5g" decimals="-3" id="Tc_ebBxXoK1Ik2JJrN2TaDIMA_10_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9v4eOavRwUGUQp4vvD_aJA" decimals="-3" id="Tc_Y6qCimgPl0aqGuanYdlsvg_10_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_YizUDMc48kW7d50zZPNAlg_10_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7310000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_hB9G9A0c-E2zrJLNbNqX_w_11_2" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_2lWNPA3C3EOS6CyZNVyVsw_11_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc_x_wBy9-NcEqCtJgTF-ICKQ_11_7" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc_nPc5Q7YE402eOzqQXDm5KQ_11_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_EooCdr7S7UW9iW2nRmw1uQ" decimals="-3" id="Tc_g4gD69LJ-EWElysODPxD-w_11_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_j-hxpPIRw0SoL7Ys8QOo5g" decimals="-3" id="Tc_Q-3OC5XBYUu-myOBz0irjQ_11_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1501000 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9v4eOavRwUGUQp4vvD_aJA" decimals="-3" id="Tc_mnsCoGZxSEOeqhhpletRKA_11_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_OEIvTwpkPE-imJFAGOAJUw_11_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1501000 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_RPnREh7tT0mWX6L4FlI-bA_12_2" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IohyrzXteU-zMRpOyaaCTQ" decimals="-3" id="Tc_QN7gCLllZ0ut5qEOnYr1Vw_12_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc_BBEzZS0fuEqWS-UzZbJSHQ_12_7" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KlCrnbPJEiJseQY9_IopQ" decimals="-3" id="Tc_YYoW72WgHU-GLq2lNyQirQ_12_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nWCyZcE68kGUN85-TCFT-g" decimals="-3" id="Tc_pSJNgsfLXU65oMA2IESlFA_12_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1065000 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_EooCdr7S7UW9iW2nRmw1uQ" decimals="-3" id="Tc_Or9Lx7TPPEmls7qHq97K-A_12_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_j-hxpPIRw0SoL7Ys8QOo5g" decimals="-3" id="Tc_L4eWh_Rt9EK8gFtanARLSQ_12_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9v4eOavRwUGUQp4vvD_aJA" decimals="-3" id="Tc_Q7up-uhOrkCOxglGbh5M-Q_12_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -44967000 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_brYZnF02gk-Be4X7UTO7zQ_12_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -46032000 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i3su9UE7w0i61_jHP_SDkw" decimals="0" id="Tc_cTU_5GiabE6QWLFqlks6Rw_13_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i3su9UE7w0i61_jHP_SDkw" decimals="-3" id="Tc_pzrgFWppHEep89V0R8JrIg_13_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zBWx11Wy60i0joMyW4w0ZA" decimals="INF" id="Tc_qgtChl5050CsTik73lxXYA_13_7" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 97771698 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zBWx11Wy60i0joMyW4w0ZA" decimals="-3" id="Tc_f0c8Z51jikytxdvGgbbXzQ_13_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 979000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2U42mnIOp02K0fazELv7fg" decimals="-3" id="Tc_tshj774ICUCkLoPvkxE8XA_13_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 606686000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_w5zJosFugU293jyf1aObwA" decimals="-3" id="Tc_vWAF9nnX4E-Aw9yfm8AtoQ_13_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -8034000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_h3-0NAK9Z0mz2AXbUBvUlg" decimals="-3" id="Tc_U27biJQUCUCRynltzx4y0A_13_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -2728000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kFT36rjDSkKNER6SX1b8rA" decimals="-3" id="Tc_6dGZLEdCTk669cFRAZ7nPg_13_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -523908000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_AKJFyQ9S-0iLjp5rq0FTuw_13_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 72995000 </us-gaap:StockholdersEquity>
<casi:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="0" id="Tc_k9EZdakN7UGDAk0KsVRLmw_14_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </casi:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_1LhO3Ec89kekcSRwkVm8Ww_14_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="INF" id="Tc_tkoT3nWLt0eTvzlIUDmIzw_14_7" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 2737795 </casi:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc_Bd8uBsE-Q0iQPjxzx8_k2w_14_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 27000 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sVsrchdFGUmAmLH3wuyN7A" decimals="-3" id="Tc_e7bUIiGT2EuQ81ZlF_Wt6Q_14_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3847000 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_3spZIRCGiUmHPyyMxl3SFA" decimals="-3" id="Tc_fb_CKvgwxEW-k41WvLCsjQ_14_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember__NxDDjX1fk62PxcK16t5OQ" decimals="-3" id="Tc_otlw4mM5jUy0XHKm9-1kEA_14_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTXlXOguF0WRCe03oj2yVw" decimals="-3" id="Tc_kq1dh_ilfkWhYuthzcwh1A_14_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_W6dGwTqMSkOgzKqXI4TKQA_14_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3874000 </casi:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_Jl6nK5ixAEuaxlZ0eh8IXA_15_2" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_TnvfloylvUqkzo7zEHggtg_15_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc_IES5emUxckSZdvPnWM4UfQ_15_7" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc__oQbGmrEXEq3dNr86wTPWg_15_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sVsrchdFGUmAmLH3wuyN7A" decimals="-3" id="Tc_2x-GDsgl2Ueu9OvvVbY-wA_15_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -251000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_3spZIRCGiUmHPyyMxl3SFA" decimals="-3" id="Tc_4s9LiKFv6kCc7MhFKUSP8Q_15_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember__NxDDjX1fk62PxcK16t5OQ" decimals="-3" id="Tc_vl9MCODmoUeBKtjqYiWRCQ_15_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTXlXOguF0WRCe03oj2yVw" decimals="-3" id="Tc_Yl3hhaMCYkWCdHtub9r1UQ_15_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_At0e76zYyUiHGNobstpRFQ_15_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -251000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<casi:StockIssuedDuringPeriodSharesCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="0" id="Tc_bngzK4sUE0-0orxUaoeRXg_16_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </casi:StockIssuedDuringPeriodSharesCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_ImpLLvdZfEylHie-fgp9_g_16_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodSharesCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="INF" id="Tc_VZhdNJ24JEO4jS6gAoQ-TA_16_7" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 23434336 </casi:StockIssuedDuringPeriodSharesCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc_6vYhWFkpzkO1MEse61AN6A_16_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 234000 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sVsrchdFGUmAmLH3wuyN7A" decimals="-3" id="Tc_doKOFUs-YEaRXEZB9lUg7A_16_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 44865000 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_3spZIRCGiUmHPyyMxl3SFA" decimals="-3" id="Tc_wuO5O7f2oEKDCPc_nDfJXw_16_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember__NxDDjX1fk62PxcK16t5OQ" decimals="-3" id="Tc_YTdwNsqL2kynvbhm6rAE3g_16_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTXlXOguF0WRCe03oj2yVw" decimals="-3" id="Tc_GvPBJqaPi0yb8OKu8XpBqw_16_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_QxdEq8S8x0eKRvADXqnK3Q_16_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 45099000 </casi:StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_NcSra1h-ukmWOUEBJa4ltg_17_2" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_aStBdtEou0-AcYq9o2L9nQ_17_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc_o0TCnnpHNk-xzZxjDIlbmw_17_7" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc_5AqojcTIAEq0pphGGe05Ow_17_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sVsrchdFGUmAmLH3wuyN7A" decimals="-3" id="Tc_8RhIn_63J0a2zav8qCRS-w_17_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3028000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_3spZIRCGiUmHPyyMxl3SFA" decimals="-3" id="Tc_nLOdDIHLCEO7u4GCXuggJQ_17_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember__NxDDjX1fk62PxcK16t5OQ" decimals="-3" id="Tc_r62piXw2PEKekL0X1RAMbA_17_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTXlXOguF0WRCe03oj2yVw" decimals="-3" id="Tc_QSxhQ091N0eKuWuBnGC9hg_17_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_dVzN3PCNaEabQLZrRKZBzg_17_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3028000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_IWOCbevZXkGwFcORDTgAsw_18_2" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_nw0qLmxw2ka8JlEuKsH-ZA_18_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc_Tf7NihON7EKEWQavtnf5zw_18_7" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc_XB2TYa8QiEmRNgIfRqK1zg_18_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sVsrchdFGUmAmLH3wuyN7A" decimals="-3" id="Tc_Ms4fdQ8qdkSu-93ek8ZOVw_18_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7821000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_3spZIRCGiUmHPyyMxl3SFA" decimals="-3" id="Tc_p61WOoPFL06no__IIlgjgw_18_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember__NxDDjX1fk62PxcK16t5OQ" decimals="-3" id="Tc_0aly8YsZkUyfsAcXFfdbQw_18_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTXlXOguF0WRCe03oj2yVw" decimals="-3" id="Tc_FjFp4JzQ8EaqEKJ3nUyhyw_18_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_xSMzKXSvIEOWP6fb4U4sZA_18_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7821000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_ZLkmm8N-lkiD7ptomBJYKw_19_2" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_SO7_lB_BpUa1_GA9ve3zLw_19_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc_8b-EJIf_PEG0Dv24K3XAFQ_19_7" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc_9HkmQKPCNE6bCuAuLwecUw_19_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_3spZIRCGiUmHPyyMxl3SFA" decimals="-3" id="Tc_Vg9NLPa7PE-ePzEEzczgsg_19_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember__NxDDjX1fk62PxcK16t5OQ" decimals="-3" id="Tc_SLGwAF1vS06vJ_zpGGvYqA_19_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -3317000 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTXlXOguF0WRCe03oj2yVw" decimals="-3" id="Tc_vsqrqBfM1ES0Pj2KMcQjuA_19_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_1nGSLPpJIEWURGYX8S88qQ_19_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -3317000 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_aWVVyEY5wkSCGRziXvjOrQ_20_2" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_p9UuMVbgkUaF98k3Ne7BeQ" decimals="-3" id="Tc_A4ef8tk0JEmrqlybdb8zOQ_20_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc_qU7sAQP1nkuVLaYCC2n4dw_20_7" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-Z3s7cUAAECCENYmPJS9ng" decimals="-3" id="Tc_vrVEoTr1HESvuR7pkXEpng_20_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sVsrchdFGUmAmLH3wuyN7A" decimals="-3" id="Tc_o4GL8R_EMEuesOgvIzg1Rw_20_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1694000 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_3spZIRCGiUmHPyyMxl3SFA" decimals="-3" id="Tc_fp6kd7IY506GNK8Y_W0Yvw_20_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember__NxDDjX1fk62PxcK16t5OQ" decimals="-3" id="Tc_jbl5soJ9QEKNfGaZpLeM_A_20_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JTXlXOguF0WRCe03oj2yVw" decimals="-3" id="Tc__OAF_0USAUqh2wAdxFvINg_20_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -46593000 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_SZT7hOCiPUuSQ8f0xOaDag_20_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -48287000 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YtFsVj02rkmkMAyyUgI0IA" decimals="-3" id="Tc_0u7jcBjfrE2-bA6dirf00g_21_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YtFsVj02rkmkMAyyUgI0IA" decimals="-3" id="Tc_2CJ2j2n1WU-U9MSFWD2gdQ_21_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aq6dyGNJ0UqFkXfLsv0A2g" decimals="INF" id="Tc_5lbS4Uchw0GtmjzHZ59B1A_21_7" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 123943829 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aq6dyGNJ0UqFkXfLsv0A2g" decimals="-3" id="Tc_p2FXO-Kb0UeA7ndj2H1b0Q_21_10" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1240000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0lW_GWG8UEqJN4q0M1MYng" decimals="-3" id="Tc_Ao5IVCFB2kiXZVl6XzIpRQ_21_13" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 658246000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_SZppL-HxnkeSRbfcJFngcQ" decimals="-3" id="Tc_m5JPinmPSEW0QUjKGUrW3A_21_16" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -8034000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aBOEG7xMi0uzQi15BKVVUA" decimals="-3" id="Tc_Iui-G42s1UyRsrhkJmh-FA_21_19" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 589000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aJRR-E8ZokW_bhR9AbaoVw" decimals="-3" id="Tc_8XYXGFqZEE6p8Ealh8AqjA_21_22" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -570501000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_t4OslXJ3x0qxqxps4Yq67w_21_25" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 81540000 </us-gaap:StockholdersEquity>
<us-gaap:ProfitLoss contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_vQJVrJ9nG0eKCbH667eZvg_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -47511000 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_u2mk2sp2pEW6oeSI7nzo4Q_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -45362000 </us-gaap:ProfitLoss>
<us-gaap:DepreciationAndAmortization contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_L4yonn8SHUOqfDCQwTXiJg_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 562000 </us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_ojMvmtYruEeHkbtdIlOxIQ_6_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 603000 </us-gaap:DepreciationAndAmortization>
<us-gaap:GainLossOnDispositionOfAssets contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_xHE7BPq9Z0egKkz8AUMWMg_7_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:GainLossOnDispositionOfAssets>
<us-gaap:GainLossOnDispositionOfAssets contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_0hUCamN0xE6ogiDVXH_FOA_7_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -2000 </us-gaap:GainLossOnDispositionOfAssets>
<casi:AmortizationOfIntangibleAssetsAndHeldForSale contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_e4hX03Vi50efw55QWup2Hg_8_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1397000 </casi:AmortizationOfIntangibleAssetsAndHeldForSale>
<casi:AmortizationOfIntangibleAssetsAndHeldForSale contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_ZSwaLzfm3EeOEExFqm-lag_8_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1550000 </casi:AmortizationOfIntangibleAssetsAndHeldForSale>
<casi:ReductionInCarryingAmountOfRightOfUseAssets contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_zLMUfisPDU2e3poDrJ9B4g_9_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1272000 </casi:ReductionInCarryingAmountOfRightOfUseAssets>
<casi:ReductionInCarryingAmountOfRightOfUseAssets contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_BzE9pZKdM0aiwHAOE6JnPA_9_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 424000 </casi:ReductionInCarryingAmountOfRightOfUseAssets>
<us-gaap:InventoryWriteDown contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_Ku2Pk8DSEkqruC1whS633g_10_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:InventoryWriteDown>
<us-gaap:InventoryWriteDown contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_kKCwg_JaY0Ch7IIxtPALbw_10_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 152000 </us-gaap:InventoryWriteDown>
<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_9YYvPv34YEGPuHR1d5XKfg_11_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1152000 </us-gaap:GainLossOnDispositionOfIntangibleAssets>
<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_8JNuTTyl40-dIDuM44ymkw_11_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -408000 </us-gaap:GainLossOnDispositionOfIntangibleAssets>
<us-gaap:TangibleAssetImpairmentCharges contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_VS6_YJk3gUmpxJcDnovxqA_12_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:TangibleAssetImpairmentCharges>
<us-gaap:TangibleAssetImpairmentCharges contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_B7G3dAYHOkag9r2BEp0OyA_12_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 386000 </us-gaap:TangibleAssetImpairmentCharges>
<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_HPEoFT8mQk-FmQ0ynBazNw_13_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1537000 </us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_kVBFSbA6KUyZQtOEzAKmwQ_13_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
<us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_k0t5D-P9p0WnjNhWU2NO4g_14_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7821000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_rAHAMHlPEE-qwLcPLnUwgA_14_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7310000 </us-gaap:ShareBasedCompensation>
<casi:ResearchAndDevelopmentInProcessAcquired contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_Cof4rpSljkOioQCCcP2mGA_15_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 17828000 </casi:ResearchAndDevelopmentInProcessAcquired>
<casi:ResearchAndDevelopmentInProcessAcquired contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_crSn0nzHLEatqsnV9_g6IA_15_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6967000 </casi:ResearchAndDevelopmentInProcessAcquired>
<us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc__5bK-8FtA0KypeJE08FsLg_16_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4322000 </us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
<us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_g_bzAYDVfkOGqaQvFwd0sw_16_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -288000 </us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
<us-gaap:PaidInKindInterest contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_xgW-BVtiU0a1JRxsERiDKA_17_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:PaidInKindInterest>
<us-gaap:PaidInKindInterest contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_HdFknnsFr0SJmT_1YB0w8g_17_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1000 </us-gaap:PaidInKindInterest>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_c3GTYgAPr0Sz0KegrRWc9w_19_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3352000 </us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_QLKGlP2EsUWbEnrA5whYyQ_19_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1293000 </us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInInventories contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_RRX2aHdQPkiwyV3niOoDiA_20_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -3186000 </us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_si6jKKiKe0m6JDO60xgWlQ_20_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4411000 </us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_Ze1svOIqmkuUL4E8vtqnqw_21_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 184000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_Ge1r49v7GUWqcUmaxLUFtA_21_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -5751000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_o2F-pn9YskitXFJwLgaPjw_22_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1540000 </us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_b6Ephx_RPEiL166D2t02tA_22_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4001000 </us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_CHcszvon2EST_E9ENKRR0A_23_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_pXebD5h_v0yStpsxRYDS6g_23_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 153000 </us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_4vd4vWqv00qFTxkGaWjCkw_24_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1393000 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_5GPjza6E1keWXPa5LDAa9A_24_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -173000 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_L0sYZ31REUu0Oj6uYiDImw_25_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -35000 </us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_iHsQa4v-8kqrdvBDvlSI-Q_25_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_GQmPE1ZhT0iQ-7lWyMfRkw_26_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -25886000 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_nuEp5g_aIEyo2fD39F2xeg_26_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -23243000 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_NVD_BmO5DUeTypoi_o2Wag_29_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2700000 </us-gaap:ProceedsFromSaleOfIntangibleAssets>
<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_A0VUDHjizkuuXa9jak4UhQ_29_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:ProceedsFromSaleOfIntangibleAssets>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_NfMnsLFujECRV1kgL2qpOQ_30_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1499000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_pTcLff_00ESnjHuJHYuFAA_30_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 427000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<casi:PaymentToAcquireLandUseRights contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_kiTBGh641EqnFLNS4ln_Cw_31_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:PaymentToAcquireLandUseRights>
<casi:PaymentToAcquireLandUseRights contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_VSLEZlSpJ0CInsEWrfawWA_31_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6626000 </casi:PaymentToAcquireLandUseRights>
<us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_ZV0lCsQ_YUWx99I7prlZaw_32_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 10033000 </us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
<us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_TEieXKkLvEOAUzqasUgWFQ_32_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
<us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_MCwMFSt7aUKRilSBsHlZXg_33_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 10033000 </us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
<us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_QlOyn3jPXUSuVtHT9ReTxg_33_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_ZuStC1T5zE2fXvKwmr8Vng_34_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 17828000 </us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_LRGV-RXhBEWxQtdwDaS_OQ_34_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6967000 </us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
<us-gaap:PaymentsToAcquireInvestments contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_casi_BlackBeltTxLimitedMember_VS4mLhYQkEK-24qXg_iocg" decimals="-3" id="Tc_1UQKjdmRVEal46l0I-io7w_35_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 83000 </us-gaap:PaymentsToAcquireInvestments>
<us-gaap:PaymentsToAcquireInvestments contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_casi_BlackBeltTxLimitedMember_N1DkVcLcfU6EGh4lrjqwXQ" decimals="-3" id="Tc_8kTs9PAIekCZQwPrGiTRTg_35_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2250000 </us-gaap:PaymentsToAcquireInvestments>
<us-gaap:PaymentsToAcquireInvestments contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_casi_JuventasCellTherapyLtdMember_MCcbO8_0-kCT1l5Yw081aw" decimals="-3" id="Tc_OfVjXYta5Umyd-n0HeLLJw_36_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:PaymentsToAcquireInvestments>
<us-gaap:PaymentsToAcquireInvestments contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_casi_JuventasCellTherapyLtdMember_SUoa4o6J8UW4Bo7q6VoBSA" decimals="-3" id="Tc_WJkSlWwN1EK5CDdbjuIaWA_36_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 11788000 </us-gaap:PaymentsToAcquireInvestments>
<us-gaap:PaymentsToAcquireInvestments contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_casi_BioinventInternationalAbMember_uDKy_-S9-ESVayoQKVnGEg" decimals="-3" id="Tc_7ysaQQao50SFwcvAgfR8_g_37_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6318000 </us-gaap:PaymentsToAcquireInvestments>
<us-gaap:PaymentsToAcquireInvestments contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_casi_BioinventInternationalAbMember_YqQgtqDDpUC-sOnD3uMw7g" decimals="-3" id="Tc_s3ClX5i-EEiekR3sxuDb6Q_37_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:PaymentsToAcquireInvestments>
<casi:ReceiptOfGovernmentGrant contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_o6eKpSpCtkWNp4ZFGTkdeQ_38_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2309000 </casi:ReceiptOfGovernmentGrant>
<casi:ReceiptOfGovernmentGrant contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_6wo4RxD4qkqJD_5NLGCzUw_38_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:ReceiptOfGovernmentGrant>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_ncuAOXQNskm-n3z1dY-CAA_39_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -20719000 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_Lep57P_k50OuFxnPPpMdQw_39_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -28058000 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromNotesPayable contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_mq-PmOUeREqhucEb1Fr50A_42_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 466000 </us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromNotesPayable contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_P_lze43w90GALpYoTKU4LQ_42_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromLinesOfCredit contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_ni-LmInkwke4wpbk4yDyUA_43_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 783000 </us-gaap:ProceedsFromLinesOfCredit>
<us-gaap:ProceedsFromLinesOfCredit contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_amyUlJaT5E-g7FLJoJW8Ig_43_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:ProceedsFromLinesOfCredit>
<us-gaap:RepaymentsOfNotesPayable contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_htXxd6fci0OF1bkbFx1YbA_44_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_oytUtnDKNECW-jBRi7yr9A_44_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1500000 </us-gaap:RepaymentsOfNotesPayable>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_YJy04xKyS06obnlHzMwG8g_45_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2818000 </us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_PwCbMWBMT0uDK1fRUSnTqg_45_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 190000 </us-gaap:PaymentsOfStockIssuanceCosts>
<casi:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_RmZojsJPfUue3uYI9p-v4Q_46_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 45099000 </casi:ProceedsFromIssuanceOfCommonStockAndWarrants>
<casi:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_vKoOqZuyh0uZImBr8cKoFQ_46_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 182000 </casi:ProceedsFromIssuanceOfCommonStockAndWarrants>
<us-gaap:ProceedsFromMinorityShareholders contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_1cyNt7puDUaZcS73jkLcLg_47_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:ProceedsFromMinorityShareholders>
<us-gaap:ProceedsFromMinorityShareholders contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_YmTMkRk_oUGRvbFBhcVMsA_47_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 20000000 </us-gaap:ProceedsFromMinorityShareholders>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_ngHTvcr5WUaoc3glpgsDog_48_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3874000 </us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_M0nclLJS_UaS-KrbhVzsNw_48_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 854000 </us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_6S8KZlLQfU-YLjg7xnPgjA_49_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 251000 </us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_RRTHy5rImE-gbkVWCjIcYw_49_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 367000 </us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:ProceedsFromWarrantExercises contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_B4YuQ89-HEGTLd8-OI3Rrw_50_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_3oDQPhS88065DeJYXZje4w_50_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3275000 </us-gaap:ProceedsFromWarrantExercises>
<casi:PaymentOfDeferredOfferingCosts contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_ZrCeSREU1EGDNftu3B7dcQ_51_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:PaymentOfDeferredOfferingCosts>
<casi:PaymentOfDeferredOfferingCosts contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_5l6a8rMgrkeLFp7dHC2JXQ_51_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 209000 </casi:PaymentOfDeferredOfferingCosts>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_nXrqYpuIxEWOtLgGDF6-MQ_52_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 47153000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_vwUqGHGCNUyoPW2LofTuLw_52_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 22045000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_4BNZzQb1_kuVbOmkUTRzcA_54_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2895000 </us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_BhznmbFREkOBGBClYUt1sg_54_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1328000 </us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_KVyCxfAuUEStDbhr75lXVw_55_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3443000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_60ihuvyWEUCEcwYFBXe9TA_55_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -30584000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_fW3c5mclQU6qn_3tNcaEog_57_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 53621000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="As_Of_12_31_2018_Qx1IVz1wIUe3rkaVNstInA" decimals="-3" id="Tc_YUhXcODvRkmh2hgZlbbuuw_57_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 84205000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_RcL-piYJzkqPexUfr3PnHg_58_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 57064000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_jOsZb5LfJkKdVN8VsD-0tw_58_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 53621000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:InterestPaidNet contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_7YJEBa45ikibtUEqlLQChA_61_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_anaxIrcO_EqutvrfkP10rQ_61_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 30000 </us-gaap:InterestPaidNet>
<us-gaap:IncomeTaxesPaidNet contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_UHPSWQvGO02e10zCfIBQmQ_62_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:IncomeTaxesPaidNet>
<us-gaap:IncomeTaxesPaidNet contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_rf66hVQO0kKIsJhq26uWTA_62_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:IncomeTaxesPaidNet>
<us-gaap:BasisOfAccounting contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_eH95HvGXDEOJSaGzkWXrAA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">CASI Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Notes to Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">December 31, 2020 and 2019</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.      DESCRIPTION OF BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CASI Pharmaceuticals, Inc. (“CASI” or the “Company”) (Nasdaq: CASI) is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market leveraging its China-based regulatory, clinical and commercial competencies and its global drug development expertise.  The Company’s operations in China are conducted primarily through two of its subsidiaries: (i) CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is wholly owned and is located in Beijing, China, and (ii) CASI Pharmaceuticals (Wuxi) Co., Ltd. (“CASI Wuxi”), which is located in Wuxi, China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company launched in China the Company’s first commercial product, EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (Melphalan for Injection) in August 2019. In China EVOMELA is approved for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The Company’s other core hematology/oncology assets in the Company’s pipeline include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">CNCT19</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> is an autologous CD19 CAR-T investigative product (CNCT19) being developed by the Company’s partner Juventas Cell Therapy Ltd (“Juventas”) for which the Company has co-commercial and profit-sharing rights.   CNCT19 is being developed as a potential treatment for patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia (“B-ALL”) and B-cell non-Hodgkin lymphoma (“B-NHL”).  China Phase 1 studies have been substantially completed by Juventas, with the Phase 2 B-NHL registration study in China currently enrolling.   The Phase 2 B-ALL registration study is expected to start by the end of March 2021.</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;"> </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> In December 2020, Juventas received a breakthrough therapy designation for CNCT19 in the treatment of adults with relapsed/refractory B-ALL from the Chinese Center for Drug Evaluation, a division of the China National Medical Products Administration.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">BI-1206</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> is an antibody which has a novel mode-of-action, blocking the inhibitory antibody checkpoint receptor FcγRIIB to unlock anti-cancer immunity in both hematological malignancies and solid tumors for which the Company has exclusive greater China rights BI-1206 is being investigated in a Phase 1/2 trial, in combination with anti-PD1 therapy Keytruda® (pembrolizumab), in solid tumors, and in a Phase 1/2a trial in combination with MabThera® (rituximab) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). BioInvent International AB, released positive interim results from its Phase 1/2a trial that suggests that novel anti-FcyRIIB antibody BI-1206 restores activity of rituximab in patients with relapsed/refractory non-Hodgkin’s lymphoma. An FDA End of Phase 1 meeting for the NHL development program is planned for the third quarter of 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">CB-5339</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> is a novel VCP/p97 inhibitor, in mainland China, Taiwan, Hong Kong and Macau. Cleave is a clinical-stage biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response and other cellular stress pathways for therapeutic use in cancer.  CB-5339, an oral second-generation, small molecule VCP/p97 inhibitor, is being evaluated in a Phase 1 clinical trial in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), while the National Cancer Institute (NCI) is sponsoring and evaluating CB-5339 in a Phase 1 clinical trial of patients with solid tumors and lymphomas.  The Company entered into an exclusive license with Cleave Therapeutics, Inc. (Cleave”) for the development and commercialization of CB-5339 in March 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">CID-103</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> is a full human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that has demonstrated encouraging preclinical efficacy & safety profile compared to other anti-CD38 monoclonal antibodies for which the Company has exclusive global rights.  CID-103 is being developed for the treatment of patients with multiple myeloma.  The CID-103 Phase 1 study in EU was initiated in March 2021.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Other assets in the Company’s pipeline for which the Company has exclusive rights in China are Octreotide Long Acting Injectable (“LAI”), for which the Company plan to begin the China registration study in 2021, and a novel formulation of Thiotepa, for which the Company’s partner plans to begin the China registration study in 2021.  Thiotepa is used as a conditioning treatment for certain allogeneic haemopoietic stem cell transplants.  Subject to regulatory and marketing approvals, the Company intends to advance and commercialize these established products in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company’s assets include a few FDA-approved ANDAs which the Company is evaluating due to generic drug pricing reforms by the Chinese government and its impact on the pricing and competitiveness of these products.  The Company also has greater China rights to ZEVALIN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (Ibritumomab Tiuxetan), a CD20-directed radiotherapeutic antibody that is approved in the U.S. to treat patients with non-Hodgkin lymphoma (“NHL”) and MARQIBO<sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">®</sup><i style="font-style:italic;"> </i>(vincristine sulfate LIPOSOME injection) a novel, sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.  However, due to the evolving standard of care environment, the rare and niche indication for these products, and the Company’s commitment to prioritize resources, the Company is currently evaluating its options for these products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company’s business development strategy is currently focused on acquiring additional targeted drugs and immuno-oncology therapeutics through licensing that will expand its hematology-oncology franchise. In many cases its business development strategy includes direct equity investments in the licensor company.  The Company intends for its pipeline to reflect a diversified and risk-balanced set of assets that include (1) late-stage clinical drug candidates in-licensed for China regional rights, (2) proprietary or licensed innovative drug candidates, and (3) select high quality pharmaceuticals that fit its therapeutic focus. The Company uses a market-oriented approach to identify pharmaceutical/biotechnology candidates that the Company believes to have the potential for gaining widespread market acceptance, either globally or in China, and for which development can be accelerated under the Company’s global drug development strategy. Although oncology with a focus on hematological malignancies is its principal clinical and commercial target, The Company is opportunistic about other therapeutic areas that can address unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the second quarter 2020, the Company completed a plan to change the manufacturing site for EVOMELA to an alternative manufacturer that significantly reduced the cost of revenue since the third quarter of 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the long-term strategy to support the Company’s future clinical and commercial manufacturing needs and to manage the Company’s supply chain for certain products, on December 26, 2018, the Company established CASI Pharmaceuticals (Wuxi) Co., Ltd. (“CASI Wuxi”).  In November 2019, CASI Wuxi entered into a fifty-year lease agreement for the right to use state-owned land in China for the construction of a manufacturing facility.  In April 2020, CASI Wuxi received RMB 15.9 million (equivalent to $2.2 million) from the Jiangsu Province Wuxi Huishan Economic Development Zone as government grant for this development project which was recorded as deferred income in April 2020. On August 27, 2020, CASI Wuxi entered into a Construction Project Contract for RMB 74,588,000 (equivalent to $10,923,000) to complete the phase 1 project of CASI Wuxi's research and development production base (see Note 21). The estimated completion date is October 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Certain line items, as disclosed below, in the December 31, 2019 consolidated financial statements have been reclassified to conform to the December 31, 2020 presentation.  Loss on disposal of intangible assets in the amount of $0.4 million for the year ended December 31, 2019, which was previously included in research and development, has been separately presented on the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019. Assets held-for-sale in the amount of $3.2 million as of December 31, 2019, which was previously included in intangible assets, and has  been reclassified as assets held-for-sale and separately presented on the consolidated balance sheet as of December 31, 2019 (see Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Liquidity Risks and Management’s Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Since its inception in 1991, the Company has incurred significant losses from operations and, as of December 31, 2020, has incurred an accumulated deficit of $570.5 million. In 2012, with new leadership, the Company shifted its business strategy to China and has since built an infrastructure in China that includes sales and marketing, medical affairs, regulatory and clinical development and in the foreseeable future, manufacturing. In 2014, the Company changed its name to “CASI Pharmaceuticals, Inc.” The majority of the Company’s operations are now located in China. The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical and development activities and expansion of the Company’s operations. The Company’s operations in China are conducted primarily through two of the Company’s subsidiaries, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”) and CASI Pharmaceuticals (Wuxi) Co., Ltd. (“CASI Wuxi”). The Company’s Beijing office is primarily responsible for the Company’s day-to-day operations and the Company’s commercial team of over 80 hematology and oncology sales and marketing specialists based in China.  CASI Wuxi is part of the long-term strategy to support the Company’s future clinical and commercial manufacturing needs, to manage the Company’s supply chain for certain products, and to develop a GMP manufacturing facility in China.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On July 24, 2020, the Company closed an underwritten public offering of 23 million shares of common stock (the "Offering") and received gross proceeds of $43.7 million before deducting the underwriting discounts and commissions and offering expenses payable by CASI. Certain insiders, including CASI's Chairman and CEO, and CASI's President, purchased shares of common stock in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">the Offering at the public offering price and on the same terms as the other purchasers in this Offering (see Note 12). The Company is using the net proceeds of this Offering for working capital and general corporate purposes, which include, but are not limited to advancing the Company's product portfolio, acquiring the rights to new product candidates and general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On November 20, 2020, the Company filed a Form S-3 registration statement with the SEC utilizing a “shelf” registration process. On December 2020, the Form S-3 registration statement was declared effective by the SEC. Pursuant to this shelf registration statement, the Company may sell debt or equity securities in one or more offerings up to a total public offering price of $150 million. As a result of the Company’s failure to timely file a periodic report with the SEC in connection with the adoption of its amended and restated bylaws, absent a waiver of the Form S-3 eligibility requirements, the Company is ineligible to use or file new short form registration statements on Form S-3 until October 1, 2021, assuming the Company continues to timely file the Company’s required Exchange Act reports. In the interim, however, the Company may raise capital pursuant to a registration statement on Form S-1 or on a private placement basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 24, 2021, the Company closed an underwriting agreement (the “Underwriting Agreement”) <span style="color:#212529;">with Oppenheimer & Co. Inc., as representative of the several underwriters named therein (the “Underwriters”), providing for the offer and sale of </span><span style="color:#212529;">15,853,658</span><span style="color:#212529;"> shares of the Company’s common stock (the “Offering”) at a price to the public of </span><span style="color:#212529;">$2.05</span><span style="color:#212529;"> per share. In addition, the Company granted the Underwriters an option to purchase up to an additional </span><span style="color:#212529;">2,378,048</span><span style="color:#212529;"> shares of common stock, which terminates on the earlier of </span><span style="color:#212529;">30 days</span><span style="color:#212529;"> and the day before the Company files to the Securities and Exchange Commission (“SEC”) the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The Offering closed on March 26, 2021.  The gross proceeds to CASI from the Offering are approximately </span><span style="color:#212529;">$32.5</span><span style="color:#212529;"> million, excluding the over-allotment option and before deducting the underwriting discounts and commissions and offering expenses payable by CASI.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;">Certain insiders, including CASI’s Chairman and Chief Executive Officer, purchased shares of common stock in the Offering at the public offering price and on the same terms as the other purchasers in this Offering. The Company has agreed to pay the underwriters a commission of </span><span style="color:#212529;">1%</span><span style="color:#212529;"> of the gross proceeds raised from certain such insiders, and </span><span style="color:#212529;">6%</span><span style="color:#212529;"> of the gross proceeds raised in the offering from other investors. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;">The Offering is being made by means of a written prospectus supplement and accompanying prospectus forming part of a shelf registration statement on Form S-3 (Registration Statement No. 333-250801), previously filed with the SEC on November 20, 2020, which was declared effective on December 2, 2020. The Company filed a final prospectus supplement, dated March 24, 2021, with the SEC relating to the Offering.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;">Pursuant to the Underwriting Agreement, the Company’s directors and executive officers entered into agreements in substantially the form agreed to by the Underwriters providing for a </span><span style="-sec-ix-hidden:Hidden_BB9kfPn1KEuNbL6aMwD11Q;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">90-day</span></span><span style="color:#212529;"> “lock-up” period with respect to sales of specified securities, subject to certain exceptions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Taking into consideration the cash and cash equivalents as of December 31, 2020, the Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the consolidated financial statements are issued. As of December 31, 2020, the Company had a balance of cash and cash equivalents of $57.1 million of which $4.5 million was held by CASI China, and $19.5 million was held by CASI Wuxi. The Company intends to continue to exercise tight controls over operating expenditures and will continue to pursue opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive capital raising arrangements or opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive capital raising arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;text-decoration:underline;text-decoration-color:#212529;">Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">The Company's business has been and may continue to be adversely affected by the COVID-19 pandemic. In March 2020, the World Health Organization characterized the outbreak of COVID-19 as a pandemic. Due to the evolving and highly uncertain nature of this event, the Company cannot predict at this time the full extent to which the COVID-19 pandemic will adversely impact its business, results and financial condition. The impact will depend on many factors that are not known at this time. These include, among others, the extent of harm to public health, the continued disruption to operations, and the impact of the global business and economic environment on liquidity and the availability of capital.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;">The Company has experienced operational interruptions as a result of COVID-19, including the temporary disruption of operations in China due to a Chinese government mandated quarantine protocol, including mandatory business closures, social distancing measures, and various travel restrictions. Although the Company's operations in China are beginning to normalize, there can be no assurance that such operations will continue to do so or that there will not be a renewed outbreak of COVID-19 due to new variants </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">of the virus or other significant contagious diseases in China or elsewhere. To the extent that such events occur, demand for the Company's products may decline, and the Chinese government or other governments may impose additional restrictions resulting in further shutdowns, further work restrictions, and the disruption of the Company’s supply and distribution channels.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">The COVID-19 pandemic has adversely affected, and may continue to adversely affect, the economies and financial markets of many countries, which may result in a period of regional, national, and global economic slowdown or regional, national, or global recessions that could affect the Company's ability to continue to commercialize and expand distribution of EVOMELA (Melphalan For Injection) or other drugs in the Company’s existing product pipeline. The effectiveness of the Company's sales teams may be negatively impacted by the lack of travel and their reduced ability to engage with decision-makers. In the first quarter of 2020, during which the peak of the pandemic occurred in China, the Company experienced some disruptions to EVOMELA marketing and sales activities due to travel restrictions and the prioritization of hospitals and physicians to attend to patients with COVID-19 infection. During the remainder of 2020, operations have returned to expected levels; however, there can be no assurance that such restrictions will not be imposed again. In addition, economic and other uncertainties may adversely affect other parties' willingness to negotiate and execute product licenses and thus hamper the Company's ability to in-license clinical-stage and late-stage drug candidates in China or elsewhere.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">The Company currently relies on a single source for its supply of EVOMELA. Due to COVID-19, the Company experienced a disruption to its supply chain for EVOMELA. That disruption, along with a change in 2020 in the manufacturer of EVOMELA, contributed to a decrease in the Company's revenue for the second quarter of 2020. The Company has returned to expected levels of sales as indicated by the increase in sales in the second half of 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">If suppliers refuse or are unable to provide products for any reason (including the occurrence of an event like the COVID-19 pandemic that makes delivery impractical), the Company would be required to negotiate an agreement with a substitute supplier, which would likely interrupt the manufacturing of EVOMELA, cause delays and increase costs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;">Clinical trials, whether planned or ongoing, may be affected by the COVID-19 pandemic. The Company's partner, Juventas, experienced some delay in the conduct of the CNCT19 clinical trials due to the COVID-19 pandemic. The COVID-19 pandemic has also impacted the Company's targeted start time of  CID-103 trial due to the lock-down of many medical facilities in Europe. Study procedures (particularly any procedures that may be deemed non-essential), site initiation, participant recruitment and enrollment, participant dosing, shipment of the Company's product candidates, distribution of clinical trial materials, study monitoring, site inspections and data analysis may be paused or delayed due to changes in hospital or research institution policies, federal, state or local regulations, prioritization of hospital and other medical resources toward COVID-19 efforts, or other reasons related to the pandemic. In addition, there could be a potential effect of COVID-19 on the operations of the health regulatory authorities, which could result in delays of reviews and approvals, including with respect to the Company's product candidates. Any prolongation or de-prioritization of the Company's clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of the Company's product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">License and Distribution Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">China Resources Guokang Pharmaceuticals Co., Ltd</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has product rights and perpetual exclusive licenses from Acrotech Biopharma L.L.C. (“Acrotech”) to develop and commercialize its commercial product EVOMELA® in the greater China region (which includes China, Taiwan, Hong Kong and Macau). On December 3, 2018, the Company received NMPA’s approval for importation, marketing and sales in China, and in August 2019 the Company launched EVOMELA in China.  The NMPA required post-marketing study is ongoing and is actively recruiting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In March 2019, the Company entered into a three-year exclusive distribution agreement with China Resources Guokang Pharmaceuticals Co., Ltd (“CRGK”) to appoint CRGK on an exclusive basis as its distributor to distribute EVOMELA in the territory of the People’s Republic of China (excluding Hong Kong, Taiwan and Macau), subject to certain terms and conditions. The Company’s internal marketing and sales team will continue to be responsible for commercial activities, including, for example, direct interaction with Key Opinion Leaders (KOL), physicians, hospital centers and the generating of sales.  Commercial sales of EVOMELA were launched in August 2019. For the year ended December 31, 2020 and 2019, the Company recognized $15.0 million and $4.1 million, respectively, of revenues from sales of EVOMELA under this arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Juventas Cell Therapy Ltd</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2019, the Company entered into a license agreement for worldwide license to commercialize an autologous anti-CD19 T-cell therapy product (CNCT19) from Juventas Cell Therapy Ltd (“Juventas”) (the “Juventas license agreement”).  Juventas is a China-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">based company engaged in cell therapy. The terms of the agreement include RMB 70 million ($10 million) of milestone payments upon the registration of Phase II clinical trial of CNCT19 and sales royalty payments.  The milestone became probable to be met during the quarter ended September 30, 2020.  As a result, the Company paid the milestone payment of RMB 70 million to Juventas in September 2020 (see Note 3), which was expensed as acquired in-process research and development in the accompanying consolidated statement of operations and comprehensive income for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In September 2020, Juventas and its shareholders (including CASI Biopharmaceuticals) agreed to certain terms and conditions required by a new third-party investor to facilitate the Series B financing of Juventas, pursuant to which the Company agreed to amend and supplement the original licensing agreement (the "Supplementary Agreement") by agreeing to pay Juventas certain percentage of profits generated from commercial sales of CNCT19. The Supplementary Agreement also specifies a minimum annual target net profit to be distributed to Juventas and certain other terms and obligations. In return, the Company obtained additional equity interests in Juventas (see Note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under the Supplementary Agreement, Juventas and the Company will jointly market CNCT19, including, but not limited to, establishing medical teams, developing medical strategies, conducting post-marketing clinical studies, establishing Standardized Cell Therapy Centers, establishing and training providers with respect to cell therapy, testing for cell therapy, and monitoring quality controls (cell collection and transfusion, etc.), and patient management (adverse reactions treatment, patients’ follow-up visits, and establishment of a database). The Company also will reimburse Juventas for a portion of Juventas’ marketing expenses as reviewed and approved by a joint commercial committee to be constituted. The Company will continue to be responsible for recruiting and establishing a sales team to commercialize CNCT19.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In November 2020, Juventas Cell Therapy Ltd completed the Series B financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BioInvent International AB </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">In October 2020, the Company entered into an exclusive licensing agreement with BioInvent International AB (“BioInvent”) for the development and commercialization of novel anti-FcγRIIB antibody, BI-1206, in mainland China, Taiwan, Hong Kong and Macau.  BioInvent is a biotechnology company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer immunotherapy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">Under the terms of the agreement, BioInvent and CASI will develop BI-1206 in both hematological malignancies and solid tumors, with CASI responsible for commercialization in China and associated markets. CASI made a </span><span style="color:#212529;">$5.9</span><span style="color:#212529;"> million upfront payment in November 2020 to BioInvent and will pay up to </span><span style="color:#212529;">$83</span><span style="color:#212529;"> million in development and commercial milestone payments plus tiered royalties in the high-single to mid-double-digit range on net sales of BI-1206.  Because BI-1206 underlying the acquired rights has not reached technological feasibility and has no alternative uses, the Company expensed </span><span style="color:#212529;">$5.9</span><span style="color:#212529;"> million as acquired in-process research and development in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">  </span>BI-1206 is an antibody which has a novel mode-of-action, blocking the inhibitory antibody checkpoint receptor FcγRIIB to unlock anti-cancer immunity in both hematological malignancies and solid tumors for which the Company has exclusive greater China rights BI-1206 is the Company’s partner’s lead drug candidate and is being investigated in a Phase 1/2 trial, in combination with anti-PD1 therapy Keytruda® (pembrolizumab), in solid tumors, and in a Phase 1/2a trial in combination with MabThera® (rituximab) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). BioInvent International AB, released positive interim results from its Phase 1/2a trial that suggests that novel anti-FcyRIIB antibody BI-1206 restores activity of rituximab in patients with relapsed/refractory non-Hodgkin’s lymphoma. An FDA End of Phase 1 meeting for the NHL development program is planned for the third quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Black Belt Therapeutics Limited</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In April 2019, the Company entered into a license agreement with Black Belt Therapeutics Limited (“Black Belt”) for exclusive worldwide rights to CID-103, an investigational anti-CD38 monoclonal antibody (Mab) (formerly known as TSK011010). The CID-103 Phase 1 study is scheduled to begin in EU in March 2021.  The Company expects that its clinical materials and commercial inventory will be supplied by one or more contract manufacturers with whom the Company is in current discussions.  Under the terms of the agreement, CASI obtained global rights to CID-103 for an upfront payment of 5 million euros ($5.7 million) as well as certain milestone and royalty payments. Because CID-103 underlying the acquired rights has not reached technological feasibility and has no alternative uses, the Company expensed 5 million euros as acquired in-process research and development in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cleave Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2021, the Company entered into an exclusive license with Cleave Therapeutics, Inc. (“Cleave”) for the development and commercialization of CB-5339, an oral novel VCP/p97 inhibitor, in both hematological malignancies and solid tumors, in Mainland China, Hong Kong, Macau and Taiwan.  Cleave is a clinical-stage biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response and other cellular stress pathways for therapeutic use in cancer.  CB-5339 is being evaluated in a Phase 1 clinical trial in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), while the National Cancer Institute (NCI) is sponsoring and evaluating CB-5339 in a Phase 1 clinical trial of patients with solid tumors and lymphomas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pharmathen Global BV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On October 29, 2019, the Company entered into an exclusive distribution agreement with Pharmathen Global BV ("Pharmathen") for the development and distribution of octreotide long acting injectable (Octreotide LAI) microsphere in China.  Octreotide LAI formulations, which are approved in various European countries, are considered a standard of care for the treatment of acromegaly and the control of symptoms associated with certain neuroendocrine tumors. Subject to regulatory and marketing approvals, the Company intends to advance and commercialize these established products in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The terms of the agreement include an upfront payment of 1 million euros which was paid by the Company in 2019, and up to 2 million euros of additional milestone payments. During the year ended December 31, 2020, milestones were achieved related to Pharmathen's approval of Octreotide in the UK, which triggered a 1 million euros payment to Pharmathen, and related to the first submission to the National Medical Products Administration in China, triggering a 500,000 euros payment to Pharmathen. The 1.5 million euros ($1.7 million) was expensed as acquired in-process research and development in the accompanying consolidated statement of operations and comprehensive income for the year ended December 31, 2020. CASI is responsible for the development, import drug registration, product approval and commercialization in China. CASI has a 10-year non-royalty exclusive distribution period after the product launch at agreed supply costs for the first three years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Riemser Pharma GmbH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2019, the Company entered into an distribution agreement in China with Riemser Pharma GmbH (“Riemser”) to a novel formulation of thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to allogenic hematopoietic stem cell transplantation. Thiotepa has a long history of established use in the hematology/oncology setting. Pursuant to the distribution agreement, CASI obtained the exclusive distribution right of the products in China, and Riemser will be responsible for manufacturing and supplying CASI with clinical materials and commercial inventory.  Subject to regulatory and marketing approvals, the Company intends to advance and commercialize these established products in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
</us-gaap:BasisOfAccounting>
<casi:NumberOfSubsidiaries contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="INF" id="Narr_qwl8odJbFku-wQlJOlTLHw" unitRef="Unit_Standard_subsidiary_mJH4TjT7ikaUUEtVaN0L7g"> 2 </casi:NumberOfSubsidiaries>
<us-gaap:LessorOperatingLeaseTermOfContract contextRef="As_Of_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_kjsYxa-Bz0eaH9B0KN-7bw" id="Narr_mPxMsJUUh06ruWosg6Qhpw"> P50Y </us-gaap:LessorOperatingLeaseTermOfContract>
<casi:ProceedsFromGovernmentGrant contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_FPImBeVQ6ECFNmosNPG3jQ" decimals="-5" id="Narr_TwgZuAfi40SCAAV5kRd5PA" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 15900000 </casi:ProceedsFromGovernmentGrant>
<casi:ProceedsFromGovernmentGrant contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_FPImBeVQ6ECFNmosNPG3jQ" decimals="-5" id="Narr_LMD6HHuOzkChM-SSznyaDg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2200000 </casi:ProceedsFromGovernmentGrant>
<casi:ConstructionProjectContractContractPrice contextRef="As_Of_8_27_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_hXZDZBgK3EqZJeFfmlyPRw" decimals="0" id="Narr_nE7W6YoG_UqrEuUgAcEruQ" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 74588000 </casi:ConstructionProjectContractContractPrice>
<casi:ConstructionProjectContractContractPrice contextRef="As_Of_8_27_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_hXZDZBgK3EqZJeFfmlyPRw" decimals="0" id="Narr_tPANclIqlEqFScp6qHzZoQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 10923000 </casi:ConstructionProjectContractContractPrice>
<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-5" id="Narr_F0j1YXfsg0mPYssOnfW0-g" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -400000 </us-gaap:GainLossOnDispositionOfIntangibleAssets>
<us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-5" id="Narr_dp3mmyRJcEui4JoGVQX-HQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3200000 </us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-5" id="Narr_hTy6sTlrM0Kg2bmWg592HA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -570500000 </us-gaap:RetainedEarningsAccumulatedDeficit>
<casi:NumberOfSubsidiaries contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="INF" id="Narr_SHWJQosj4U-_An8N60ICvg" unitRef="Unit_Standard_subsidiary_mJH4TjT7ikaUUEtVaN0L7g"> 2 </casi:NumberOfSubsidiaries>
<casi:NumberOfHematologyAndOncologySalesAndMarketingSpecialists contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_XPJAlt51aUKS4_V2bDdnJA" decimals="0" id="Narr_1CFT_1kxF0qnN8K7g8FpgA" unitRef="Unit_Standard_person_f5DA5054Ykmk0LWf8_a9Cg"> 80 </casi:NumberOfHematologyAndOncologySalesAndMarketingSpecialists>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_24_2020_To_7_24_2020_ihrUHlk_VUqYlRnsRY2Bkw" decimals="-6" id="Narr_2GrtYTNuLU2iK4YaH2bGNQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 23000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_7_24_2020_To_7_24_2020_ihrUHlk_VUqYlRnsRY2Bkw" decimals="-5" id="Narr_lb69rmWHVUiLvitCRlQUqw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 43700000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<casi:PublicOfferingPrice contextRef="As_Of_11_20_2020_E8azgY6PLEaD6_ypT2LlDQ" decimals="-6" id="Narr_ePIRA3Zu9kOEU0x9Cwym9Q" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 150000000 </casi:PublicOfferingPrice>
<us-gaap:ExcessStockSharesAuthorized contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_m6l7tJZXbESjwZOx5NIjhA" decimals="INF" id="Narr_rntUVFVfN0eed3s02ZUpxQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 15853658 </us-gaap:ExcessStockSharesAuthorized>
<us-gaap:SharePrice contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_m6l7tJZXbESjwZOx5NIjhA" decimals="2" id="Narr_BBFPTCp8H0mVmkh--qsXDQ" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.05 </us-gaap:SharePrice>
<us-gaap:ExcessStockSharesAuthorized contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FOGLCtLtX0W7vhAYtY48Tw" decimals="INF" id="Narr_wbquCmFgh0uqxXtwxHchEw" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 2378048 </us-gaap:ExcessStockSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_3_24_2021_To_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f6dLbzT0Y0-fGMZpVgN2rw" id="Narr_Ou39OzwL0UW_hZi9fJrksQ"> P30D </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_W4eyun0Gp0mlsMHffm3HDQ" decimals="-5" id="Narr_F5yaO68hW0agjozSTxvZaQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 32500000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<casi:PercentageOfUnderwritersCommission contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_srt_TitleOfIndividualAxis_casi_BoardOfDirectorsChairmanAndChiefExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_O2Fp4rasTECUr6UjLSJjfQ" decimals="4" id="Narr_Bdx4Z_nXFUu_ZfY7eE1X7w" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.01 </casi:PercentageOfUnderwritersCommission>
<casi:PercentageOfUnderwritersCommission contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mLDF7BJ3akakLuxfMK7juA" decimals="4" id="Narr_T01HRTXuuE-qhXClEw8gWg" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.06 </casi:PercentageOfUnderwritersCommission>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-5" id="Narr_UlIS_f0b7UCyyNrGaYv3LQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 57100000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:Cash contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_casi_CasiChinaMember_71qQbn-EyECwAn9lEEMaIg" decimals="-5" id="Narr_wbEgu-n2ak2Nducvx9EGhw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4500000 </us-gaap:Cash>
<us-gaap:Cash contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_y_UDporeOk2GvbA3fWsFdg" decimals="-5" id="Narr_FJODyIoOXkidZODbYeDnuw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 19500000 </us-gaap:Cash>
<casi:NonRoyaltyExclusiveDistributionPeriod contextRef="Duration_3_1_2019_To_3_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_GuokangPharmaceuticalsCoLtdMember__PbLeb60hEau-iz8Am8RXA" id="Narr_BrvXqj7Sd063Sf25lD6a7w"> P3Y </casi:NonRoyaltyExclusiveDistributionPeriod>
<us-gaap:Revenues contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_GuokangPharmaceuticalsCoLtdMember_ejTdGKSUFEGUZsdgeE5rSg" decimals="-5" id="Narr_PUunEU1UsEu7GflnRLGK0A" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 15000000.0 </us-gaap:Revenues>
<us-gaap:Revenues contextRef="Duration_1_1_2019_To_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_GuokangPharmaceuticalsCoLtdMember_fZsl75EJ5kGTspLFOYTRCA" decimals="-5" id="Narr_qO1YaTTLH0OmbDpdWwEUlA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4100000 </us-gaap:Revenues>
<casi:LicenseAgreementMilestonePayment contextRef="Duration_9_1_2020_To_9_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_nJ9U7Pnbj067zCKADaCrpg" decimals="-6" id="Narr_6mCOULlPUkazs3fHZQQY9g" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 70000000 </casi:LicenseAgreementMilestonePayment>
<casi:LicenseAgreementMilestonePayment contextRef="Duration_9_1_2020_To_9_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_nJ9U7Pnbj067zCKADaCrpg" decimals="-6" id="Narr__ygtV5sHMECqHsWwVwmRqA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 10000000 </casi:LicenseAgreementMilestonePayment>
<casi:LicenseAgreementMilestonePayment contextRef="Duration_9_1_2020_To_9_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_nJ9U7Pnbj067zCKADaCrpg" decimals="-6" id="Narr_XBIC2oPld0aT9AMH5B0vDQ" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 70000000 </casi:LicenseAgreementMilestonePayment>
<casi:UpfrontPayment contextRef="Duration_11_1_2020_To_11_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_WiVJTV4LD0-xqH_HvMbUqA" decimals="-5" id="Narr_Iilwcxa21k2UWefV3RIpOw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5900000 </casi:UpfrontPayment>
<casi:PotentialMilestonePaymentAndRoyalty contextRef="Duration_11_1_2020_To_11_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_srt_RangeAxis_srt_MaximumMember_lvxrE5RiIU-OIjfVH_l5Ww" decimals="-6" id="Narr_XwZKmBgFgkK2Mbz1tWcWUQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 83000000 </casi:PotentialMilestonePaymentAndRoyalty>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_Qqp3IKhp4EiuKj2iNZ3R_A" decimals="-5" id="Narr_8ijpiDMKU0WUoRpjjFQ1ag" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5900000 </us-gaap:ResearchAndDevelopmentInProcess>
<casi:UpfrontPayment contextRef="Duration_4_1_2019_To_4_30_2019_srt_CounterpartyNameAxis_casi_BlackBeltTherapeuticsLimitedMember_GmGeAS7djE-GDT5nQW_znw" decimals="-6" id="Narr__B3x0h7Lc0S4bvwK7aQLPQ" unitRef="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg"> 5000000 </casi:UpfrontPayment>
<casi:UpfrontPayment contextRef="Duration_4_1_2019_To_4_30_2019_srt_CounterpartyNameAxis_casi_BlackBeltTherapeuticsLimitedMember_GmGeAS7djE-GDT5nQW_znw" decimals="-5" id="Narr_eVgpgKbDL06twLILERvgiQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5700000 </casi:UpfrontPayment>
<casi:UpfrontPayment contextRef="Duration_4_1_2019_To_4_30_2019_srt_CounterpartyNameAxis_casi_BlackBeltTherapeuticsLimitedMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicenseAgreementTermsMember_QQy-_m59uEmyClAtafXP_A" decimals="-6" id="Narr_JRVP2DcNfU257aID1N4kvg" unitRef="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg"> 5000000 </casi:UpfrontPayment>
<casi:UpfrontPayment contextRef="Duration_1_1_2019_To_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_11q5ArWy6kaLcVKbNhif2w" decimals="-6" id="Narr_GiV2WVfBrk21o5o8ucPIGQ" unitRef="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg"> 1000000 </casi:UpfrontPayment>
<casi:AdditionalMilestonePayments contextRef="Duration_1_1_2019_To_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_srt_RangeAxis_srt_MaximumMember_LuPsA4ND1UaU3cQe63-_WA" decimals="-6" id="Narr_tYgy7zsU3kmIe4o4CbScsA" unitRef="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg"> 2000000 </casi:AdditionalMilestonePayments>
<casi:LicenseAgreementMilestonePayment contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_kc-NooqXmE2NjmxJx3QuNA" decimals="-6" id="Narr__GcxBPb3NUef3a3sXjmFzA" unitRef="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg"> 1000000 </casi:LicenseAgreementMilestonePayment>
<casi:AdditionalMilestonePayments contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_kc-NooqXmE2NjmxJx3QuNA" decimals="0" id="Narr_WhYE8gfXHki48m_exjQULA" unitRef="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg"> 500000 </casi:AdditionalMilestonePayments>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_kc-NooqXmE2NjmxJx3QuNA" decimals="-5" id="Narr_i46aX2z580yOVKk6zkVXEg" unitRef="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg"> 1500000 </us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_kc-NooqXmE2NjmxJx3QuNA" decimals="-5" id="Narr_JFOfJuAmIE-dpwazOKJeaw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1700000 </us-gaap:ResearchAndDevelopmentInProcess>
<casi:NonRoyaltyExclusiveDistributionPeriod contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_kc-NooqXmE2NjmxJx3QuNA" id="Narr_VmU3NmwR40KXzMnh-n1aIA"> P10Y </casi:NonRoyaltyExclusiveDistributionPeriod>
<casi:NonRoyaltyExclusiveDistributionSupplyCostDeterminationPeriodConsidered contextRef="Duration_10_29_2019_To_10_29_2019_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_UCAuvvHB60ai4ZsxJQRFRA" id="Narr_4NI5maj34EybunTyWwpbgw"> P3Y </casi:NonRoyaltyExclusiveDistributionSupplyCostDeterminationPeriodConsidered>
<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_x4foQYNoWEeIsi14I0gQQw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">2.      SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company's significant accounting estimates relate to recoverability of operating lease right-of-use assets, intangible assets and long-term investments, net realizable value and obsolescence allowance for inventory, deferred tax assets and valuation allowance, allowance for doubtful accounts, stock-based arrangements and fair value of investments in equity securities in Juventas. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results may differ from those estimates, and such differences may be material to the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, in which CASI, directly or indirectly, has a controlling financial interest. These subsidiaries include Miikana Therapeutics, Inc. ("Miikana"), CASI China, CASI Wuxi and CASI Biopharmaceuticals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">CASI China is a non-stock Chinese entity with 100% of its interest owned by CASI. CASI China received approval for a business license from the Beijing Industry and Commercial Administration in August 2012 and has operating facilities in Beijing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">CASI Wuxi was established on December 26, 2018 in China to develop a manufacturing facility in China. CASI Biopharmaceuticals is a wholly owned subsidiary of CASI Wuxi and was established in April 2019. The Company controls CASI Wuxi through 80% voting rights. Accordingly, the financial statements of CASI Wuxi have been consolidated in the Company's consolidated financial statements since its inception. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All inter-company balances and transactions have been eliminated in consolidation. The Company currently operates in one operating segment, which is the development of innovative therapeutics addressing cancer and other unmet medical needs for the global market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Foreign Currency Translation and Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements of the Company are reported in US dollars. The financial position and results of operations of the Company’s subsidiaries in the PRC are measured using the Renminbi (RMB), which is the local and functional currency of these entities. Assets and liabilities of the Company’s PRC subsidiaries are translated into US$ using the exchange rates in effect at the consolidated balance sheet date. The revenues and expenses of these entities are translated into US$ at the weighted average exchange rates for the period. The resulting translation gains (losses) are recorded in accumulated other comprehensive income (loss) as a component of shareholders’ equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing on the transaction dates. Foreign currency denominated financial assets and liabilities are remeasured at the exchange rates prevailing at the balance sheet date. Net gains or losses resulting from foreign currency denominated transactions are recorded in foreign exchange gain (losses) in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Product sales recognized in the consolidated statements of operations are considered revenue from contracts with customers and, accordingly, the Company recognizes revenue using the following steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Identification of the contract, or contracts, with a customer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Identification of the performance obligations in the contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Determination of the transaction price, including the identification and estimation of variable consideration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Allocation of the transaction price to the performance obligations in the contract; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Recognition of revenue when the Company satisfies a performance obligation.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes revenue on sales of EVOMELA when the control of the product is transferred to the distributor, which occurs upon delivery of the product to the carrier appointed by the distributor, in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product, excluding amounts collected on behalf of third parties (e.g. value-added taxes). Payment terms for these sales are due within 90 days. The arrangement does not include any variable consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The costs of assurance type warranties that provide the customer the right to exchange purchased product that does meet appropriate quality standards are recognized when they are probable and are reasonably estimable. There was no product exchange during the years ended December 31, 2020 and 2019. As of December 31, 2020 and 2019, the Company did not incur, and therefore did not defer, any material costs to obtain or fulfill contracts. The Company did not have any contract assets or contract liabilities as of December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Concentrations of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash Concentration Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company maintains its U.S. and RMB cash in bank deposit accounts, which, at times, may exceed regulated insured limits. The Company believes it is not exposed to significant credit risk on cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Vendor Concentration Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has a sole supplier for its EVOMELA product. Through the second quarter of 2020, it was sourced solely from Spectrum Pharmaceuticals, Inc. (“Spectrum”) and its suppliers.  Starting with the third quarter of 2020, and all future needs will be sourced from Acrotech and its suppliers. The Company’s ability to select other providers of EVOMELA is limited by FDA regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Accounts Receivable and Credit Concentration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">CRGK is the sole customer of the Company's EVOMELA product sales in China. All consolidated revenues for the year ended December 31, 2020 and 2019 were generated from sales to CRGK in China, and all the Company's accounts receivable balance as of December 31, 2020 and 2019 were due from CRGK. Accounts receivable consist of CRGK receivables of $4.6 million and $1.3 million as of December 31, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company extends credit to CRGK on an unsecured basis and maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable. In establishing the required allowance, management considers the historical losses, customer’s financial condition, the amount of accounts receivables in dispute, the accounts receivables aging and the customer’s payment pattern. The Company determined that no allowance for doubtful accounts were necessary as of December 31, 2020 and 2019. The balance of accounts receivable as of December 31, 2020 has been subsequently collected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The majority of the Company’s financial instruments (consisting principally of cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable, accrued liabilities, bank borrowings, and notes payable) are carried at cost which approximates their fair values due to the short-term nature of the instruments. The Company’s investment in equity securities is carried at fair value, and its investment in convertible loan-AFS are carried at fair value (see Note 3). The Company also had a note payable which was paid off during the year ended December 31, 2019 (see Note 11). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">See Note 18 for additional fair value disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents include cash and highly liquid investments with original maturities of less than 90 days that are readily convertible to known amounts of cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Inventories consist of EVOMELA finished goods and raw materials to be used in production of ANDAs and are stated at the lower of cost or net realizable value. Cost is determined using a first-in, first-out method. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Adjustments are recorded to write down the carrying amount of any obsolete and excess inventory to its estimated net realizable value based on historical and forecasted demand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Property, Plant and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment are stated at cost, less accumulated depreciation and impairment, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Costs incurred in the construction of property, plant and equipment, including down payments and progress payments, are initially capitalized as construction-in-progress and transferred into their respective asset categories when the assets are ready for their intended use, at which time depreciation commences. Furniture and equipment are depreciated over their estimated useful lives of <span style="-sec-ix-hidden:Hidden_mBCIWDY5tEq4f381jaHwFw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">3</span></span> to 5 years. Leasehold improvements are amortized over the shorter of their useful lives or the lease term. Depreciation and amortization expense are determined on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Costs of Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Costs of revenues consist primarily of the cost of inventories of EVOMELA and sales-based royalties related to the sale of EVOMELA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Investment in equity securities with readily determinable fair value are measured at fair values, and any changes in fair value are recognized in earnings. Where the fair value of an investment in equity securities is not readily determinable, the Company recognizes such investment in long-term investments, and uses the measurement alternative of cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For equity investments measured at fair value with changes in fair value recorded in earnings, the Company does not assess whether those securities are impaired. For equity investments without readily determinable fair value, at each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Impairment indicators that the Company considers include, but are not limited to, (i) the deterioration of earnings performance, credit rating, asset quality, or business prospects of the investee, (ii) a significant adverse change in the regulatory, economic, or technological environment of the investee, (iii) a significant adverse change in the general market condition of either the geographic area or the industry in which the investee operates. If a qualitative assessment indicates that the investment is impaired, the Company has to estimate the investment’s fair value and if the fair value is less than the investment’s carrying value, the Company recognizes an impairment loss in non-operating expenses equal to the difference between the carrying value and fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Dividend income is recognized in other income when earned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company adopted Accounting Standards Update (“ASU”) No. 2016-02, <i style="font-style:italic;">Leases (Topic 842)</i> (“ASC 842”) and subsequent amendments issued by FASB on January 1, 2019, using a modified retrospective method for leases that exist at, or are entered into after, January 1, 2019, and has not recast the comparative periods presented in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Prior to the adoption of ASC 842, operating leases were not recognized on the balance sheet of the Company, instead rent expenses with fixed escalating payments and/or rent holidays were recognized on a straight-line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Upon adoption of ASC 842, ROU assets and lease liabilities are recognized upon lease commencement for operating leases based on the present value of lease payments over the lease term. As the rate implicit in the lease cannot be readily determined, the Company uses incremental borrowing rate at the lease commencement date in determining the imputed interest and present value of lease payments. The incremental borrowing rate was determined based on the rate of interest that the Company would have to borrow an amount equal to the lease payments on a collateralized basis over a similar term. The incremental borrowing rate is primarily influenced by the risk-free interest rate of China and the US, the Company’s credit rating and lease term, and is updated for measurement of new lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For operating leases, the Company recognizes a single lease cost on a straight-line basis over the remaining lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has elected not to recognize ROU assets or lease liabilities for leases with an initial term of 12 months or less; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. In addition, the Company has elected not to separate non-lease components (e.g., common area maintenance fees) from the lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Land use rights acquired are assessed in accordance with ASC 842 and recognized in right-of-use assets if they meet the definition of lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Long-lived assets, including property, plant and equipment, operating lease right-of-use (“ROU”) assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Such events and circumstances include the use of the asset or asset group in current research and development projects and any potential alternative uses of the asset or asset group. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.  Impairment charges related to property, plant and equipment were $0 and $386,000 for the years ended in December 31, 2020 and 2019, respectively.  Impairment charges related to intangibles were $1.5 million and $0 for the years ended in December 31, 2020 and 2019, respectively.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with pre-clinical testing and clinical trials of the Company’s product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses, along with the amortization of acquired ANDAs. Research and development costs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company records compensation expense associated with service and performance-based stock options in accordance with provisions of authoritative guidance. The estimated fair value of service-based awards is determined using option pricing models that use unobservable inputs and is generally recognized on a straight-line basis over the requisite service period and based on the proportionate amount of the requisite service period that has been rendered during each reporting period. The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Government Grants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Government grants are recognized when there is reasonable assurance that the Company will comply with required conditions and the grants will be received. Government grants related to assets are presented as deferred income that is recognized on a systematic basis over the useful life of the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Income tax expense is recognized using the asset and liability method.  Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities and operating loss and tax credit carryforwards as measured by the enacted tax rates that will be in effect when these differences reverse. A valuation allowance is provided to reduce the amount of deferred income tax assets if it is considered more likely than not that some portion or all of the deferred income tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes in its consolidated financial statements the impact of a tax position if a tax return position or future tax position is “more likely-than-not” to be sustained upon examination, based on the technical merits of the position. Tax positions that meet the “more-likely-than-not” recognition threshold are measured at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement.  The Company recognizes interest and penalties related to uncertain tax positions, if any, in income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Net loss per share (basic and diluted) was computed by dividing net loss attributable to common shareholders by the weighted average number of shares of common stock outstanding. As of December 31, 2020, and 2019, outstanding stock options totaling 16,746,238 and 18,268,372, respectively, and outstanding warrants totaling 8,271,709 and 9,843,720, respectively, were anti-dilutive, and therefore, were not included in the computation of weighted average shares used in computing diluted loss per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">New Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Recently Adopted Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Effective January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-02, Leases (“Topic 842”). The guidance amends the accounting requirements for leases and requires lessees to recognize assets and liabilities related to long-term leases on the balance sheets and expands disclosure requirements regarding leasing arrangements. The Company adopted this guidance on a modified retrospective basis and used the following practical expedients:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The Company did not reassess if any expired or existing contracts are or contain leases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The Company did not reassess the classification of any expired or existing leases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;"> </span>Additionally, the Company made ongoing accounting policy elections whereby it (i) does not recognize Right-of-use (“ROU”) assets or lease liabilities for short-term leases (those with original terms of 12-months or less) and (ii) combines lease and non-lease components for facilities leases, which primarily relate to ancillary expenses such as common area maintenance charges and management fees of operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Upon adoption of the new guidance on January 1, 2019, the Company recorded right of use assets of $3.0 million and recognized lease liabilities of $3.2 million.  There was no cumulative effect impact to accumulated deficit as of January 1, 2019. No adjustments were made to prior comparative periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The new guidance requires a customer in a cloud computing arrangement (i.e., hosting arrangement) that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The update is effective for calendar-year public business entities in 2020. For all other calendar-year entities, it is effective for annual periods beginning in 2021 and interim periods in 2022. Early adoption is permitted. The Company early adopted this guidance effective January 1, 2019. The net impact to the financial statements was $140,000 of capitalized cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 eliminates, adds and modifies certain disclosure requirements for fair value measurements. The amendments applicable to the disclosures of changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. This ASU is effective for all entities for fiscal years beginning after December 15, 2019, including interim periods therein. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted, and an entity is also permitted to early adopt any removed or modified disclosures and delay adoption of the additional disclosures until their effective date. The Company adopted this guidance effective January 1, 2020. The adoption of this new accounting standard did not have a significant impact on the Company's consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments — Credit Losses (Topic 326) (“ASU 2016-13”) and subsequent amendments to the initial guidance including ASU No. 2018-19, ASU No. 2019-04, and ASU No. 2019-05 (collectively, “Topic 326”). Topic 326 requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This standard is effective for public business entities, excluding entities eligible to be smaller reporting companies for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, this standard is effective for annual and interim periods beginning after December 15, 2022 and early adoption is permitted for annual and interim periods beginning after December 15, 2018. As a smaller reporting company, the Company expects to adopt this standard in fiscal year 2023. The Company is currently assessing the impact that the adoption of this ASU will have on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company’s financial position, results of operations or cash flows.</p>
</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_uzRNu39Cdka0s-BuGdN8Iw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</p>
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_npEU-xIBS02vSqnOEDQsGg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company's significant accounting estimates relate to recoverability of operating lease right-of-use assets, intangible assets and long-term investments, net realizable value and obsolescence allowance for inventory, deferred tax assets and valuation allowance, allowance for doubtful accounts, stock-based arrangements and fair value of investments in equity securities in Juventas. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results may differ from those estimates, and such differences may be material to the consolidated financial statements.</p>
</us-gaap:UseOfEstimates>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_DTL0dMBqUk-RFXD4ca8ddw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, in which CASI, directly or indirectly, has a controlling financial interest. These subsidiaries include Miikana Therapeutics, Inc. ("Miikana"), CASI China, CASI Wuxi and CASI Biopharmaceuticals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">CASI China is a non-stock Chinese entity with 100% of its interest owned by CASI. CASI China received approval for a business license from the Beijing Industry and Commercial Administration in August 2012 and has operating facilities in Beijing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">CASI Wuxi was established on December 26, 2018 in China to develop a manufacturing facility in China. CASI Biopharmaceuticals is a wholly owned subsidiary of CASI Wuxi and was established in April 2019. The Company controls CASI Wuxi through 80% voting rights. Accordingly, the financial statements of CASI Wuxi have been consolidated in the Company's consolidated financial statements since its inception. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All inter-company balances and transactions have been eliminated in consolidation. The Company currently operates in one operating segment, which is the development of innovative therapeutics addressing cancer and other unmet medical needs for the global market.</p>
</us-gaap:ConsolidationPolicyTextBlock>
<casi:PercentageOfOwnershipInterestInNonStockSubsidiary contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="2" id="Narr_kFy5a70pVEuxZPQAabnX3g" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 1 </casi:PercentageOfOwnershipInterestInNonStockSubsidiary>
<casi:PercentageOfOwnershipInterestInNonStockSubsidiary contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_y_UDporeOk2GvbA3fWsFdg" decimals="2" id="Narr_3tkBtOd8iEqN9TedLx2lIw" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.80 </casi:PercentageOfOwnershipInterestInNonStockSubsidiary>
<us-gaap:NumberOfOperatingSegments contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="INF" id="Narr_6ZuOMPngmUK3BdhrZFukxQ" unitRef="Unit_Standard_segment_F6mrK1_Rg0OWuMCKw-6xVg"> 1 </us-gaap:NumberOfOperatingSegments>
<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_RjOyq7AWyEasKKnq4Do1TQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Foreign Currency Translation and Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements of the Company are reported in US dollars. The financial position and results of operations of the Company’s subsidiaries in the PRC are measured using the Renminbi (RMB), which is the local and functional currency of these entities. Assets and liabilities of the Company’s PRC subsidiaries are translated into US$ using the exchange rates in effect at the consolidated balance sheet date. The revenues and expenses of these entities are translated into US$ at the weighted average exchange rates for the period. The resulting translation gains (losses) are recorded in accumulated other comprehensive income (loss) as a component of shareholders’ equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing on the transaction dates. Foreign currency denominated financial assets and liabilities are remeasured at the exchange rates prevailing at the balance sheet date. Net gains or losses resulting from foreign currency denominated transactions are recorded in foreign exchange gain (losses) in the consolidated statements of operations.</p>
</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
<us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_Xs9AsDdSuEqROU9KJkuCtA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Product sales recognized in the consolidated statements of operations are considered revenue from contracts with customers and, accordingly, the Company recognizes revenue using the following steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Identification of the contract, or contracts, with a customer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Identification of the performance obligations in the contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Determination of the transaction price, including the identification and estimation of variable consideration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Allocation of the transaction price to the performance obligations in the contract; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Recognition of revenue when the Company satisfies a performance obligation.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes revenue on sales of EVOMELA when the control of the product is transferred to the distributor, which occurs upon delivery of the product to the carrier appointed by the distributor, in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product, excluding amounts collected on behalf of third parties (e.g. value-added taxes). Payment terms for these sales are due within 90 days. The arrangement does not include any variable consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The costs of assurance type warranties that provide the customer the right to exchange purchased product that does meet appropriate quality standards are recognized when they are probable and are reasonably estimable. There was no product exchange during the years ended December 31, 2020 and 2019. As of December 31, 2020 and 2019, the Company did not incur, and therefore did not defer, any material costs to obtain or fulfill contracts. The Company did not have any contract assets or contract liabilities as of December 31, 2020 and 2019.</p>
</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
<us-gaap:ConcentrationRiskCreditRisk contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_rpdg2YPPuEuRIjYTFDt6xQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Concentrations of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash Concentration Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company maintains its U.S. and RMB cash in bank deposit accounts, which, at times, may exceed regulated insured limits. The Company believes it is not exposed to significant credit risk on cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Vendor Concentration Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has a sole supplier for its EVOMELA product. Through the second quarter of 2020, it was sourced solely from Spectrum Pharmaceuticals, Inc. (“Spectrum”) and its suppliers.  Starting with the third quarter of 2020, and all future needs will be sourced from Acrotech and its suppliers. The Company’s ability to select other providers of EVOMELA is limited by FDA regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Accounts Receivable and Credit Concentration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">CRGK is the sole customer of the Company's EVOMELA product sales in China. All consolidated revenues for the year ended December 31, 2020 and 2019 were generated from sales to CRGK in China, and all the Company's accounts receivable balance as of December 31, 2020 and 2019 were due from CRGK. Accounts receivable consist of CRGK receivables of $4.6 million and $1.3 million as of December 31, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company extends credit to CRGK on an unsecured basis and maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable. In establishing the required allowance, management considers the historical losses, customer’s financial condition, the amount of accounts receivables in dispute, the accounts receivables aging and the customer’s payment pattern. The Company determined that no allowance for doubtful accounts were necessary as of December 31, 2020 and 2019. The balance of accounts receivable as of December 31, 2020 has been subsequently collected.</p>
</us-gaap:ConcentrationRiskCreditRisk>
<us-gaap:AccountsReceivableNet contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_ChinaResourcesGuokangPharmaceuticalsCo.Ltd.Member_Y0DxXxW0Jku9xDP0ovUk6w" decimals="-5" id="Narr_JVO_J0Wh4EeKOFQpF1ubYQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4600000 </us-gaap:AccountsReceivableNet>
<us-gaap:AccountsReceivableNet contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_ChinaResourcesGuokangPharmaceuticalsCo.Ltd.Member_Ubi5dcaUuUG6ZZP8_hZHNA" decimals="-5" id="Narr_ukPG6PgDl0ymXeB7Bty2Kg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1300000 </us-gaap:AccountsReceivableNet>
<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Narr_BzC8BDDFqUekeOORV5MJug" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Narr_GrFot8BH3EWR9IfJkc8VOA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_soWOFOwJOEqRTu4gKVdCag">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The majority of the Company’s financial instruments (consisting principally of cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable, accrued liabilities, bank borrowings, and notes payable) are carried at cost which approximates their fair values due to the short-term nature of the instruments. The Company’s investment in equity securities is carried at fair value, and its investment in convertible loan-AFS are carried at fair value (see Note 3). The Company also had a note payable which was paid off during the year ended December 31, 2019 (see Note 11). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">See Note 18 for additional fair value disclosures.</p>
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_ieu-NbpbxEiYx5SukDd0Sg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents include cash and highly liquid investments with original maturities of less than 90 days that are readily convertible to known amounts of cash.</p>
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:InventoryPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_AsXb2Vqy1E2UalM_Ybd6gw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Inventories consist of EVOMELA finished goods and raw materials to be used in production of ANDAs and are stated at the lower of cost or net realizable value. Cost is determined using a first-in, first-out method. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Adjustments are recorded to write down the carrying amount of any obsolete and excess inventory to its estimated net realizable value based on historical and forecasted demand.</p>
</us-gaap:InventoryPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_Z4YUgAReuEiF7R3bIn_5CA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Property, Plant and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment are stated at cost, less accumulated depreciation and impairment, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Costs incurred in the construction of property, plant and equipment, including down payments and progress payments, are initially capitalized as construction-in-progress and transferred into their respective asset categories when the assets are ready for their intended use, at which time depreciation commences. Furniture and equipment are depreciated over their estimated useful lives of <span style="-sec-ix-hidden:Hidden_mBCIWDY5tEq4f381jaHwFw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">3</span></span> to 5 years. Leasehold improvements are amortized over the shorter of their useful lives or the lease term. Depreciation and amortization expense are determined on a straight-line basis.</p>
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_casi_FurnitureAndEquipmentMember_qSQ_8HCuskOkOfUj96vdIA" id="Narr_ZCxULLaHF02iGmXogUdOiQ"> P5Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:CostOfSalesPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_-QwKcHjG60-DEpgYlvI0vA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Costs of Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Costs of revenues consist primarily of the cost of inventories of EVOMELA and sales-based royalties related to the sale of EVOMELA.</p>
</us-gaap:CostOfSalesPolicyTextBlock>
<us-gaap:InvestmentPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_BMxz0ndyIk-H6QGPDbvtOA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Investment in equity securities with readily determinable fair value are measured at fair values, and any changes in fair value are recognized in earnings. Where the fair value of an investment in equity securities is not readily determinable, the Company recognizes such investment in long-term investments, and uses the measurement alternative of cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For equity investments measured at fair value with changes in fair value recorded in earnings, the Company does not assess whether those securities are impaired. For equity investments without readily determinable fair value, at each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Impairment indicators that the Company considers include, but are not limited to, (i) the deterioration of earnings performance, credit rating, asset quality, or business prospects of the investee, (ii) a significant adverse change in the regulatory, economic, or technological environment of the investee, (iii) a significant adverse change in the general market condition of either the geographic area or the industry in which the investee operates. If a qualitative assessment indicates that the investment is impaired, the Company has to estimate the investment’s fair value and if the fair value is less than the investment’s carrying value, the Company recognizes an impairment loss in non-operating expenses equal to the difference between the carrying value and fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Dividend income is recognized in other income when earned.</p>
</us-gaap:InvestmentPolicyTextBlock>
<us-gaap:LesseeLeasesPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_ZfUJs34l1kqHX4lfDy2NEg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company adopted Accounting Standards Update (“ASU”) No. 2016-02, <i style="font-style:italic;">Leases (Topic 842)</i> (“ASC 842”) and subsequent amendments issued by FASB on January 1, 2019, using a modified retrospective method for leases that exist at, or are entered into after, January 1, 2019, and has not recast the comparative periods presented in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Prior to the adoption of ASC 842, operating leases were not recognized on the balance sheet of the Company, instead rent expenses with fixed escalating payments and/or rent holidays were recognized on a straight-line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Upon adoption of ASC 842, ROU assets and lease liabilities are recognized upon lease commencement for operating leases based on the present value of lease payments over the lease term. As the rate implicit in the lease cannot be readily determined, the Company uses incremental borrowing rate at the lease commencement date in determining the imputed interest and present value of lease payments. The incremental borrowing rate was determined based on the rate of interest that the Company would have to borrow an amount equal to the lease payments on a collateralized basis over a similar term. The incremental borrowing rate is primarily influenced by the risk-free interest rate of China and the US, the Company’s credit rating and lease term, and is updated for measurement of new lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For operating leases, the Company recognizes a single lease cost on a straight-line basis over the remaining lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has elected not to recognize ROU assets or lease liabilities for leases with an initial term of 12 months or less; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. In addition, the Company has elected not to separate non-lease components (e.g., common area maintenance fees) from the lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Land use rights acquired are assessed in accordance with ASC 842 and recognized in right-of-use assets if they meet the definition of lease.</p>
</us-gaap:LesseeLeasesPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_ZDljDCFkgU6cytSVkh4ZCA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Long-lived assets, including property, plant and equipment, operating lease right-of-use (“ROU”) assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Such events and circumstances include the use of the asset or asset group in current research and development projects and any potential alternative uses of the asset or asset group. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.  Impairment charges related to property, plant and equipment were $0 and $386,000 for the years ended in December 31, 2020 and 2019, respectively.  Impairment charges related to intangibles were $1.5 million and $0 for the years ended in December 31, 2020 and 2019, respectively.  </p>
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:TangibleAssetImpairmentCharges contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_iHVdGiNc2EefpaeaYfrXIA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:TangibleAssetImpairmentCharges>
<us-gaap:TangibleAssetImpairmentCharges contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_RnYaMUS3q0mqgy5f2sKRMQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 386000 </us-gaap:TangibleAssetImpairmentCharges>
<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-5" id="Narr_DCBXOlJt8keM_4yCBTEBCw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1500000 </us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-5" id="Narr_4y7covT_qEyvik9y23JYkQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_G8hg6D-MekWKoJvhHJfCFQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with pre-clinical testing and clinical trials of the Company’s product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses, along with the amortization of acquired ANDAs. Research and development costs are expensed as incurred.</p>
</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_sAc0PZnonEeyzltsIkrfZg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company records compensation expense associated with service and performance-based stock options in accordance with provisions of authoritative guidance. The estimated fair value of service-based awards is determined using option pricing models that use unobservable inputs and is generally recognized on a straight-line basis over the requisite service period and based on the proportionate amount of the requisite service period that has been rendered during each reporting period. The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved.</p>
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<casi:GovernmentGrantsPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_bigVz-OQbkymp67nsQRsYA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Government Grants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Government grants are recognized when there is reasonable assurance that the Company will comply with required conditions and the grants will be received. Government grants related to assets are presented as deferred income that is recognized on a systematic basis over the useful life of the asset.</p>
</casi:GovernmentGrantsPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_Fvei_BCRUk6oOHZltkEy-A">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Income tax expense is recognized using the asset and liability method.  Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities and operating loss and tax credit carryforwards as measured by the enacted tax rates that will be in effect when these differences reverse. A valuation allowance is provided to reduce the amount of deferred income tax assets if it is considered more likely than not that some portion or all of the deferred income tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes in its consolidated financial statements the impact of a tax position if a tax return position or future tax position is “more likely-than-not” to be sustained upon examination, based on the technical merits of the position. Tax positions that meet the “more-likely-than-not” recognition threshold are measured at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement.  The Company recognizes interest and penalties related to uncertain tax positions, if any, in income tax expense.</p>
</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_qrQPjmkz3kyRxrUjQVmhKw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Net loss per share (basic and diluted) was computed by dividing net loss attributable to common shareholders by the weighted average number of shares of common stock outstanding. As of December 31, 2020, and 2019, outstanding stock options totaling 16,746,238 and 18,268,372, respectively, and outstanding warrants totaling 8,271,709 and 9,843,720, respectively, were anti-dilutive, and therefore, were not included in the computation of weighted average shares used in computing diluted loss per share.</p>
</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_casi_OptionsMember_C2Tr0pDxQUGtmZ9DJrjCdQ" decimals="INF" id="Narr_FGqmJS_lC0OxH8-_v3dIUg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 16746238 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_casi_OptionsMember_e00VDPx4NUODzSfPbm57qA" decimals="INF" id="Narr_DOhhbDkuP0eE-4Vinw0cLw" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 18268372 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_20Bl-uHQakKIxHD-KsfnTA" decimals="INF" id="Narr_oRD9UXWG50KsBuo6iwcIRQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 8271709 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_3Y8tjRmooE6126cW6DY2FA" decimals="INF" id="Narr_WZBnffYFxkaJdePRmLncFg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 9843720 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_pEEYTWvxRkqXt1qy24ksfA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">New Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Recently Adopted Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Effective January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-02, Leases (“Topic 842”). The guidance amends the accounting requirements for leases and requires lessees to recognize assets and liabilities related to long-term leases on the balance sheets and expands disclosure requirements regarding leasing arrangements. The Company adopted this guidance on a modified retrospective basis and used the following practical expedients:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The Company did not reassess if any expired or existing contracts are or contain leases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The Company did not reassess the classification of any expired or existing leases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;"> </span>Additionally, the Company made ongoing accounting policy elections whereby it (i) does not recognize Right-of-use (“ROU”) assets or lease liabilities for short-term leases (those with original terms of 12-months or less) and (ii) combines lease and non-lease components for facilities leases, which primarily relate to ancillary expenses such as common area maintenance charges and management fees of operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Upon adoption of the new guidance on January 1, 2019, the Company recorded right of use assets of $3.0 million and recognized lease liabilities of $3.2 million.  There was no cumulative effect impact to accumulated deficit as of January 1, 2019. No adjustments were made to prior comparative periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The new guidance requires a customer in a cloud computing arrangement (i.e., hosting arrangement) that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The update is effective for calendar-year public business entities in 2020. For all other calendar-year entities, it is effective for annual periods beginning in 2021 and interim periods in 2022. Early adoption is permitted. The Company early adopted this guidance effective January 1, 2019. The net impact to the financial statements was $140,000 of capitalized cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 eliminates, adds and modifies certain disclosure requirements for fair value measurements. The amendments applicable to the disclosures of changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. This ASU is effective for all entities for fiscal years beginning after December 15, 2019, including interim periods therein. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted, and an entity is also permitted to early adopt any removed or modified disclosures and delay adoption of the additional disclosures until their effective date. The Company adopted this guidance effective January 1, 2020. The adoption of this new accounting standard did not have a significant impact on the Company's consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments — Credit Losses (Topic 326) (“ASU 2016-13”) and subsequent amendments to the initial guidance including ASU No. 2018-19, ASU No. 2019-04, and ASU No. 2019-05 (collectively, “Topic 326”). Topic 326 requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This standard is effective for public business entities, excluding entities eligible to be smaller reporting companies for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, this standard is effective for annual and interim periods beginning after December 15, 2022 and early adoption is permitted for annual and interim periods beginning after December 15, 2018. As a smaller reporting company, the Company expects to adopt this standard in fiscal year 2023. The Company is currently assessing the impact that the adoption of this ASU will have on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company’s financial position, results of operations or cash flows.</p>
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="As_Of_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_MCe69bbxj02l1rXtQX7Xbw" decimals="-5" id="Narr_S49tOZApUkWC2jMybBvhew" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3000000.0 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseLiability contextRef="As_Of_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_MCe69bbxj02l1rXtQX7Xbw" decimals="-5" id="Narr_4pnxY_NGxE-iRsuYprGmmA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3200000 </us-gaap:OperatingLeaseLiability>
<casi:NewAccountingPronouncementOrChangeInAccountingPrincipleEffect contextRef="Duration_1_1_2019_To_1_1_2019_SbE1vx3xVkeWIt2v6rjU6A" decimals="0" id="Narr_MJ4UqvixOEm32AibgoIM5g" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 140000 </casi:NewAccountingPronouncementOrChangeInAccountingPrincipleEffect>
<us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_vA5mc487LUWGuSAR4h-8yQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.      INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Investment in equity securities, at fair value</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">MaxCyte Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has an equity investment in the common stock of MaxCyte, a publicly traded company. The Company’s investment in this equity security is carried at its fair value, with changes in fair value reported in the statement of operations each </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">reporting period. The fair value of this security was measured using its quoted market price, a Level 1 input, and was $2.7 million as of December 31, 2020 and $0.6 million on December 31, 2019 (see Note 18).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BioInvent International AB</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In October 2020, in conjunction with its license agreement entered into with BioInvent (see Note 1), a publicly traded company, CASI made a $6.3 million investment (equivalent to SEK 53.8 million) to acquire 1.2 million new shares (after 25:1 reverse stock split) of BioInvent, and 14,700,000 warrants, each warrant with a right to subscribe for 0.04 shares (after 25:1 reverse stock split)  in BioInvent within a period of five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The investments in the ordinary shares and warrants of BioInvent are carried at fair value, with changes in fair value reported in the statement of operations each reporting period. The fair value of the ordinary shares was measured using its quoted market price, a Level 1 input, and was  $6.6 million as of December 31, 2020 (see Note 18).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The fair value of the warrants was measured using observable market-based inputs other than quoted prices in active markets for identical assets or liabilities, level 2 inputs.  The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of warrants. The fair value of the warrants was $841,000 as of December 31, 2020 (see Note 18), with assumptions including an expected life of 4.91 years, an assumed volatility of 47.63%, and a risk-free interest rate of 0.36%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company’s investments in equity securities at Fair Value as of December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.49%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> MaxCyte - equity interest</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,729</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,729</p></td></tr><tr><td style="vertical-align:bottom;width:35.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> BioInvent - equity interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 919</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,580</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Unrealized gain (losses) on the Company’s equity investment for the year ended December 31, 2020 and 2019 were $3.2 million and ($288,000), respectively, and are recognized as change in fair value of investment in equity securities in the accompanying consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Long-term investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Long-term investments consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Available-for-sale debt securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Black Belt Tx Limited - convertible loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Securities measured at fair value:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">BioInvent International AB - warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity securities without readily determinable fair value:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Black Belt Tx Limited - equity interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,250</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Juventas Cell Therapy Ltd - equity interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,059</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,355</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Juventas Cell Therapy Ltd - put option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 433</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,442</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,038</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Black Belt Tx Limited</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In April 2019, in conjunction with its license agreement entered into with Black Belt (see Note 1), the Company made a 2 million euros ($2,249,600) equity investment in the ordinary shares of a newly established, privately held UK Company, Black Belt Tx Ltd ("Black Belt Tx"), representing a 14.1% equity interest with the right to appoint a non-voting board observer. As the Company does not have significant influence over operating and financial policies of Black Belt Tx, and the equity interests do not have readily determinable fair value, the investment in Black Belt Tx is stated at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment. The Company did not record any adjustments or impairments during the year ended December 31, 2020 and 2019 related to this investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In July 2020, the Company entered into a three-year convertible loan agreement with Black Belt Tx (the "Black Belt Tx Loan") in the amount of 211,800 euros ($250,000) with a non-compounding annual interest rate of 6% payable at maturity. The principal balance is also due at maturity. The proceeds will support and advance Black Belt Tx's programs and general operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The loan principal will be disbursed in three equal installments of 70,600 euros ($83,000). The first tranche was disbursed upon execution of the loan agreement in August 2020. The second tranche was disbursed in February 2021. In the first quarter of 2021, Black Belt Tx reached certain operational circumstances as stipulated in the loan agreement, and Black Belt Tx’s Board of Directors met in February 2021 to approve disbursement of the second tranche.  The third tranche will be disbursed in the event Black Belt Tx reaches again certain operational circumstances as stipulated in the loan agreement and with Black Belt Tx's Board of Directors' approval.    </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In the event that Black Belt Tx, on or prior to the maturity date, completes an equity financing round of at least 5,000,000 euros ($5.9 million), then the outstanding principal amount shall be automatically converted into such shares at 80% of the price per share issued divided by a compensating factor based on the number of years that the Black Belt Tx Loan has been outstanding. The investment in convertible loan is accounted for as investment in debt securities as available-for-sale instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Juventas Cell Therapy Ltd</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In June 2019, in conjunction with its license agreement entered into with Juventas (see Note 1), the Company, through CASI Biopharmaceuticals, a wholly-owned subsidiary of CASI Wuxi, made an RMB 80 million ($11,788,000) investment in Juventas, a privately held, China-based company, in Juventas' Series A plus equity, which represented a 16.327% equity interest on a fully diluted basis, and the right to appoint a non-voting board observer. The Company was entitled with substantive liquidation preference over the founding shareholder of Juventas. In addition, the Juventas' founding shareholder provided a put option to the Company pursuant to which the Company can put the equity investment to the founding shareholder at a fixed return of 8% per annum upon occurrence of certain events. The investment in the equity interests of the Juventas and the investment in put option to the founding shareholder were accounted for as investments in equity securities using the measurement alternative at its cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, as the fair value of the equity securities of Juventas is not readily determinable. The consideration of RMB 80 million ($11,788,000) was allocated into investment in equity interests and investment in put option based on their relative fair value on the transaction date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In September 2020, in conjunction with the Supplementary Agreement entered into with Juventas (see Note 1), the Company obtained additional Series A plus equity interest in Juventas with substantive liquidation preference over Juventas' founding shareholder, resulting in the Company's equity ownership increasing to 16.45% (post-Juventas Series B financing) on a fully diluted basis. CASI Biopharmaceuticals is also entitled to appoint a director to Juventas’ board of directors. Juventas' founding shareholder also provided a put option to the Company pursuant to which the Company can put the additional equity investment to the founding shareholder at RMB 70 million plus a fixed return of 8% per annum upon occurrence of certain events. The transaction closed on September 29, 2020. The fair value of the Company's additional equity interest in Juventas and the new put option was RMB 83.7 million ($12.3 million) and RMB 0.4 million ($64,000) on September 29, 2020, respectively, which was estimated using significant estimates and assumptions, including multiples of selected comparable companies in applying the market approach model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Since the equity interest with substantive liquidation preference is not in-substance common stock, the investment in the additional equity interests of Juventas was accounted for as an investment in equity securities at transaction date fair value with a corresponding credit to Other Liabilities. The profit-sharing liability represents the Company's obligation to pay an increased share of future profits pursuant to the Supplementary Agreement (see Note 1) which was conveyed by the Company in exchange for the additional equity interests in Juventas. The Company views this as a payment from a vendor that should reduce cost of revenues over the period of royalty payments. The long-term liability will be derecognized as payments are made on a systematic and rational basis representing the pattern in which the Company expects to settle the profit-sharing payment during the commercialization period of CNCT19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The investments are measured using the measurement alternative at its cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, as the fair value of the equity securities of Juventas is not readily determinable. In addition, the changes in the fair value of the original investment in equity interests and put option in the amount of $1,116,000 resulting from the observable price in this transaction was recognized during the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2020, the Company entered into a one-year loan agreement with Juventas in the amount of RMB 30,000,000 ($4,243,000) with an annual interest rate of 20%. In August 2020, the Company entered into another one-year loan with Juventas in the amount of RMB 40 million ($5,790,000) for one year with an annual interest rate of 20%. In September 2020, the Company received </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">early repayments for both principals and accrued interest from Juventas. For the year ended December 31, 2020, the Company recognized interest income of $351,000 and $375,000, respectively.</p>
</us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock>
<us-gaap:EquityMethodInvestmentsFairValueDisclosure contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_MaxcyteIncMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_v0T2gbZM-EuXjhritfArfQ" decimals="-5" id="Narr_hnfc5JqUNU-fCE0rlMxLJw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2700000 </us-gaap:EquityMethodInvestmentsFairValueDisclosure>
<us-gaap:EquityMethodInvestmentsFairValueDisclosure contextRef="As_Of_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_MaxcyteIncMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_C5hxQ1huVUacBZp6zWAt3w" decimals="-5" id="Narr_y5MIsMRrvU2YgnziV5_NSg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 600000 </us-gaap:EquityMethodInvestmentsFairValueDisclosure>
<casi:EquityMethodInvestmentInvestmentToBeMade contextRef="As_Of_10_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_IUudb4TwOk2ozeSRncvThQ" decimals="-5" id="Narr_55Y4LcX400KqcS6o06TnyA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6300000 </casi:EquityMethodInvestmentInvestmentToBeMade>
<casi:EquityMethodInvestmentInvestmentToBeMade contextRef="As_Of_10_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_IUudb4TwOk2ozeSRncvThQ" decimals="-5" id="Narr_yFzOj9P1ZEixoZ_jLN2kvQ" unitRef="Unit_Standard_SEK_HamDqLO41U2OnRnGDD3WNw"> 53800000 </casi:EquityMethodInvestmentInvestmentToBeMade>
<casi:NumberOfSharesToBeSubscribed contextRef="Duration_10_1_2020_To_10_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_l4nV_VQrlEyRIzncxfJ4yQ" decimals="-5" id="Narr_anwIG65LH0e6LeiBkYomoA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 1200000 </casi:NumberOfSharesToBeSubscribed>
<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="Duration_10_1_2020_To_10_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_l4nV_VQrlEyRIzncxfJ4yQ" decimals="0" id="Narr_z1u0tvLnHEGZahw-lq3tkA" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 25 </us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
<casi:NumberOfNewWarrantsSubscribed contextRef="Duration_10_1_2020_To_10_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_l4nV_VQrlEyRIzncxfJ4yQ" decimals="INF" id="Narr_sf-eA9bWGk6qhiliybdrLw" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 14700000 </casi:NumberOfNewWarrantsSubscribed>
<casi:NumberOfWarrantsSubscribedPerShare contextRef="As_Of_10_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_IUudb4TwOk2ozeSRncvThQ" decimals="2" id="Narr_rYA4xVuZBkyYy1NP6Q23-w" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.04 </casi:NumberOfWarrantsSubscribedPerShare>
<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="Duration_10_1_2020_To_10_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_l4nV_VQrlEyRIzncxfJ4yQ" decimals="0" id="Narr_3ndm4H-Zp024jDRfiUVmMQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 25 </us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
<casi:SubscriptionPeriodForWarrants contextRef="Duration_10_1_2020_To_10_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_l4nV_VQrlEyRIzncxfJ4yQ" id="Narr_8p8OBUlH9E2cLSRhtm8fZQ"> P5Y </casi:SubscriptionPeriodForWarrants>
<us-gaap:EquityMethodInvestmentsFairValueDisclosure contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_oNqeeSSFfEOVlCSI5Kmzrw" decimals="-5" id="Narr__ZXS7xF3ZEeNeWtYDElxGw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6600000 </us-gaap:EquityMethodInvestmentsFairValueDisclosure>
<casi:WarrantsAndRightsOutstandingFairValueDisclosure contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_fd2NxIMso0qDmLK3pGbFiw" decimals="0" id="Narr_uuaiMStJpU-i7kPLYmHWjQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 841000 </casi:WarrantsAndRightsOutstandingFairValueDisclosure>
<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_fd2NxIMso0qDmLK3pGbFiw" id="Narr_zEK-Wl0Zd0yD41Ui7PSt4g"> P4Y10M28D </us-gaap:WarrantsAndRightsOutstandingTerm>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_4qf8IQUT3E20OqBsMiMhBA" decimals="4" id="Narr_s6v5QiP37kq86y57UAs9xw" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.4763 </us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_n8E96oQwBkSgs0z7diWOIQ" decimals="4" id="Narr_QRXucVVXwka-yK9ojM53PQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.0036 </us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_HBFrOqrYNkqN9AR_dJHSVg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.49%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> MaxCyte - equity interest</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,729</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,729</p></td></tr><tr><td style="vertical-align:bottom;width:35.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> BioInvent - equity interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 919</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,580</p></td></tr></table>
</us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock>
<us-gaap:EquitySecuritiesFvNiUnrealizedGain contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_MaxcyteIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__IeYP4vqGky5MvkjFQwrsQ" decimals="-3" id="Tc_gfYe_hGikEqxxofssygm0w_4_8" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2729000 </us-gaap:EquitySecuritiesFvNiUnrealizedGain>
<us-gaap:InvestmentsFairValueDisclosure contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_MaxcyteIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eVM7R57doUmjvZ6eEPxSdQ" decimals="-3" id="Tc_4-QhyhxANEatIBdXmzXdaQ_4_11" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2729000 </us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:InvestmentOwnedAtCost contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__qtdhHzhcUWblgAuWNIs-g" decimals="-3" id="Tc_b6j5v1b63EKD5sUYj25Jsg_5_5" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5661000 </us-gaap:InvestmentOwnedAtCost>
<us-gaap:EquitySecuritiesFvNiUnrealizedGain contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fZPPvi-QO0WpNkW17udjPg" decimals="-3" id="Tc_N90qnH-nLESDLNmiuHKFVg_5_8" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 919000 </us-gaap:EquitySecuritiesFvNiUnrealizedGain>
<us-gaap:InvestmentsFairValueDisclosure contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__qtdhHzhcUWblgAuWNIs-g" decimals="-3" id="Tc_x_YJ3Uf-MUCHsxccjDm57Q_5_11" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6580000 </us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:AssetsFairValueAdjustment contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-5" id="Narr_ur243BUy7kuw5QkhrFkoIw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3200000 </us-gaap:AssetsFairValueAdjustment>
<us-gaap:AssetsFairValueAdjustment contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_k1xtANDCEEyQTBWeOLD3Ww" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -288000 </us-gaap:AssetsFairValueAdjustment>
<casi:ScheduleOfLongTermInvestmentsTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_nRpvP2sY6EamAafyN9eBew">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Available-for-sale debt securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Black Belt Tx Limited - convertible loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Securities measured at fair value:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">BioInvent International AB - warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity securities without readily determinable fair value:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Black Belt Tx Limited - equity interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,250</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Juventas Cell Therapy Ltd - equity interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,059</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,355</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Juventas Cell Therapy Ltd - put option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 433</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,442</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,038</p></td></tr></table>
</casi:ScheduleOfLongTermInvestmentsTableTextBlock>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_I1fcxHe9skaWq8RXBH0G3Q" decimals="-3" id="Tc_4Dapw4FlF0GxTpsABjrPng_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 83000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
<us-gaap:EquitySecuritiesFvNi contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_us-gaap_FinancialInstrumentAxis_casi_InvestmentsInEquityWarrantsMember_H_94ekLjB0i-85gMQzLVFQ" decimals="-3" id="Tc_E1U4FFA8fUGYFN7RrjyDcA_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 840000 </us-gaap:EquitySecuritiesFvNi>
<us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_kUV7crttSEabXMBT5Xm0eg" decimals="-3" id="Tc_wBSnzG658kaYBPz5dY_l9g_8_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2250000 </us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
<us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="As_Of_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_8rO34GsaZE-z80jXhic9jQ" decimals="-3" id="Tc_Nv8dfK9aiEa0PWOhpoa0Cw_8_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2250000 </us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
<us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_fBKf4Egy40unCyw8gaVITA" decimals="-3" id="Tc_uEdTo7tBlk-QvUoWRT0QzQ_9_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 26059000 </us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
<us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="As_Of_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_L19nzOTRm0aWhhnCVxTl6g" decimals="-3" id="Tc_LLV9iZv090Wfnm5CPO9Knw_9_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 11355000 </us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
<us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="As_Of_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_FinancialInstrumentAxis_us-gaap_PutOptionMember_7VN6hUMvYUu48nv0jred5w" decimals="-3" id="Tc_3QVK-UEJ_UKn37v77e8j0g_10_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 210000 </us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
<us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="As_Of_12_31_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_FinancialInstrumentAxis_us-gaap_PutOptionMember_eOGOIIHry0y8FUmrgm1dRg" decimals="-3" id="Tc_iYMLLS_OO0K3UnOX8yeHKg_10_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 433000 </us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
<us-gaap:LongTermInvestments contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_5pMxerR7PUqcQVbj79DJKw_11_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 29442000 </us-gaap:LongTermInvestments>
<us-gaap:LongTermInvestments contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_FdWKr7OFsECQNCar4JRjyQ_11_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 14038000 </us-gaap:LongTermInvestments>
<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="Duration_4_1_2019_To_4_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_Fq9W1J_0B0W3fxLZRghNLg" decimals="-6" id="Narr_-avMehKSC0aHht0yhtUz_Q" unitRef="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg"> 2000000 </us-gaap:PaymentsToAcquireEquityMethodInvestments>
<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="Duration_4_1_2019_To_4_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_Fq9W1J_0B0W3fxLZRghNLg" decimals="0" id="Narr__KnyCLeIM0GfvEQ1uHfccg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2249600 </us-gaap:PaymentsToAcquireEquityMethodInvestments>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="As_Of_4_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_G4YIlnuvuk64KuwL1D_g0Q" decimals="3" id="Narr_XYiIzTOXjECH2ZkWqQ76wQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.141 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:DebtInstrumentTerm contextRef="Duration_7_1_2020_To_7_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_xYdiaNxtwUylPiiorEew3A" id="Narr_IJ4hAc_qs0yg4c8KhGmpMQ"> P3Y </us-gaap:DebtInstrumentTerm>
<casi:LoanToBeAdvanced contextRef="Duration_7_1_2020_To_7_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_xYdiaNxtwUylPiiorEew3A" decimals="0" id="Narr_gB_uowt6akyPfF57aS9eXg" unitRef="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg"> 211800 </casi:LoanToBeAdvanced>
<casi:LoanToBeAdvanced contextRef="Duration_7_1_2020_To_7_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_xYdiaNxtwUylPiiorEew3A" decimals="0" id="Narr_YlkCiz9SVUG10f8yccRuYg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 250000 </casi:LoanToBeAdvanced>
<us-gaap:RelatedPartyTransactionRate contextRef="Duration_7_1_2020_To_7_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_xYdiaNxtwUylPiiorEew3A" decimals="4" id="Narr_osIC5jOI2k6IcaeVoqOL5w" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.06 </us-gaap:RelatedPartyTransactionRate>
<casi:LoansAdvancedToRelatedPartyAmountOfEqualInstallments contextRef="Duration_7_1_2020_To_7_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_xYdiaNxtwUylPiiorEew3A" decimals="0" id="Narr_KgXGsgRMYku2Di6F1xu8kA" unitRef="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg"> 70600 </casi:LoansAdvancedToRelatedPartyAmountOfEqualInstallments>
<casi:LoansAdvancedToRelatedPartyAmountOfEqualInstallments contextRef="Duration_7_1_2020_To_7_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_xYdiaNxtwUylPiiorEew3A" decimals="0" id="Narr_yoaIXUIA3kCeiDVes-Ew6A" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 83000 </casi:LoansAdvancedToRelatedPartyAmountOfEqualInstallments>
<casi:UpfrontPayment contextRef="Duration_7_1_2020_To_7_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_xYdiaNxtwUylPiiorEew3A" decimals="0" id="Narr_96IyQBxPQUyi8nzylbbPkg" unitRef="Unit_Standard_EUR_6ElBY75G70WLTw0gHnnQGg"> 5000000 </casi:UpfrontPayment>
<casi:MinimumEquityFinancing contextRef="As_Of_7_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_KiL3CVBteEW1dcXh5JnEug" decimals="-5" id="Narr_2QmBW9zce0mrzptUe1yYJQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5900000 </casi:MinimumEquityFinancing>
<casi:LoansAdvancedToRelatedPartyPercentageOfPricePerShareIssuedAtWhichOutstandingPrincipalLoanIsToBeConverted contextRef="Duration_7_1_2020_To_7_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_xYdiaNxtwUylPiiorEew3A" decimals="2" id="Narr_7sB8Y17fjUe1mE6WAiBV7A" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.80 </casi:LoansAdvancedToRelatedPartyPercentageOfPricePerShareIssuedAtWhichOutstandingPrincipalLoanIsToBeConverted>
<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="Duration_6_1_2019_To_6_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_KYklM8q9p0SUd0FzRmImXw" decimals="-6" id="Narr_XIX-h5EMkEaqMn4WA6076A" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 80000000 </us-gaap:PaymentsToAcquireEquityMethodInvestments>
<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="Duration_6_1_2019_To_6_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_KYklM8q9p0SUd0FzRmImXw" decimals="0" id="Narr_WPD_NVWmGU6WQPswWXgCNA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 11788000 </us-gaap:PaymentsToAcquireEquityMethodInvestments>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="As_Of_6_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_zCmsA8hwp0im2PhSRcM0gQ" decimals="5" id="Narr_ata5y1LpikiuZwk5ZarYpQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.16327 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:RelatedPartyTransactionRate contextRef="Duration_6_1_2019_To_6_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_KYklM8q9p0SUd0FzRmImXw" decimals="2" id="Narr_sqXDSUHj0UaWyXRwZA7rbA" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.08 </us-gaap:RelatedPartyTransactionRate>
<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="Duration_6_1_2019_To_6_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_KYklM8q9p0SUd0FzRmImXw" decimals="-6" id="Narr_tZh2Vel-WEizAyNA5G5IPw" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 80000000 </us-gaap:PaymentsToAcquireEquityMethodInvestments>
<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="Duration_6_1_2019_To_6_30_2019_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_KYklM8q9p0SUd0FzRmImXw" decimals="0" id="Narr_H5GhHB4KdUOwyVnc2aVa4w" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 11788000 </us-gaap:PaymentsToAcquireEquityMethodInvestments>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="As_Of_9_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_mHBLAO5l9U2V98sujFDEug" decimals="4" id="Narr_k8YotF-IOUC6vQ8PlR1Dzg" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.1645 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<casi:MilestonePaymentToBeWaived contextRef="Duration_9_29_2020_To_9_29_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_rUjsP-x6pU6mClOZZsbgOQ" decimals="-6" id="Narr_IJJFLZh3IECcSogiuEV9Sw" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 70000000 </casi:MilestonePaymentToBeWaived>
<us-gaap:RelatedPartyTransactionRate contextRef="Duration_9_1_2020_To_9_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_nJ9U7Pnbj067zCKADaCrpg" decimals="2" id="Narr_TZhLszlqdEWlKQUZVuBmNw" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.08 </us-gaap:RelatedPartyTransactionRate>
<us-gaap:EquityMethodInvestmentsFairValueDisclosure contextRef="As_Of_9_29_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_0291pJlo6EugGh_XSP-pTw" decimals="-5" id="Narr_8HKuQYXHl0W9TA25grqwQA" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 83700000 </us-gaap:EquityMethodInvestmentsFairValueDisclosure>
<us-gaap:EquityMethodInvestmentsFairValueDisclosure contextRef="As_Of_9_29_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_0291pJlo6EugGh_XSP-pTw" decimals="-5" id="Narr_fRvd1bIbYEiqpzhZfyCl4g" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 12300000 </us-gaap:EquityMethodInvestmentsFairValueDisclosure>
<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="Duration_9_29_2020_To_9_29_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_PutOptionMember_ZX6XI1FrG0WsJokPrMOrpw" decimals="-5" id="Narr_hFDt_SKnFkWa-6fVo1Wx2w" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 400000 </us-gaap:PaymentsToAcquireEquityMethodInvestments>
<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="Duration_9_29_2020_To_9_29_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_PutOptionMember_ZX6XI1FrG0WsJokPrMOrpw" decimals="0" id="Narr_PDiabMXcZEuD-zWccC3ZZQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 64000 </us-gaap:PaymentsToAcquireEquityMethodInvestments>
<us-gaap:AssetsFairValueAdjustment contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_KJ985i4PHkO4b0jbK6cM1g" decimals="0" id="Narr_0uuf3WtdckSvsROExPNMxg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1116000 </us-gaap:AssetsFairValueAdjustment>
<casi:LoansAdvancedToRelatedPartyTerm contextRef="Duration_6_1_2020_To_6_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementJune2020Member_Pb62VgCchUyWlIkip9HV8A" id="Narr_0O0l-9adrEuIzVXSDHylmw"> P1Y </casi:LoansAdvancedToRelatedPartyTerm>
<casi:LoansAdvancedToRelatedPartyMaximumBorrowingCapacity contextRef="Duration_6_1_2020_To_6_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementJune2020Member_Pb62VgCchUyWlIkip9HV8A" decimals="0" id="Narr_t73lBtcubE68_kYRPR7bpQ" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 30000000 </casi:LoansAdvancedToRelatedPartyMaximumBorrowingCapacity>
<casi:LoansAdvancedToRelatedPartyMaximumBorrowingCapacity contextRef="Duration_6_1_2020_To_6_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementJune2020Member_Pb62VgCchUyWlIkip9HV8A" decimals="0" id="Narr_325XZAC6VUCWFoai_MhC7g" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4243000 </casi:LoansAdvancedToRelatedPartyMaximumBorrowingCapacity>
<us-gaap:RelatedPartyTransactionRate contextRef="Duration_6_1_2020_To_6_30_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementJune2020Member_Pb62VgCchUyWlIkip9HV8A" decimals="2" id="Narr_OMy40ssmnU-9pXBGfVREeA" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.20 </us-gaap:RelatedPartyTransactionRate>
<casi:LoansAdvancedToRelatedPartyTerm contextRef="Duration_8_1_2020_To_8_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementAugust2020Member_7cvAc7MSxEqhWTLNRIuAxQ" id="Narr_wYvzi5sxwkalo1ciR220DQ"> P1Y </casi:LoansAdvancedToRelatedPartyTerm>
<casi:LoansAdvancedToRelatedPartyMaximumBorrowingCapacity contextRef="Duration_8_1_2020_To_8_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementAugust2020Member_7cvAc7MSxEqhWTLNRIuAxQ" decimals="-6" id="Narr_pD6Ou9E130CM5sCac7PDOQ" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 40000000 </casi:LoansAdvancedToRelatedPartyMaximumBorrowingCapacity>
<casi:LoansAdvancedToRelatedPartyMaximumBorrowingCapacity contextRef="Duration_8_1_2020_To_8_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementAugust2020Member_7cvAc7MSxEqhWTLNRIuAxQ" decimals="0" id="Narr_Mu6UAxvxhUqTImmqQJXZbg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5790000 </casi:LoansAdvancedToRelatedPartyMaximumBorrowingCapacity>
<casi:LoansAdvancedToRelatedPartyTerm contextRef="Duration_8_1_2020_To_8_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementAugust2020Member_7cvAc7MSxEqhWTLNRIuAxQ" id="Narr_K1EI2EF4HECk05m7WY2IkQ"> P1Y </casi:LoansAdvancedToRelatedPartyTerm>
<us-gaap:RelatedPartyTransactionRate contextRef="Duration_8_1_2020_To_8_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementAugust2020Member_7cvAc7MSxEqhWTLNRIuAxQ" decimals="2" id="Narr_VlM04vm0jUqdhhhhpHquHg" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.20 </us-gaap:RelatedPartyTransactionRate>
<us-gaap:InterestIncomeRelatedParty contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementJune2020Member_VYuk8JHoUUSqygYQ-DwJvg" decimals="0" id="Narr_5Igd-axSSU2qoVFH0r8Atw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 351000 </us-gaap:InterestIncomeRelatedParty>
<us-gaap:InterestIncomeRelatedParty contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_JuventasCellTherapyLtdMember_us-gaap_DebtInstrumentAxis_casi_LoanAgreementAugust2020Member_oq_BBhDaIkmyqxDKGkgojg" decimals="0" id="Narr_EwubS63of026OlLbsGfuwA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 375000 </us-gaap:InterestIncomeRelatedParty>
<us-gaap:InventoryDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_TQjbaUWy1kGeCHkqlhPKxQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">4.      INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Inventories at December 31, 2020 and 2019 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,356</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,514</p></td></tr><tr><td style="vertical-align:bottom;width:70.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 28</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,356</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,542</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">No provisions to write down the carrying amount of inventory have been recorded in the year ended December 31, 2020. Provisions to write-down the carrying amount of obsolete inventory related to ANDAs were $152,000, and were recorded as expenses in the consolidated statements of comprehensive loss for the year ended December 31, 2019. </p>
</us-gaap:InventoryDisclosureTextBlock>
<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_eVhSNB_WCEuSpABYzE6HIg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,356</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,514</p></td></tr><tr><td style="vertical-align:bottom;width:70.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 28</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,356</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,542</p></td></tr></table>
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_aMPUF9meukqsGFvLXiEJyA_3_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1356000 </us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_bbz9lXT0Fk-2kxwjFf2M0g_3_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4514000 </us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_bdXzQxEW30KSffKYsHyOUA_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 28000 </us-gaap:InventoryRawMaterialsNetOfReserves>
<us-gaap:InventoryNet contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_e4YJkXFQCEuoBpFSowNNmw_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1356000 </us-gaap:InventoryNet>
<us-gaap:InventoryNet contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_6-1oXy9auUeCOJnyVVaAUA_5_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4542000 </us-gaap:InventoryNet>
<us-gaap:InventoryWriteDown contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Narr_zK79TKvhDEOfDSokPPjcoQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:InventoryWriteDown>
<us-gaap:InventoryWriteDown contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_0eCYTvqHL0qeM9MrJIz5GA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 152000 </us-gaap:InventoryWriteDown>
<us-gaap:LesseeOperatingLeasesTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_Vakisq7Vn0CXpEJCqhCg_g">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">5.      LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As discussed in Note 2, effective January 1, 2019, the Company adopted Topic 842. At the inception of a contract, the Company determines if the arrangement is, or contains, a lease. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has made accounting policy elections whereby it (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months or less) and (ii) combines lease and non-lease components for facilities leases, which primarily relate to ancillary expenses such as common area maintenance charges and management fees of its operating leases. Operating lease liabilities (see below) are included in accrued liabilities and other current liabilities, and other liabilities (noncurrent) in the consolidated balance sheets as of December 31, 2020. As of December 31, 2020, the Company did not have any finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All of the Company’s existing leases as of December 31, 2020 are classified as operating leases. As of December 31, 2020, the Company has seven material operating leases for land, facilities and office equipment with remaining terms expiring from 2021 through 2069 and a weighted average remaining lease term of 38.37 years. The Company has fair value renewal options for many of the Company’s existing leases, none of which are considered reasonably certain of being exercised or included in the minimum lease term. Weighted average discount rates used in the calculation of the lease liability is 3.72%. The discount rates reflect the estimated incremental borrowing rate, which includes an assessment of the credit rating to determine the rate that the Company would have to pay to borrow, on a collateralized basis for a similar term, an amount equal to the lease payments in a similar economic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In November 2019, CASI Wuxi entered into a fifty-year lease agreement for the right to use state-owned land in China for the construction of a manufacturing facility. The land parcel is 74,028.40 square meters.  The Company classifies this lease as an operating lease. The Company prepaid all of the lease payments for the land use right in 2019 in the amount of RMB45 million (equivalent to $6.5 million).  During 2020, the Company entered into two 3-year lease agreements for office space in China each of which continue through August 2023 and September 2023, respectively, and one 5-year lease agreement for a Research and Development facility also in China which continues through March 2025. The Company recorded right-of-use assets of $1.3 million and related lease liabilities of $1.2 million at lease commencement date. The Company classifies these leases as operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In the fourth quarter of 2020, the company terminated one lease of office space twelve months earlier than the lease term and recognized a loss of $13,000 from this lease termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Rent expense for the years ended December 31, 2020 and December 31, 2019 was $1,600,000 and $1,315,000. There were no variable lease costs or sublease income for leased assets for the years ended December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Right of use assets and liabilities as of December 31, 2020 and December 31, 2019 consolidated balance sheets were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,696</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,708</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_VP2HSlCBzke7mrrpg8iwKg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Accrued liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 939</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,182</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_sbQuffdDGk-anSqhdPChlA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ofosIaxQlEKKZFtF1U43EQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Total lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,904</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,201</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Supplemental cash flow information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,315</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets obtained in exchange for lease obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,157</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">A maturity analysis of the Company’s operating leases as of December 31, 2020 follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Future undiscounted cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,052</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 626</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount factor</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (96)</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,904</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amounts due within 12 months</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 939</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current lease liability</p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 965</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p>
</us-gaap:LesseeOperatingLeasesTextBlock>
<casi:NumberOfOperatingLeases contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="INF" id="Narr_ZbROnKX1o0OgZiIOzopEuA" unitRef="Unit_Standard_lease_lPgwyBdVyEynXNo_4iSlQg"> 7 </casi:NumberOfOperatingLeases>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" id="Narr__6JPJ0bsN0GQS-v7O7OC3g"> P38Y4M13D </us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="4" id="Narr_gSvpmzeISEiNStVMEZ101g" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.0372 </us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:LessorOperatingLeaseTermOfContract contextRef="As_Of_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_kjsYxa-Bz0eaH9B0KN-7bw" id="Narr_v0iBLSJNcEig-fLxjgqbsA"> P50Y </us-gaap:LessorOperatingLeaseTermOfContract>
<us-gaap:AreaOfLand contextRef="As_Of_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_kjsYxa-Bz0eaH9B0KN-7bw" decimals="2" id="Narr_gt8lW-zZ3Uy-OPe8udmfrg" unitRef="Unit_Standard_sqm_5nOihD7L7kmLecswPxNXyA"> 74028.40 </us-gaap:AreaOfLand>
<casi:PrepaidOperatingLeasePayments contextRef="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_V0P7PHHzRE2gkPiJuJmjuQ" decimals="-6" id="Narr_XRQATBWshEW7sqdky4YcYQ" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 45000000 </casi:PrepaidOperatingLeasePayments>
<casi:PrepaidOperatingLeasePayments contextRef="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_V0P7PHHzRE2gkPiJuJmjuQ" decimals="-5" id="Narr_uI5XTKl1i0GVYUj5qtjUUg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6500000 </casi:PrepaidOperatingLeasePayments>
<casi:LesseeOperatingLeaseNumberOfLeaseAgreements contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_CN_us-gaap_LeaseContractualTermAxis_casi_OfficeSpaceLeaseMember_BZws6bnsN0mMRwpA5vsoJA" decimals="INF" id="Narr_3i_wIVo76kua8njh_IQa9w" unitRef="Unit_Standard_lease_lPgwyBdVyEynXNo_4iSlQg"> 2 </casi:LesseeOperatingLeaseNumberOfLeaseAgreements>
<us-gaap:LessorOperatingLeaseTermOfContract contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_CN_us-gaap_LeaseContractualTermAxis_casi_OfficeSpaceLeaseMember_uCOjljswCEi3J-a7ki01yw" id="Narr_n8IX9ozpF0y8k4DcXbDloA"> P3Y </us-gaap:LessorOperatingLeaseTermOfContract>
<casi:LesseeOperatingLeaseNumberOfLeaseAgreements contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_CN_us-gaap_LeaseContractualTermAxis_casi_ResearchAndDevelopmentFacilityLeaseMember_qJBJAyCzrUqZVLhbrgzA9g" decimals="INF" id="Narr_fFsO9f0pAkS4Ewzb44jr4A" unitRef="Unit_Standard_lease_lPgwyBdVyEynXNo_4iSlQg"> 1 </casi:LesseeOperatingLeaseNumberOfLeaseAgreements>
<us-gaap:LessorOperatingLeaseTermOfContract contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_CN_us-gaap_LeaseContractualTermAxis_casi_ResearchAndDevelopmentFacilityLeaseMember_H5UVztDX6USVVT9wJ01ZYA" id="Narr_GeRaJUCbhkCGGffW0zdsaw"> P5Y </us-gaap:LessorOperatingLeaseTermOfContract>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_CN_uCPV6GlxvECLOcBrt3KrIg" decimals="-5" id="Narr_jx8qcbiekEC4ikAbDNq7WA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1300000 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseLiability contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_CN_uCPV6GlxvECLOcBrt3KrIg" decimals="-5" id="Narr_unsYZYAL7U2SggwYKuFILA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1200000 </us-gaap:OperatingLeaseLiability>
<casi:LesseeOperatingLeaseNumberOfLeaseTerminated contextRef="Duration_10_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_CN_us-gaap_LeaseContractualTermAxis_casi_OfficeSpaceLeaseMember_PQTnsPp6mEOIDggZtPgIQQ" decimals="INF" id="Narr_hfqvTVBcdkWznQ4oaXtToA" unitRef="Unit_Standard_lease_lPgwyBdVyEynXNo_4iSlQg"> 1 </casi:LesseeOperatingLeaseNumberOfLeaseTerminated>
<us-gaap:GainLossOnTerminationOfLease contextRef="Duration_10_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_CN_us-gaap_LeaseContractualTermAxis_casi_OfficeSpaceLeaseMember_PQTnsPp6mEOIDggZtPgIQQ" decimals="0" id="Narr_H4cEoYTvOkSGMBExE8i6KQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 13000 </us-gaap:GainLossOnTerminationOfLease>
<us-gaap:OperatingLeaseExpense contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_fonOunO5w0SyZ80SOSeJug" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1600000 </us-gaap:OperatingLeaseExpense>
<us-gaap:OperatingLeaseExpense contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_TYsptA9z30K151HIuxG-lQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1315000 </us-gaap:OperatingLeaseExpense>
<casi:DisclosureOfLeaseOnConsolidatedBalanceSheetTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_oNsNVrR7EESHJ5BVtdMWjQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,696</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,708</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_VP2HSlCBzke7mrrpg8iwKg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Accrued liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 939</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,182</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_sbQuffdDGk-anSqhdPChlA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ofosIaxQlEKKZFtF1U43EQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Total lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,904</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,201</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table>
</casi:DisclosureOfLeaseOnConsolidatedBalanceSheetTableTextBlock>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_VcbNY6sGpEuVzfPzbcB6qA_3_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 8696000 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_qt7Fu1hVtUeUE_CPTldOZQ_3_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 8708000 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseLiability contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_8XJ-VCcwakKprpoLtzi8kw" decimals="-3" id="Tc_OkY7EtacC0CbFhC92ztAgA_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 939000 </us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseLiability contextRef="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_1qDyHgjkSkScg3XBvS_eNA" decimals="-3" id="Tc_448xpHCCFEyYWxtm9Nfzbg_5_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1182000 </us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseLiability contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_RWh-RP3-R0iFwQZ8pCtu1Q" decimals="-3" id="Tc_J5R9-2Yti0Kb9gUaQSdzwQ_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 965000 </us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseLiability contextRef="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_PkStkoceF0e7jELXRQvUsw" decimals="-3" id="Tc_eNkiflXBVESyK6Y3TNFRYw_6_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1019000 </us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseLiability contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_uIINmE9GIkqs5IrJfcvDnQ_7_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1904000 </us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseLiability contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_HXJv-ACGrE2MAnCkLt56FA_7_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2201000 </us-gaap:OperatingLeaseLiability>
<casi:DisclosureOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_DEOoRzj85ECMcLkBg1phCg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,315</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets obtained in exchange for lease obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,157</p></td></tr></table>
</casi:DisclosureOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
<us-gaap:OperatingLeasePayments contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_yWcaPMwW2UKJ0UEIIKQoYg_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1375000 </us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeasePayments contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_t0iG5-b8mkKRUWxUcNEvHw_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1315000 </us-gaap:OperatingLeasePayments>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_FBZmT7cjY0miiuG2umulJw_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1196000 </us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_G_lTQObav02nTBRVgmt9Sw_6_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2157000 </us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_O1vMumRRrEKdvRhbQp-mXg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,052</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 626</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount factor</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (96)</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,904</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amounts due within 12 months</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 939</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current lease liability</p></td><td style="vertical-align:bottom;white-space:normal;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 965</p></td></tr></table>
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_CkLIqrgLv0iAr5JmOFXHLQ_2_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1052000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_lnrpndlb1U2gyK25zpWo0w_3_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 626000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc__wS5cjguakChJG4fcJ7Rwg_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 280000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
<casi:LesseeOperatingLeaseLiabilityPaymentsDueThereafter contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_Wv1Jnbu6tUiGE1wUxKPfhQ_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 42000 </casi:LesseeOperatingLeaseLiabilityPaymentsDueThereafter>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_8RxyEXeb2ky0PPgGEeLqEA_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2000000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_lf5EGPWcZkOHVauZelw7Ow_8_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 96000 </us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:OperatingLeaseLiability contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_2_M27Oxljk-E2hxxeRcrvQ_9_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1904000 </us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_SgM-XzLL0kied0Okw4N77g_10_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 939000 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_KihJkUNtXEO1Jakkk0znXg_11_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 965000 </us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_BCpMEhwDuEOaklXYAT15xg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">6.      PROPERTY, PLANT AND EQUIPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In November 2019, CASI Wuxi entered into a lease agreement for the right to use state-owned land in China for the construction of a manufacturing facility. Pursuant to the agreement, CASI Wuxi commits to invest land use right and property, plant and equipment of RMB 1 billion (equivalent to $143 million).  On August 27, 2020, CASI Wuxi entered into a Construction Project Contract (the "Construction Contract") with China Electronic System Engineering No. 2 Construction Co., Ltd. ("China Engineering"). Pursuant to the Construction Contract, CASI Wuxi will pay a contract price of RMB 74,588,000 (equivalent to  $10,923,000) to retain China Engineering to complete the phase 1 project of CASI Wuxi's research and development production base, consisting of construction and installation of a combined factory building, warehouse, guard house and public works. The estimated completion date is October 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Construction in progress (“CIP”) is included in Property, Plant and Equipment (“PP&E”). CIP is stated at cost and includes costs incurred to acquire, construct, or install PP&E. CIP overhead is expensed as incurred. Construction in progress is not depreciated until such time when the asset is substantially completed and ready for its intended use.  At December 31, 2020, CIP is $1.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Furniture and equipment are stated at cost and are depreciated over their estimated useful lives of 3 to 5 years. Leasehold improvements are stated at cost and are amortized over the shorter of their useful lives or the lease term. Depreciation and amortization expense are determined on a straight-line basis. Depreciation and amortization expense were $562,000 and $603,000 in 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property, plant and equipment consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,622</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,305</p></td></tr><tr><td style="vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 792</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,193</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property, plant and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,097</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,322)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (726)</p></td></tr><tr><td style="vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Impairment of property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (416)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (386)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,062</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 985</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognized no impairment during the year ended December 31, 2020, and $386,000 during the year ended December 31, 2019 related to equipment which was leased to a related party (see Note 19).</p>
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<casi:LandUseRightAndPropertyPlantAndEquipmentCommitmentAmount contextRef="Duration_11_1_2019_To_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_dYsiMUDgcEaYApPduIKx9Q" decimals="-9" id="Narr_DRB6TIyWdUCOt4OypDxgKg" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 1000000000 </casi:LandUseRightAndPropertyPlantAndEquipmentCommitmentAmount>
<casi:LandUseRightAndPropertyPlantAndEquipmentCommitmentAmount contextRef="Duration_11_1_2019_To_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_dYsiMUDgcEaYApPduIKx9Q" decimals="-6" id="Narr_v5WfNDOYNUiQshjQ_RR6sg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 143000000 </casi:LandUseRightAndPropertyPlantAndEquipmentCommitmentAmount>
<casi:ConstructionProjectContractContractPrice contextRef="As_Of_8_27_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_hXZDZBgK3EqZJeFfmlyPRw" decimals="0" id="Narr_XLlLlRCFW0e9USR4p2Hrqg" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 74588000 </casi:ConstructionProjectContractContractPrice>
<casi:ConstructionProjectContractContractPrice contextRef="As_Of_8_27_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_hXZDZBgK3EqZJeFfmlyPRw" decimals="0" id="Narr_R6-VT5UekUuhrpnNgbwuzg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 10923000 </casi:ConstructionProjectContractContractPrice>
<us-gaap:ConstructionInProgressGross contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-5" id="Narr_-ecqBNA6UE-sNBGNrP7jkw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1200000 </us-gaap:ConstructionInProgressGross>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_0esdaLs8n0679GyzfMH_9A" id="Narr_uBgGdsRd30endgn5Yv2PPg"> P3Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_FDAXWmiR7UGiK3T94vDFwQ" id="Narr_LLMALYSTm0SPHtoAo9p59Q"> P5Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_DpYOcMw1rECqduKM-MCGNA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 562000 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_1R3HK6GjEUuwX-FzbJwelA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 603000 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_be0UyTC0nECGg6_bFXLYvw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property, plant and equipment consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,622</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,305</p></td></tr><tr><td style="vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 792</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,193</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property, plant and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,097</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,322)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (726)</p></td></tr><tr><td style="vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Impairment of property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (416)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (386)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,062</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 985</p></td></tr></table>
</us-gaap:PropertyPlantAndEquipmentTextBlock>
<casi:FurnitureAndEquipmentGross contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_2Dk083DEZEWD_gtLX22t1Q_3_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1622000 </casi:FurnitureAndEquipmentGross>
<casi:FurnitureAndEquipmentGross contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_pbieu96RAE2TXZBujB-kRw_3_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1305000 </casi:FurnitureAndEquipmentGross>
<us-gaap:LeaseholdImprovementsGross contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_uWnTLLmk4UeXm9okct_Ghw_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 985000 </us-gaap:LeaseholdImprovementsGross>
<us-gaap:LeaseholdImprovementsGross contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_bBrfOn0e1U24hEYE-h4Gsg_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 792000 </us-gaap:LeaseholdImprovementsGross>
<us-gaap:ConstructionInProgressGross contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_1QsRtcEkJkm8vZUv7nqazw_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1193000 </us-gaap:ConstructionInProgressGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_YeHne7SzXEWDtZmnsHH5DQ_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3800000 </us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_Pd07Cq6xLkK1tdspBimdwA_6_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2097000 </us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_qZ-qkefz70W3Z2s2-XpRVg_7_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1322000 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_bIEImLOl9E2iHoDFnWu5Og_7_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 726000 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<casi:TangibleAssetImpairmentChargesIncludingForeignCurrencyTranslation contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_RTVk1Qu8S0S0D9SU7RFCZQ_8_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -416000 </casi:TangibleAssetImpairmentChargesIncludingForeignCurrencyTranslation>
<casi:TangibleAssetImpairmentChargesIncludingForeignCurrencyTranslation contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_dyc_-m5BSEOl19rG14T3vA_8_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -386000 </casi:TangibleAssetImpairmentChargesIncludingForeignCurrencyTranslation>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_DO0tSIxOOkeUcZPYcgtOYQ_9_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2062000 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_aaiR6SkB3kyAPtqfW495qA_9_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 985000 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:TangibleAssetImpairmentCharges contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_ls-_ciBP5U6y2T3W4gkoZA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:TangibleAssetImpairmentCharges>
<us-gaap:TangibleAssetImpairmentCharges contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_tDaX9VG_9UumTp_5PvIAcg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 386000 </us-gaap:TangibleAssetImpairmentCharges>
<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_xAGByp3ndkmnxNAxRbl6jQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">7.      INTANGIBLE ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Intangible assets include ANDAs that were acquired as part of 2018 asset acquisitions and US marketed generic products and capitalized cost related to a cloud computing arrangement (CCA). These intangible assets were originally recorded at relative estimated fair values based on the purchase price for the asset acquisitions and are stated net of accumulated amortization and impairment, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The ANDAs are amortized over their estimated useful lives of 13 years, using the straight-line method. The cloud computing arrangement is amortized over its useful life of 5 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In February 2020, the Company entered into an agreement with Chartwell Rx Sciences, LLC (“Chartwell”) in which the Company sold and transferred the control of seven U.S. FDA-approved ANDAs to Chartwell in exchange for $450,000 in cash, which the Company received in March 2020. These ANDAs had a net book value of $0 at the time of sale. The Company is entitled to an additional $1 million, contingent upon Chartwell receiving certain FDA approvals relating to certain of these ANDAs. The Company recognized a gain on disposal of intangible assets in the amount of $450,000 in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2020. The additional $1 million is treated as variable consideration. Because the amount of variable consideration is highly susceptible to factors outside the Company's influence and the Company’s experience with similar types of contracts is limited, the Company did not include the amount of variable consideration in recognition of gain on disposal of intangible assets for the year ended December 31, 2020. The Company will recognize the variable consideration and additional gain on disposal of intangible assets when the constraint on variable consideration is resolved, i.e., Chartwell receives relevant FDA approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Intangible assets at December 31, 2020 consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Purchase Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated useful lives</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ANDAs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,832</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,721)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">13 years</p></td></tr><tr><td style="vertical-align:bottom;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5 years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,029</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,819)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="background-color:#00ff00;margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The changes in intangible assets for the year ended December 31, 2020 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,674</p></td></tr><tr><td style="vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Disposal of 7 ANDAs at $0 net book value</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,289)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 825</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,210</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Expected future amortization expense is as follows as of December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,321</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,321</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,321</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,288</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,288</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,671</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p>
</us-gaap:IntangibleAssetsDisclosureTextBlock>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_epqcBoht20abZ3M1ndr6rQ" id="Narr_qD6tmLUpw0i8G9VMgoMBMw"> P13Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_CloudComputingArrangementMember_sh84kcuUvkaRoEGq1g-YsA" id="Narr_ZtmcxRGGFEGaWFIKo-xJfQ"> P5Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<casi:NumberOfIntangibleAssetsSold contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_us-gaap_TypeOfArrangementAxis_casi_ChartwellRxSciencesLlcMember_8yegX2qWFUWs6FfHTkZS4w" decimals="INF" id="Narr_m82jZrKbZU6NTBuY6QvWCg" unitRef="Unit_Standard_item_flJTMRpAMk2GmooQY-riJQ"> 7 </casi:NumberOfIntangibleAssetsSold>
<casi:AggregateConsiderationReceivableOnSaleOfIntangibleAssets contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_us-gaap_TypeOfArrangementAxis_casi_ChartwellRxSciencesLlcMember_8yegX2qWFUWs6FfHTkZS4w" decimals="0" id="Narr_oSv8A3ejkkm2fnMxgetdsg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 450000 </casi:AggregateConsiderationReceivableOnSaleOfIntangibleAssets>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="As_Of_2_29_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_us-gaap_TypeOfArrangementAxis_casi_ChartwellRxSciencesLlcMember_RHtSUlatJUGV_OgD-R5pSQ" decimals="0" id="Narr_im17jH_yikyLTziIGnqhWQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:FiniteLivedIntangibleAssetsNet>
<casi:RemainingConsiderationReceivableOnSaleOfIntangibleAssets contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_us-gaap_TypeOfArrangementAxis_casi_ChartwellRxSciencesLlcMember_8yegX2qWFUWs6FfHTkZS4w" decimals="-6" id="Narr_pVdrsafzpU6AEoFw9pnwBg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1000000 </casi:RemainingConsiderationReceivableOnSaleOfIntangibleAssets>
<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="Duration_2_1_2020_To_2_29_2020_4bJnhMZQ9k6dW7cnRMxw3Q" decimals="0" id="Narr_f5dQ_258Xk6aGqlNzofvRg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 450000 </us-gaap:GainLossOnDispositionOfIntangibleAssets>
<casi:RemainingConsiderationReceivableOnSaleOfIntangibleAssets contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_us-gaap_TypeOfArrangementAxis_casi_ChartwellRxSciencesLlcMember_8yegX2qWFUWs6FfHTkZS4w" decimals="-6" id="Narr_W-5Cb0qmVEKMzcrrr7-hdA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1000000 </casi:RemainingConsiderationReceivableOnSaleOfIntangibleAssets>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_5QRlnys-dE-U0nakZToc4w">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Purchase Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated useful lives</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ANDAs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,832</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,721)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">13 years</p></td></tr><tr><td style="vertical-align:bottom;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5 years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,029</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,819)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr></table>
</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="As_Of_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_43-3WISlG0ayISQ9cDD6KA" decimals="-3" id="Tc_yDzB0gpZ302RmA36hLlfcQ_3_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 15832000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_43-3WISlG0ayISQ9cDD6KA" decimals="-3" id="Tc_O16EeA1Kq0iLqGuJur0AoQ_3_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2721000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_epqcBoht20abZ3M1ndr6rQ" id="Tc_Iv1CJ5ev6UCKQdKdXHn0xQ_3_8"> P13Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="As_Of_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember__pSyNYoukEidePcebzjm_w" decimals="-3" id="Tc_9C0k04ns7UGlHzLB2MfdLA_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 197000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember__pSyNYoukEidePcebzjm_w" decimals="-3" id="Tc_1hLvu97ELECof7cfje6BzA_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 98000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember_G_aMSXOd2EqTf_hSi4fATw" id="Tc_FBEefb9ZS0OYxKlkDOHfTQ_4_8"> P5Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_vjO9WfHyjUqolTmePjeJ9Q_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 16029000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_uRfNM6gr2U-VT6OMnMIFOA_5_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2819000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_ZGFTg2V_BkqEtreBbLvdKw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,674</p></td></tr><tr><td style="vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Disposal of 7 ANDAs at $0 net book value</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,289)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 825</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,210</p></td></tr></table>
</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_n1ibvJliHEiCz7bHs8yx7A_2_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 13674000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<casi:NumberOfIntangibleAssetsSold contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_us-gaap_TypeOfArrangementAxis_casi_ChartwellRxSciencesLlcMember_8yegX2qWFUWs6FfHTkZS4w" decimals="INF" id="Narr_hyCkVEw4U0yDW0gzUTxSNQ" unitRef="Unit_Standard_item_flJTMRpAMk2GmooQY-riJQ"> 7 </casi:NumberOfIntangibleAssetsSold>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="As_Of_2_29_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_AbbreviatedNewDrugApplicationsMember_us-gaap_TypeOfArrangementAxis_casi_ChartwellRxSciencesLlcMember_RHtSUlatJUGV_OgD-R5pSQ" decimals="0" id="Narr_Z6iyqNvFWkum4L5ezRbAyQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_5CZwb3XcFkCoO_tGCLFaeQ_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1289000 </us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_cn20HQ42EEO17Fe14dMRvQ_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 825000 </us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_TerQRJBvlE2shY5c_P0nMQ_7_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 13210000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_ZxIGS4BzTUiBz1dn_v7Apw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,321</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,321</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,321</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,288</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,288</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,671</p></td></tr></table>
</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_9p2hAxxFpU6AOCVLjJXrow_2_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1321000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_MI6ZbiLXDEmEfkoRtdp-ag_3_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1321000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_TLpr_Owd-kST0PiCrCMOcg_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1321000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_RFzSNhZc_USmz9sezylMfg_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1288000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_N-ozHAhQe0O8KzE67Fxkug_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1288000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_dZKS5mB8WUS9df8z6Jo18Q_7_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6671000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
<casi:AssetsHeldForSaleDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_1eICOCj7EESDAuTmID7CXA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">8.      ASSETS HELD FOR SALE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the year ended December 31, 2020, the Company classified 14 ANDAs as assets held for sale as it committed to plans to sell these assets within one year and actively market the assets in their current condition at a price that is reasonable in relation to their estimated fair value. The Company reclassified the comparable balance sheet amounts related to these fourteen ANDAs in the amount of $3.2 million as of December 31, 2019 from intangible assets to assets held for sale. The Company recorded an impairment related to these assets held for sale of $1.5 million during the year ended December 31, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In July 2020, the Company entered into an agreement with Rubicon Research Private Limited (“Rubicon”) in which the Company sold and transferred the control of four U.S. FDA-approved ANDAs to Rubicon in exchange for $1.25 million in cash, which the Company received in July 2020. These ANDAs had a net book value of $1.25 million at the time of sale resulting in no gain or loss on the sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2020, the Company entered into an agreement with Chartwell pursuant to which the Company sold and transferred the control of 10 ANDAs to Chartwell in exchange for $1.0 million in cash, which the Company received in the fourth quarter of 2020. These ANDAs had a net book value of $0.3 million at the time of sale, resulting in a gain on sale of assets of $0.7 million in the fourth quarter of 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Assets held-for-sale at December 31, 2019 consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of intangible assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,074</p></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (853)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,221</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p>
</casi:AssetsHeldForSaleDisclosureTextBlock>
<casi:NumberOfIntangibleAssetsClassifiedAsHeldForSale contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_RXB7SHbTW0OVSdz6WUn3bA" decimals="INF" id="Narr_WYWJ0MCWKUSE1KPvic5wvA" unitRef="Unit_Standard_item_flJTMRpAMk2GmooQY-riJQ"> 14 </casi:NumberOfIntangibleAssetsClassifiedAsHeldForSale>
<casi:NumberOfIntangibleAssetsClassifiedAsHeldForSale contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_RXB7SHbTW0OVSdz6WUn3bA" decimals="INF" id="Narr_iTMGmi1XjU-kPTwOW5d8Yw" unitRef="Unit_Standard_item_flJTMRpAMk2GmooQY-riJQ"> 14 </casi:NumberOfIntangibleAssetsClassifiedAsHeldForSale>
<casi:BalanceOfAssetsHeldForSaleOnReclassifiedFromIntangibleAssets contextRef="As_Of_12_31_2019_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_3RFfkjq4JkqbR9wdYfWdug" decimals="-5" id="Narr_5Of4_e_UNUCkdgJzyBkizw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3200000 </casi:BalanceOfAssetsHeldForSaleOnReclassifiedFromIntangibleAssets>
<casi:ImpairmentOfIntangibleAssetsToBeDisposedOff contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_RXB7SHbTW0OVSdz6WUn3bA" decimals="-5" id="Narr_j4GmLDC4F0mnzJ95WvLHtA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1500000 </casi:ImpairmentOfIntangibleAssetsToBeDisposedOff>
<casi:NumberOfIntangibleAssetsSold contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_AQWaElCDiEOyldG0TKpKaw" decimals="INF" id="Narr_S36SkezKh0eupmxMMMOzFw" unitRef="Unit_Standard_item_flJTMRpAMk2GmooQY-riJQ"> 4 </casi:NumberOfIntangibleAssetsSold>
<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_AQWaElCDiEOyldG0TKpKaw" decimals="-4" id="Narr_9e5h21GerU652IqWN8TJRQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1250000 </us-gaap:ProceedsFromSaleOfIntangibleAssets>
<casi:BalanceOfAssetsHeldForSaleOnReclassifiedFromIntangibleAssets contextRef="As_Of_7_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_x33t8c8cE0WXqLTQUKDi1g" decimals="-4" id="Narr_vcsV3QHk90uIWuf_tYwqmA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1250000 </casi:BalanceOfAssetsHeldForSaleOnReclassifiedFromIntangibleAssets>
<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_AQWaElCDiEOyldG0TKpKaw" decimals="-3" id="Narr_tIEQxjQjU0apIqhjj0smew" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:GainLossOnDispositionOfIntangibleAssets>
<casi:NumberOfIntangibleAssetsSold contextRef="Duration_10_1_2020_To_12_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_NUAraEzblEODqs8qOYfH3g" decimals="0" id="Narr_x3n2j6Nkdkuv0o64GvaGUQ" unitRef="Unit_Standard_item_flJTMRpAMk2GmooQY-riJQ"> 10 </casi:NumberOfIntangibleAssetsSold>
<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="Duration_10_1_2020_To_12_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_NUAraEzblEODqs8qOYfH3g" decimals="-5" id="Narr_FVlI7nRvqUitRCohHyILYg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1000000.0 </us-gaap:ProceedsFromSaleOfIntangibleAssets>
<casi:BalanceOfAssetsHeldForSaleOnReclassifiedFromIntangibleAssets contextRef="As_Of_12_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_p8_bCiWIGUqizVMxzZ5O5Q" decimals="-5" id="Narr_I_bcK-NsDE-azysQeO0AEw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 300000 </casi:BalanceOfAssetsHeldForSaleOnReclassifiedFromIntangibleAssets>
<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="Duration_10_1_2020_To_12_31_2020_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_casi_AbbreviatedNewDrugApplicationsMember_NUAraEzblEODqs8qOYfH3g" decimals="-5" id="Narr_bJuBp5TIS0OCxk-7X5J-LA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 700000 </us-gaap:GainLossOnDispositionOfIntangibleAssets>
<casi:ScheduleOfComponentsOfAssetsHeldForSaleTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_FysZLh22ZkCP6mGszpUJTw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of intangible assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,074</p></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (853)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,221</p></td></tr></table>
</casi:ScheduleOfComponentsOfAssetsHeldForSaleTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="As_Of_12_31_2019_us-gaap_FairValueByAssetClassAxis_casi_AssetsHeldForSaleNotPartOfDisposalGroupMember_tRbj_qPHtEahbIxDPt7lFQ" decimals="-3" id="Tc_qhZfBdhP5kiGZO08MrmzRQ_2_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4074000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_12_31_2019_us-gaap_FairValueByAssetClassAxis_casi_AssetsHeldForSaleNotPartOfDisposalGroupMember_tRbj_qPHtEahbIxDPt7lFQ" decimals="-3" id="Tc_aaakHYLo6km5-ZYFhMqFWQ_3_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 853000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="As_Of_12_31_2019_us-gaap_FairValueByAssetClassAxis_casi_AssetsHeldForSaleNotPartOfDisposalGroupMember_tRbj_qPHtEahbIxDPt7lFQ" decimals="-3" id="Tc_hEf1lZ5WEk-t099KsOYuBQ_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3221000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<casi:GrantsDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_eaO2ExPVK0aGO4lEQpPX3w">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">9.      GRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In November 2019, CASI Wuxi entered into a fifty-year lease agreement for the right to use state-owned land in China for the construction of a manufacturing facility (see Note 5). In November 2019, the Company entered into a grant agreement with the Administrative Committee of Wuxi Huishan Economic Development Zone, under which, the Company is eligible for grants up to RMB 25 million (equivalent to $3.6 million) to support the development of CASI Wuxi’s manufacturing site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In April 2020, CASI Wuxi received RMB 15.9 million (equivalent to $2.2 million) from the Jiangsu Province Wuxi Huishan Economic Development Zone as a government grant for this development project which was recorded as deferred income in April 2020.  The grant will be amortized over the term of the lease of the land.  The Company recognized $35,000 of other income during the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p>
</casi:GrantsDisclosureTextBlock>
<us-gaap:LessorOperatingLeaseTermOfContract contextRef="As_Of_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_kjsYxa-Bz0eaH9B0KN-7bw" id="Narr_w49Pd6oxgkqnVFiLCysvvw"> P50Y </us-gaap:LessorOperatingLeaseTermOfContract>
<casi:GrantsEligible contextRef="As_Of_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_srt_RangeAxis_srt_MaximumMember_xrQKFAqNhECS5dDZvqPzIg" decimals="-6" id="Narr_BHqhvPbXskWuAGk6CO7i0Q" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 25000000 </casi:GrantsEligible>
<casi:GrantsEligible contextRef="As_Of_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_srt_RangeAxis_srt_MaximumMember_xrQKFAqNhECS5dDZvqPzIg" decimals="-5" id="Narr__hJsxXM00E61kixs7dWHiw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3600000 </casi:GrantsEligible>
<casi:ProceedsFromGovernmentGrant contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_FPImBeVQ6ECFNmosNPG3jQ" decimals="-5" id="Narr_8uw4a2n_z0eV8gDxNyd3KA" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 15900000 </casi:ProceedsFromGovernmentGrant>
<casi:ProceedsFromGovernmentGrant contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_FPImBeVQ6ECFNmosNPG3jQ" decimals="-5" id="Narr_RkSv-hxL40Skni0NqrKKaw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2200000 </casi:ProceedsFromGovernmentGrant>
<us-gaap:OtherIncome contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_7Ru0TzG_nUSjfq8Tgk75Cw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 35000 </us-gaap:OtherIncome>
<casi:LineOfCreditFacilityTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_YXAcXWfmU0iFm8UeBSvwQQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">10.</b></span><b style="font-weight:bold;">BANK BORROWINGS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On November 3, 2020, Beijing Branch of China CITIC Bank Corporation Limited approved a guaranteed line of Credit (“Bank Borrowings) to the Company with maximum borrowings of RMB 10.0 million ($1.5 million).  The joint and several liability guarantee was provided by Beijing Capital Financing Guarantee Co, Ltd.  At December 31, 2020, the Company had outstanding borrowings under the Bank Borrowings of RMB 5.4 million ($826,000), which matures on November 7, 2021, and bears interest at a fixed rate of 3.35% per annum.   Interest expense of $1,000 was recorded in the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p>
</casi:LineOfCreditFacilityTextBlock>
<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="As_Of_11_3_2020_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_I2VI4HrT3keKtvZbfnRZoA" decimals="-5" id="Narr_5qAi9W7rOE2HrM5ucmW8fg" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 10000000.0 </us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="As_Of_11_3_2020_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_I2VI4HrT3keKtvZbfnRZoA" decimals="-5" id="Narr_e9otiGNsQEGEG4h9CbDwow" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1500000 </us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
<us-gaap:LineOfCredit contextRef="As_Of_12_31_2020_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_s_05U-xn10KXMgGcwjhKCw" decimals="-5" id="Narr_ehy1dyqcDU-odKKUzduZRA" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 5400000 </us-gaap:LineOfCredit>
<us-gaap:LineOfCredit contextRef="As_Of_12_31_2020_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_s_05U-xn10KXMgGcwjhKCw" decimals="0" id="Narr_A42wwoyaN0Spyw3-8adBcA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 826000 </us-gaap:LineOfCredit>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_12_31_2020_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_s_05U-xn10KXMgGcwjhKCw" decimals="4" id="Narr_PByhp-ZuD0CwsjVWgYz2fw" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.0335 </us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:InterestExpense contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_tisilmNFMkG5-CGrMXeKgg" decimals="0" id="Narr_dzXwJeXUREaxH5Mv7aaMuQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1000 </us-gaap:InterestExpense>
<us-gaap:DebtDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_X9CZVhXCXUW0eze5hdBmMA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">11.      NOTES PAYABLE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On April 27, 2020, M&T Bank approved a $465,595 loan to the Company under the Paycheck Protection Program (PPP) pursuant to the Coronavirus Aid, Relief and Economic Security (CARES) Act that was signed into law on March 27, 2020. The loan, evidenced by a promissory note to M&T Bank as lender and dated April 29, 2020, has a term of two years, is unsecured, and is guaranteed by the Small Business Administration (SBA). The loan bears interest at a fixed rate of one percent per annum.  Some or all of the loan may be forgiven if the Company complies with certain relevant conditions.  In June 2020, the PPP was amended through enactment of the Paycheck Protection Program Flexibility Act of 2020 (PPPFA).  Under the new act, the Company’s payments of principal and interest are deferred until October 2021.  The Company has until August 2021 to apply for loan forgiveness before potential loan payments would begin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Interest expense of $3,100 was recorded in the year ended December 31, 2020.</p>
</us-gaap:DebtDisclosureTextBlock>
<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="As_Of_4_27_2020_QoUNjSU7SEmhu8IjmUa8GA" decimals="0" id="Narr_ebyCaHoKJ02DmtzlP1X-FQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 465595 </us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
<us-gaap:DebtInstrumentTerm contextRef="Duration_4_27_2020_To_4_27_2020_us-gaap_LineOfCreditFacilityAxis_casi_MTBankMember_DX0xioOoykqBh9iAG3tKYQ" id="Narr_NN4j7ZGWzkGrApJqpu-zcg"> P2Y </us-gaap:DebtInstrumentTerm>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_4_29_2020_us-gaap_LineOfCreditFacilityAxis_casi_MTBankMember_0nZMYOICtUaAGKqjNb_aHA" decimals="INF" id="Narr_rS-qd3Oto0SBWPCbb7mZXw" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.01 </us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:InterestExpense contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_uiteZc-xdkK-SMHOJTWzjg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3100 </us-gaap:InterestExpense>
<us-gaap:MinorityInterestDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_tqReXFqPak6Du6THrM3fag">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">12.      REDEEMABLE NONCONTROLLING INTEREST</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On December 26, 2018, the Company, together with Wuxi Jintou Huicun Investment Enterprise, a limited partnership organized under Chinese law (“Wuxi LP”) established CASI Wuxi to build and operate a manufacturing facility in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China. The Company holds 80% of the equity interests in CASI Wuxi and will invest, over time, $80 million in CASI Wuxi. The Company’s investment will consist of (i) $21 million in cash (paid in February 2019), (ii) a transfer of selected ANDAs valued at $30 million (transferred in May 2019), and (iii) an additional $29 million cash payment within three years from the date of establishment of CASI Wuxi. Wuxi LP holds 20% of the equity interest in CASI Wuxi through its investment in RMB of $20 million in cash (paid in March 2019). As the transfer of ANDAs, valued at $30 million, was to the Company’s consolidated subsidiary (CASI Wuxi), the Company recognized the transfer of the ANDAs at their carrying value and did not recognize a gain on the transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the investment contract between the Company and Wuxi LP and Articles of Association of CASI Wuxi, the Company has the call option to purchase the 20% equity interest in CASI Wuxi held by Wuxi LP at any time within 5 years from the date of establishment of CASI Wuxi (i.e. up to December 26, 2023). Wuxi LP has the put option to require the Company to redeem the 20% equity interest in CASI Wuxi at any time after December 26, 2023. The redemption value under both the Company’s embedded put option and Wuxi LP’s embedded call option is equal to $20 million plus interest at the bank loan interest rate issued by the People's Bank of China for the period beginning with the initial capital contribution by Wuxi LP to the date of redemption. In addition, Wuxi LP has the put option to require the Company to redeem the 20% equity interest in CASI Wuxi at $20 million upon the occurrence of any of the following conditions: (i) the Company fails to fulfill its investment obligation to CASI Wuxi; (ii) CASI Wuxi suffers serious losses, discontinued operation, dissolution, goes into process of bankruptcy liquidation; or (iii) the Company substantially violates the investment contract and Articles of Association of CASI Wuxi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The investment of Wuxi LP in CASI Wuxi is treated as redeemable noncontrolling interest and is classified outside of permanent equity on the consolidated balance sheets because (1) the noncontrolling interest is not mandatorily redeemable financial instruments, and (2) it is redeemable at the option of the holder, or upon the occurrence of an event that is not solely within the control of the Company. The Company initially recorded the redeemable noncontrolling interest at its fair value of $20 million. The carrying amount of the redeemable noncontrolling interest is subsequently recorded at the greater of the amount of (1) the initial carrying amount, increased or decreased for the redeemable noncontrolling interest’s share of net income or loss in CASI Wuxi or (2) the redemption value, assuming the noncontrolling interest is redeemable at the balance sheet date. Accretion of the carrying amount of redeemable noncontrolling interest to the redemption value is recorded in additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Changes in redeemable noncontrolling interest during the year ended December 31, 2020 and 2019 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,670</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash contribution by Wuxi LP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share of CASI Wuxi net (loss)/income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (918)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (395)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of redeemable noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 587</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 22,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p>
</us-gaap:MinorityInterestDisclosureTextBlock>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="As_Of_12_26_2018_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_w7ApvLwYaUSAQ5DRQbgUKw" decimals="2" id="Narr_rD1W9WDQFEen1dL6yWARHg" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.80 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<casi:InvestmentCommitment contextRef="As_Of_12_26_2018_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_w7ApvLwYaUSAQ5DRQbgUKw" decimals="-6" id="Narr_h5SNMsuAu0eYqGsC2nek1A" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 80000000 </casi:InvestmentCommitment>
<casi:InitialCashInvestment contextRef="As_Of_2_28_2019_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_eDnJ6ICqy0SfiOTl5H3aEg" decimals="-6" id="Narr_vVOnK_bcCUSH0KfJ4EuvwQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 21000000 </casi:InitialCashInvestment>
<casi:SelectedAndasToBeTransferred contextRef="Duration_5_1_2019_To_5_31_2019_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_PqAaNOusu0yGkv02KBsb3Q" decimals="-6" id="Narr_lRLpliW8XkevsySzXRepuw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 30000000 </casi:SelectedAndasToBeTransferred>
<casi:PaymentsToBePaidWithinThreeYears contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_smYZdRh4o0mSgr634rIWaw" decimals="-6" id="Narr_abM3-sEP4UOfqhmEhKlXlA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 29000000 </casi:PaymentsToBePaidWithinThreeYears>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="As_Of_3_31_2019_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_9hPCAcLin0-Jul_tK4viEQ" decimals="2" id="Narr_m6D8YY6HXky8T5Ya5I4dbA" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.20 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:PaymentsToAcquireInvestments contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_BYNc2K7eUkKwF2lKu3KRMw" decimals="-6" id="Narr_6N8R-WE6IUi6jwRZB1BV2g" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 20000000 </us-gaap:PaymentsToAcquireInvestments>
<casi:SelectedAndasToBeTransferred contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-6" id="Narr_jInjpQWZ4Eagtu4ClUQuXw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 30000000 </casi:SelectedAndasToBeTransferred>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="As_Of_12_31_2020_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_8XITJn-_fE-O31gS2WKzSA" decimals="2" id="Narr_9Wk4PCHno0CpqzCAnat0QA" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.20 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<casi:CallOptionToPurchaseInvestmentPeriod contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_smYZdRh4o0mSgr634rIWaw" id="Narr_ucx4RY0Ppk2AnrSJ7wIE7Q"> P5Y </casi:CallOptionToPurchaseInvestmentPeriod>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="As_Of_12_31_2020_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_PutOptionMember_DGJnZYRQPUixdwZ_FFoEQw" decimals="2" id="Narr_CYzw6YSaSUmPiZ-crz9rFg" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.20 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:PaymentsToAcquireInvestments contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_smYZdRh4o0mSgr634rIWaw" decimals="-6" id="Narr_LdDcXyBs5EqUs4a7_zDHUA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 20000000 </us-gaap:PaymentsToAcquireInvestments>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="As_Of_12_31_2020_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_PutOptionMember_DGJnZYRQPUixdwZ_FFoEQw" decimals="2" id="Narr_sF7Q60cakkOYbKW7e9dDuQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.20 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:PaymentsToAcquireInvestments contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_casi_CASIWuxiMember_smYZdRh4o0mSgr634rIWaw" decimals="-6" id="Narr_fincnXonrEeAUItJMVJySw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 20000000 </us-gaap:PaymentsToAcquireInvestments>
<us-gaap:PaymentsToAcquireInvestments contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_HczeXupWC029Mz1AoKJcFQ" decimals="-6" id="Narr_tp8tBTmwbU2GcOYckOOOfg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 20000000 </us-gaap:PaymentsToAcquireInvestments>
<us-gaap:RedeemableNoncontrollingInterestTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_3ALTx4Bye0e2y1dKfLYpDQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,670</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash contribution by Wuxi LP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share of CASI Wuxi net (loss)/income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (918)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (395)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of redeemable noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 587</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 22,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table>
</us-gaap:RedeemableNoncontrollingInterestTableTextBlock>
<us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_1veAhkPwjUOgn2uQb6__rA_3_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 20670000 </us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount>
<us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount contextRef="As_Of_12_31_2018_Qx1IVz1wIUe3rkaVNstInA" decimals="-3" id="Tc_ml-gsA8yBkGnnVgXMC3HeQ_3_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount>
<us-gaap:ProceedsFromMinorityShareholders contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_TKGgQLceW02BXTt3b-q8vQ_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:ProceedsFromMinorityShareholders>
<us-gaap:ProceedsFromMinorityShareholders contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_98M1PteS7EuVuImZRdR5IQ_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 20000000 </us-gaap:ProceedsFromMinorityShareholders>
<us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_-HIWTLiGwkSsOjnhDke6FQ_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -918000 </us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_PwJV6VWsg06qeiVPxGztZQ_5_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -395000 </us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
<casi:AccretionOfRedeemableNonControllingInterest contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_duLW3UCneEeNwtCmftm7Sg_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1694000 </casi:AccretionOfRedeemableNonControllingInterest>
<casi:AccretionOfRedeemableNonControllingInterest contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_eaqTlTAns0uwyFalBZSYOA_6_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1065000 </casi:AccretionOfRedeemableNonControllingInterest>
<casi:RedeemableNoncontrollingInterestEquityCommonForeignCurrencyTranslationAdjustments contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_5ryF-Fh8LUW1hb8SlWj1cw_7_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 587000 </casi:RedeemableNoncontrollingInterestEquityCommonForeignCurrencyTranslationAdjustments>
<us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_ggDadNkTEUmk4xaykiq-Cw_8_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 22033000 </us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount>
<us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_Rq-PG_izp0OBkXHX-f2ZLQ_8_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 20670000 </us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_N5xiS7oCJEGzp5U53jrIrA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">13.      STOCKHOLDERS’ EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company had 250 million of authorized common stock at December 31, 2020 and 2019, respectively. The Company had 5 million of authorized preferred stock as of December 31, 2020 and 2019. The Company held 79,545 of shares of common stock in treasury at its acquisition cost at December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">March 2021 Underwritten Public Offering </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 24, 2021, the Company closed an underwriting agreement (the “Underwriting Agreement”) <span style="color:#212529;">with Oppenheimer & Co. Inc., as representative of the several underwriters named therein (the “Underwriters”), providing for the offer and sale of </span><span style="color:#212529;">15,853,658</span><span style="color:#212529;"> shares of the Company’s common stock (the “Offering”) at a price to the public of </span><span style="color:#212529;">$2.05</span><span style="color:#212529;"> per share. In addition, the Company granted the Underwriters an option to purchase up to an additional </span><span style="color:#212529;">2,378,048</span><span style="color:#212529;"> shares of common stock, which terminates on the earlier of </span><span style="color:#212529;">30 days</span><span style="color:#212529;"> and the day before the Company files to the Securities and Exchange Commission (“SEC”) the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The Offering closed on March 26, 2021.  The gross proceeds to CASI from the Offering are approximately </span><span style="color:#212529;">$32.5</span><span style="color:#212529;"> million, excluding the over-allotment option and before deducting the underwriting discounts and commissions and offering expenses payable by CASI.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;">Certain insiders, including CASI’s Chairman and Chief Executive Officer, purchased shares of common stock in the Offering at the public offering price and on the same terms as the other purchasers in this Offering. The Company has agreed to pay the underwriters a commission of </span><span style="color:#212529;">1%</span><span style="color:#212529;"> of the gross proceeds raised from certain such insiders, and </span><span style="color:#212529;">6%</span><span style="color:#212529;"> of the gross proceeds raised in the offering from other investors. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;">The Offering is being made by means of a written prospectus supplement and accompanying prospectus forming part of a shelf registration statement on Form S-3 (Registration Statement No. 333-250801), previously filed with the SEC on November 20, 2020, which was declared effective on December 2, 2020. The Company filed a final prospectus supplement, dated March 24, 2021, with the SEC relating to the Offering.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;">Pursuant to the Underwriting Agreement, the Company’s directors and executive officers entered into agreements in substantially the form agreed to by the Underwriters providing for a </span><span style="-sec-ix-hidden:Hidden_bZKv5zLq0EK2tTW94z-Ysg;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">90-day</span></span><span style="color:#212529;"> “lock-up” period with respect to sales of specified securities, subject to certain exceptions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company intends to use the net proceeds of this offering for working capital and general corporate purposes, which include, but are not limited to advancing the Company’s product portfolio, acquiring the rights to new product candidates and general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">“Shelf “Registration Statement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On November 20, 2020, the Company filed a Form S-3 registration statement with the SEC utilizing a “shelf” registration process. In December 2020, the Form S-3 registration statement was declared effective by the SEC. Pursuant to this shelf registration statement, the Company may sell debt or equity securities in one or more offerings up to a total public offering price of $150 million. As a result of the Company’s failure to timely file a periodic report with the SEC in connection with the adoption of the Company’s amended and restated bylaws, absent a waiver of the Form S-3 eligibility requirements, the Company is ineligible to use or file new short form registration statements on Form S-3 until October 1, 2021, assuming the Company continues to timely file the required Exchange Act reports. In the interim, however, the Company may raise capital pursuant to a registration statement on Form S-1 or on a private placement basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">July 2020 Underwritten Public Offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">On July 24, 2020, the Company closed an underwritten public offering of </span><span style="font-weight:normal;">23</span><span style="font-weight:normal;"> million shares of common stock (the "Offering") and received gross proceeds of </span><span style="font-weight:normal;">$43.7</span><span style="font-weight:normal;"> million before deducting the underwriting discounts and commissions and offering expenses payable by CASI. Certain insiders, including CASI's Chairman and CEO, and CASI's President, purchased shares of common stock in the Offering at the public offering price and on the same terms as the other purchasers in this Offering. CASI's Chairman and CEO purchased </span><span style="font-weight:normal;">2,952,426</span><span style="font-weight:normal;"> shares directly and ETP Global Fund LP purchased </span><span style="font-weight:normal;">1,200,000</span><span style="font-weight:normal;"> shares. CASI's President purchased </span><span style="font-weight:normal;">20,152</span><span style="font-weight:normal;"> shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company is using the net proceeds of this offering for working capital and general corporate purposes, which include, but are not limited to advancing the Company’s product portfolio, acquiring the rights to new product candidates and general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Common Stock Sales Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On February 23, 2018, the Company entered into a Common Stock Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“HCW”). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time, at its option, shares of the Company’s common stock, through HCW, as sales agent. On July 19, 2019, the Company entered into an amendment to the Sales Agreement reducing the maximum amount that may be sold under the Sales Agreement to $20 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In 2018, the Company issued 143,248 shares under the Sales Agreement resulting in net proceeds to the Company of $475,000. As of December 31, 2020, $19.5 million remained available under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On July 19, 2019, the Company entered into an Open Market Sale Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> with Jefferies LLC (the “Open Market Agreement”). Pursuant to the terms of the Open Market Agreement, the Company may elect to sell from time to time, at its option, up to $30 million in shares of the Company’s common stock, through Jefferies LLC, as sales agent. In 2019, the Company issued 59,000 shares under the Open Market Agreement resulting in net proceeds to the Company of $182,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During 2020, the Company issued 434,000 shares under the Open Market Agreement with net proceeds of $1,357,000. As of March 30, 2021, the Company has issued 493,000 shares with net proceeds of $1,539,000. As of March 30, 2021, $28.4 million remained available under the Open Market Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock purchase warrants activity for the year ended December 31, 2020 and 2019 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,781,825</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,938,105)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.69</p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,843,720</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.43</p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,304)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.69</p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,489,707)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.75</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,271,709</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.58</p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,271,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.58</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All outstanding warrants are equity classified.</p>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="0" id="Narr_Rwx1BijHikuQYA0F7ni9jA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 250000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Narr_cwpBLMuskUqSniWQZ2aBBg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 250000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="0" id="Narr_vyRYAt9y60OSuDNqGspGDg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Narr_43gK5Dg3wUW2BJ7653X-DA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:TreasuryStockShares contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="0" id="Narr_MQEMVYeN20iVx2U6SAH1lQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 79545 </us-gaap:TreasuryStockShares>
<us-gaap:TreasuryStockShares contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Narr_wr_D2mskP0GS2nD_y7mlWA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 79545 </us-gaap:TreasuryStockShares>
<us-gaap:ExcessStockSharesAuthorized contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_m6l7tJZXbESjwZOx5NIjhA" decimals="INF" id="Narr_COfiQhd_xk6B6N7aGKPvig" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 15853658 </us-gaap:ExcessStockSharesAuthorized>
<us-gaap:SharePrice contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_m6l7tJZXbESjwZOx5NIjhA" decimals="2" id="Narr_Lky3mVkj_0yxARtVy_iZew" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.05 </us-gaap:SharePrice>
<us-gaap:ExcessStockSharesAuthorized contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FOGLCtLtX0W7vhAYtY48Tw" decimals="INF" id="Narr_90r1sVEsEE-N1_TEMOpXuA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 2378048 </us-gaap:ExcessStockSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_3_24_2021_To_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f6dLbzT0Y0-fGMZpVgN2rw" id="Narr_DZPR5XxoqEKaKDkSVepChg"> P30D </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_W4eyun0Gp0mlsMHffm3HDQ" decimals="-5" id="Narr_vEk-VmwDeUyVxL3-v4wwoA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 32500000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<casi:PercentageOfUnderwritersCommission contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_srt_TitleOfIndividualAxis_casi_BoardOfDirectorsChairmanAndChiefExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_O2Fp4rasTECUr6UjLSJjfQ" decimals="4" id="Narr_TzqMcZ1lPEKrdtpmMX_RNQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.01 </casi:PercentageOfUnderwritersCommission>
<casi:PercentageOfUnderwritersCommission contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mLDF7BJ3akakLuxfMK7juA" decimals="4" id="Narr_b_Rc5DJPnUOWZ4IgLlkfaQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.06 </casi:PercentageOfUnderwritersCommission>
<casi:PublicOfferingPrice contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-6" id="Narr_DtDVRFYcIEWa8RrPTr3AWw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 150000000 </casi:PublicOfferingPrice>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_24_2020_To_7_24_2020_ihrUHlk_VUqYlRnsRY2Bkw" decimals="-6" id="Narr_kHDcRuGN3UqtNQ-pAN_g2g" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 23000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_7_24_2020_To_7_24_2020_ihrUHlk_VUqYlRnsRY2Bkw" decimals="-5" id="Narr_NZB4LZtr-U-ujoiLN9kHnw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 43700000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_24_2020_To_7_24_2020_srt_TitleOfIndividualAxis_casi_BoardOfDirectorsChairmanAndChiefExecutiveOfficerMember_2a-h6TSJDkKk_4Tdp0nT0w" decimals="INF" id="Narr_beovCa0l0UasrysMCMP-Vg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 2952426 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_24_2020_To_7_24_2020_casi_InvestmentsContractCounterpartyAxis_casi_EtpGlobalFundLpMember_Qnqcw3TT60KYVrNPPxFOcA" decimals="INF" id="Narr_ZzarrGooS0KDjMddI2z9zg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 1200000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_24_2020_To_7_24_2020_srt_TitleOfIndividualAxis_srt_PresidentMember_6oA-J-UMbEaAx1aHuqxLTQ" decimals="INF" id="Narr_TVR7SR1oAE2qNHoO2Jd2OQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 20152 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<casi:MaximumSalesPriceFromIssuanceOfCommonStock contextRef="Duration_7_19_2019_To_7_19_2019_us-gaap_TypeOfArrangementAxis_casi_AmendmentToOpenSaleAgreementMember_f1DIgMboVkqVRCefOa9-0w" decimals="-6" id="Narr_LdD7GessM0iP0hjKzwwIcg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 20000000 </casi:MaximumSalesPriceFromIssuanceOfCommonStock>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_SubsidiarySaleOfStockAxis_casi_SalesAgreementMember_zhfoW35Ni02jmkMmd0foBA" decimals="0" id="Narr_DPK3waFlbUeO3VqdG-O0Sg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 143248 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<casi:NetProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_SubsidiarySaleOfStockAxis_casi_SalesAgreementMember_zhfoW35Ni02jmkMmd0foBA" decimals="0" id="Narr_EpDIioEjwEmf87SFSceJSw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 475000 </casi:NetProceedsFromIssuanceOfCommonStock>
<casi:RemainingDollarAmountAvailableUnderSalesAgreement contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-5" id="Narr_W_qc74aYtEK7e_2RzJbjPw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 19500000 </casi:RemainingDollarAmountAvailableUnderSalesAgreement>
<casi:MaximumSalesPriceFromIssuanceOfCommonStock contextRef="Duration_7_19_2019_To_7_19_2019_us-gaap_TypeOfArrangementAxis_casi_OpenMarketSaleAgreementMember_nTT1_EMOkEuoIeZHBhIf2Q" decimals="-6" id="Narr_ngYNXTopp0CVyY75ToyawA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 30000000 </casi:MaximumSalesPriceFromIssuanceOfCommonStock>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_casi_OpenMarketSaleAgreementMember_laWb5-D2bU6hrpgr2H0Idg" decimals="INF" id="Narr_ebFwr27oV0y0nzqcW2bWEg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 59000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<casi:NetProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_casi_OpenMarketSaleAgreementMember_laWb5-D2bU6hrpgr2H0Idg" decimals="0" id="Narr_NjJfc0Lv6k2L5cGX_hCuaQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 182000 </casi:NetProceedsFromIssuanceOfCommonStock>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_casi_OpenMarketSaleAgreementMember_UROplnlJhkWYsb5nLzfnLw" decimals="0" id="Narr_zfPA3NjBSku780EsBrsnKQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 434000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<casi:NetProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_casi_OpenMarketSaleAgreementMember_UROplnlJhkWYsb5nLzfnLw" decimals="0" id="Narr_e2SaW-0gfUuzDvqygs4wIQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1357000 </casi:NetProceedsFromIssuanceOfCommonStock>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5Adb8TPeIUuuXeqaxk1Mvw" decimals="INF" id="Narr_9GwkHE4UaEqTq-wFl9V9DQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 493000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<casi:NetProceedsFromIssuanceOfCommonStock contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5Adb8TPeIUuuXeqaxk1Mvw" decimals="0" id="Narr_BBD8JgaRZEuzGZC12Ihy0A" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1539000 </casi:NetProceedsFromIssuanceOfCommonStock>
<casi:RemainingDollarAmountAvailableUnderSalesAgreement contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_casi_OpenMarketSaleAgreementMember_9cdIM2RDtUGEXRgyHqm0kw" decimals="-5" id="Narr_JGlhgiYWj0q0lF0OFyHHgg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 28400000 </casi:RemainingDollarAmountAvailableUnderSalesAgreement>
<casi:ScheduleOfWarrantActivityTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_fSc2ohWhPku7hgRVFzCbVA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,781,825</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,938,105)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.69</p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,843,720</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.43</p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,304)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.69</p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,489,707)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.75</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,271,709</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.58</p></td></tr><tr><td style="vertical-align:bottom;width:66.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,271,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.58</p></td></tr></table>
</casi:ScheduleOfWarrantActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2018_Qx1IVz1wIUe3rkaVNstInA" decimals="0" id="Tc_8Yv-tmFUgkOeWorkj246pw_3_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 11781825 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Tc_tr7SUSMfyUKR8blFkIszrQ_5_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> -1938105 </casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod>
<casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="2" id="Tc_RosUGWrqkUehVjH9ucsC0w_5_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.69 </casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="0" id="Tc_NWrCjsAoLEeDCrtPvWursw_7_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 9843720 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="2" id="Tc_6ohR2dsPOUqmuGgkZyDadg_7_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 4.43 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Tc_FR2FhDliOUOJvE2brvwMMw_8_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="2" id="Tc_kmXYMIsmiki4q_olJeB3Gg_8_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Tc_GuUukBD2N0ClWcmO5aKEMQ_9_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> -82304 </casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod>
<casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="2" id="Tc_5EjnPrgHqUCD22jHyPnl8Q_9_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.69 </casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Tc_PhTAHO7w9Uy4qZ-kg_KTEw_10_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 1489707 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="2" id="Tc_rOJydtOLvkaqFsUyHGSLyg_10_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 3.75 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Tc_TPWZpwZueESR7olRcz95zw_11_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 8271709 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="2" id="Tc_jieu4DeldEyRLU5dSidi8Q_11_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 4.58 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Tc_QsITd92KoE2cI4_OVdaDWw_12_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 8271709 </casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
<casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="2" id="Tc_MupzGq3HoEme1zsLJjUwNg_12_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 4.58 </casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:EarningsPerShareTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_YMzP0C5FwEqsEpDA9SGDqQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">14.      NET LOSS PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Net loss per share (basic and diluted) was computed by dividing net loss attributable to common stockholders, considering the accretions to redemption value of the redeemable noncontrolling interest, by the weighted average number of shares of common stock outstanding. As of December 31, 2020, and 2019, outstanding stock options totaling 16,746,238 and 18,268,372, respectively, and outstanding warrants totaling 8,271,709 and 9,843,720, respectively, were anti-dilutive, and therefore, were not included in the computation of weighted average shares used in computing diluted loss per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The following table sets forth the basic and diluted net loss per share computation and provides a reconciliation of the numerator and denominator for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands, except per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to CASI Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (48,287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,032)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of common shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 110,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95,948</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator for basic and diluted net loss per share calculation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 110,452</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95,948</p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">— Basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.44)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.48)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p>
</us-gaap:EarningsPerShareTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_casi_OptionsMember_C2Tr0pDxQUGtmZ9DJrjCdQ" decimals="0" id="Narr_VpuZRx1iSEWyqjDeILkTMg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 16746238 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_casi_OptionsMember_e00VDPx4NUODzSfPbm57qA" decimals="0" id="Narr_r1c9_qr-7EmJs0_AYKb4cA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 18268372 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_20Bl-uHQakKIxHD-KsfnTA" decimals="0" id="Narr_90uvJhgXEUukI91tt1LzAg" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 8271709 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_3Y8tjRmooE6126cW6DY2FA" decimals="0" id="Narr_k7euI5WL70-5Uq2uTFHHng" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 9843720 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_bSvuI-Bktkmv5plUl7m6yQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands, except per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to CASI Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (48,287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,032)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of common shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 110,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95,948</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator for basic and diluted net loss per share calculation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 110,452</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95,948</p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">— Basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.44)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.48)</p></td></tr></table>
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_hiEQAhXIR0CWGPJrAgzZuw_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -48287000 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_4tji8xY0LUyGYhBCa3C5_A_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -46032000 </us-gaap:NetIncomeLoss>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Tc_qwXOvVHACE-VptSozU64Jw_6_3" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 110452 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Tc_1gHlleT27UKTAaOKrFqghg_6_6" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 95948 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Tc_tmCn1Xp0IUKNY093GZcRYg_7_3" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 110452 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Tc_DalpEAtthUObCl7y4VL6tw_7_6" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 95948 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="2" id="Tc_ASxCGpuz_EiF5HD_ozr9kQ_9_3" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> -0.44 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="2" id="Tc_uzyjD15zIkWTeKV8HLh9Dg_9_6" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> -0.48 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_APidWP7CtkuSoigNilQ8lw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">15.      EMPLOYEE BENEFIT PLAN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sponsors the CASI Pharmaceuticals, Inc. 401(k) Plan and Trust. The plan covers substantially all U.S. employees and enables participants to contribute a portion of salary and wages on a tax-deferred basis. Contributions to the plan by the Company are discretionary. Contributions by the Company totaled $250,000 and $217,000 in 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Full time employees of the Company in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the PRC subsidiaries of the Company make contributions to the government for these benefits based on certain percentages of the employees’ salaries. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $1,542,000 and $1,780,000 for the years ended December 31, 2020 and 2019, respectively.</p>
</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
<us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_YbqUIbU47kiD15JEP19p4A" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 250000 </us-gaap:DefinedBenefitPlanContributionsByEmployer>
<us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_y00mT5BiL0yhHijAu1DXEA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 217000 </us-gaap:DefinedBenefitPlanContributionsByEmployer>
<us-gaap:DefinedContributionPlanCostRecognized contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_X9jwE6xGjUK8lSrGWR2Hrw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1542000 </us-gaap:DefinedContributionPlanCostRecognized>
<us-gaap:DefinedContributionPlanCostRecognized contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_x0ihfOq__EuhjWcAtzyqlw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1780000 </us-gaap:DefinedContributionPlanCostRecognized>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_voY4-eLfwEuTXUujQs45jg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">16.      STOCK-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has adopted various stock compensation plans for executive, scientific and administrative personnel of the Company, as well as outside directors and consultants. In June 2019, the Company’s stockholders approved an amendment to the 2011 Long-Term Incentive Plan, increasing the number of shares of common stock reserved for issuance from 20,230,000 to 25,230,000 to be available for grants and awards. As of December 31, 2020, a total of 10,084,923 shares remained available for grant under the Company’s 2011 Long-Term Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s net loss for the twelve months ended December 31, 2020 and 2019 includes $7,821,000 and $7,310,000, respectively, of non-cash compensation expense related to the Company’s share-based compensation awards. The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 245</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 466</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales and Marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,537</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,844</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,310</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Compensation expense related to stock options is recognized over the requisite service period, which is generally the option vesting term of up to five years. Awards with performance conditions are expensed when it is probable that the performance condition will be achieved. For the years ended December 31, 2020 and 2019, $49,000 and $73,000 was expensed for share awards with performance conditions that became probable during the year, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of service based and performance-based stock options granted to employees. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Expected Volatility</i>—Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility based on the daily price observations of its common stock during the period immediately preceding the share-based award grant that is equal in length to the award’s expected term. The Company believes that historical volatility represents the best estimate of future long term volatility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>—This is the average interest rate consistent with the yield available on a U.S. Treasury note (with a term equal to the expected term of the underlying grants) at the date the option was granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Expected Term of Options</i>—This is the period of time that the options granted are expected to remain outstanding. The Company uses a simplified method for estimating the expected term of service based awards granted. For performance based awards, the expected term of service is based on the derived service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Expected Dividend Yield</i>—The Company has never declared or paid dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. As such, the dividend yield percentage is assumed to be zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Following are the weighted-average assumptions used in valuing the stock options granted to employees during the years ended December 31, 2020 and 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:53.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:53.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 78.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 77.30</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Range of expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">75.84% to 81.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">75.50% to 84.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Range of risk free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.31% to 1.77</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">1.62% to 2.59</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term of option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The weighted average fair value of stock options granted during the years ended December 31, 2020 and 2019 were $1.85 and $2.20, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of the Company’s stock option plans and changes in options outstanding under the plans during the years ended December 31, 2020 and 2019 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Term In Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate Intrinsic Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,429,308</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.44</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (599,002)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,124,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,834,808</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.01</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,389,652)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.17</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,000,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,268,372</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.58</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,789,473)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,856,978</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,380,686</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (117,722)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (995,625)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.78</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,746,238</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_zhrr--IXX0-dYwYVn6JgZg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 6.71</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,866,320</p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,746,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Z0Bm1zY6XUy9-pvqfpFEHA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 6.71</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,866,320</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,381,854</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.35</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_oZ7b0hzxPEmmvVmJ8xqw7Q;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 5.17</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,964,551</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The aggregate intrinsic value is calculated as the difference between (i) the closing price of the common stock at December 31, 2020 and (ii) the exercise price of the underlying awards, multiplied by the number of options that had an exercise price less than the closing price on the last trading day of the year. Cash received from option exercises under all share-based payment arrangements for the twelve months ended December 31, 2020 and 2019 was $3.9 million and $854,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In March 2018, the Compensation Committee of the Board of Directors (the “Board”) approved a grant of stock options to Dr. Wei-Wu He, the Company’s Executive Chairman at the time, exercisable for 1.0 million shares of common stock that will vest and become exercisable on the first anniversary date of the grant. In addition, the Board approved the grant of a performance-based option covering 4.0 million shares of common stock that will vest if, within 18 months of the date of grant, specific operational and strategic milestones are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In April 2019, the 2018 performance-based option awarded to Dr. He, the Company’s Chairman and CEO, covering 4 million shares of common stock was cancelled. At the date of cancellation, the performance condition of the option award was not expected to vest based on the original vesting conditions, and therefore no compensation cost was recognized on the cancellation date. On June 20, 2019, the Company’s stockholders approved a grant of stock options to Dr. He, as the Company’s Chairman and CEO at the 2019 Annual Meeting. Under the terms of the grant, Dr. He received a stock option covering 4 million shares of common stock, at an exercise price of $2.85, vesting upon the earlier of (i) the completion of a transformative event by the Company as determined at the discretion of the Company’s compensation committee and (ii) April 2, 2021, the second anniversary of the date of his appointment as CEO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following summarizes information about stock options that are outstanding at December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:35.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life in Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$0.00 - $1.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,273,853</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.19</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,273,853</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.87</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.01 - $2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,982,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4.39</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,912,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.50</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$2.01 - $4.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,955,456</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.25</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.94</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,231,072</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.10</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$4.01 - $7.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,329,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6.40</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 759,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.50</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$7.01 - $9.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 205,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7.50</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8.23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 205,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8.23</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,746,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">6.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,381,854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.35</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2020, there was $8,208,000 of total unrecognized compensation cost related to non-vested stock options, excluding not-probable performance condition options. That cost is expected to be recognized over a weighted-average period of 1.74 years.</p>
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_6_30_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_casi_LongTermIncentivePlan2011Member_MgY7WQoBlEe7EJlEbYc6cw" decimals="0" id="Narr_QVdJvyNOUE6iImaKffIzqQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 20230000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_6_30_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_casi_LongTermIncentivePlan2011Member_EICsSx9sp02x6dRKfvkihA" decimals="0" id="Narr_wGHsI1kYX0yPXW3BZ08ubA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 25230000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_casi_LongTermIncentivePlan2011Member_rQz5n9k1oUenlUMHQu4ONA" decimals="0" id="Narr_kv-sonxXxU6rMxFEeaaahw" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 10084923 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_wWNXEBTcr0eu6ASLmz4Idw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7821000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_8rrAQuSP8k2wn3e9aGlXZg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7310000 </us-gaap:ShareBasedCompensation>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_bRdC2H7cyEuvSUt-DLDI3A">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 245</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 466</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales and Marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,537</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,844</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,310</p></td></tr></table>
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ktMKlU3VbEO9iPe_PWX9wA" decimals="-3" id="Tc_B050fE-Om0O0uhAmKfdxrQ_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 245000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T8yRv0QFxkaYXnAorqVF8Q" decimals="-3" id="Tc_DPjGOhua_UedVt4Ln8admw_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 466000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_XEWtwtpWKU2N8kq6l8bDMg" decimals="-3" id="Tc_iIlfM9-MYUifY7kFmInbfw_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 39000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_dumWQGmGeEC_i91cVfcahQ" decimals="-3" id="Tc_8oVu1GELOEmf7DO508Y99g_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7537000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_eVNKWi8d5EW7yAP4nS5k_g" decimals="-3" id="Tc_8tub96G1oEiC3u-aaG6aTA_6_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6844000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_IqCi6tWZX0em_jPdSvRgSQ_7_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7821000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_vOrMzlwagEaN-FwNOAu7Xg_7_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7310000 </us-gaap:ShareBasedCompensation>
<casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedExpireTerms contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_FDAXWmiR7UGiK3T94vDFwQ" id="Narr_bisjOCiMI0e549p1J5yzfg"> P5Y </casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedExpireTerms>
<casi:PerformanceShareBasedCompensationExpense contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_ql8351qj30GtMdJOaxWckQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 49000 </casi:PerformanceShareBasedCompensationExpense>
<casi:PerformanceShareBasedCompensationExpense contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_EbpVnbqn7UWfmM5oPRb03w" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 73000 </casi:PerformanceShareBasedCompensationExpense>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="2" id="Narr_YfDAyYSXVEK42s24lxnaPA" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_wOXWIusA9UigP6IFF8VeMw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:53.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:53.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 78.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 77.30</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Range of expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">75.84% to 81.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">75.50% to 84.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Range of risk free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.31% to 1.77</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">1.62% to 2.59</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term of option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table>
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="4" id="Tc_j6OEshCVsUSLP1Hkb1d-uw_4_2" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.7870 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="4" id="Tc_B9mvwTac0kCspuBiTQaSGg_4_4" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.7730 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="4" id="Narr_WahwTRijzk-Gd6dd8vhL4g" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.7584 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="4" id="Narr_XSSObVuFXES68CFwnZozFQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.8163 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="4" id="Narr_CJRTfXps4kOscl0-DoWTHg" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.7550 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="4" id="Narr_ZKlEbITCZE-bjXCFrXkUyQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.8448 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="4" id="Narr_sCLn58q5nEK7FA4sFVg5Hg" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.0031 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="4" id="Narr_NKSWETmq9UqmFSm3YMiS0w" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.0177 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="4" id="Narr_z2E_xIxYNkuM0UkpmSfwSw" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.0162 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="4" id="Narr_i2BaaMPOIUWEN_1wBDtXqg" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.0259 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_StdMC_YVF0W0g7YZO14U6Q_7_2"> P6Y1M6D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" id="Tc_p1sSoNtf40O63uYcsCP9-Q_7_4"> P6Y18D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="4" id="Tc_P7YcM-V3TUCNjwBedLe21Q_8_2" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.0000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="4" id="Tc_jcGa3H3JPEyV8Jft_Nmzkw_8_4" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.0000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="2" id="Narr_0xDG4oT2VECMzSelJkm0Cg" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.85 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="2" id="Narr_hSeuTietq02ov1-T5QmCDg" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.20 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_3ABWUMvyoEaxvUnpS1A71g">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Term In Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate Intrinsic Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,429,308</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.44</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (599,002)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,124,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,834,808</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.01</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,389,652)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.17</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,000,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,268,372</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.58</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,789,473)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,856,978</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,380,686</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (117,722)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (995,625)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.78</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,746,238</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_zhrr--IXX0-dYwYVn6JgZg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 6.71</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,866,320</p></td></tr><tr><td style="vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,746,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Z0Bm1zY6XUy9-pvqfpFEHA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 6.71</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,866,320</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,381,854</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.35</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_oZ7b0hzxPEmmvVmJ8xqw7Q;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 5.17</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,964,551</p></td></tr></table>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2018_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_p17H9TH6Pk6g6X_CEvrwfg" decimals="0" id="Tc_665ySwaqZUCqN8YONr5A-A_3_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 18429308 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2018_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_p17H9TH6Pk6g6X_CEvrwfg" decimals="2" id="Tc_LQE4xDHga0WkDS-BwbVH3w_3_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.44 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_LBZNo3Q_F02YKbhbmUqy2Q" decimals="0" id="Tc_IonNQXPp9kG52e3Hbb4UcQ_4_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 599002 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_LBZNo3Q_F02YKbhbmUqy2Q" decimals="2" id="Tc_j2nIsq7YwkOuOMLJ0KP9hw_4_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.43 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_12_31_2018_Qx1IVz1wIUe3rkaVNstInA" decimals="0" id="Tc_ahA93kFEoEiK62hOikcL9Q_4_11" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1124000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_LBZNo3Q_F02YKbhbmUqy2Q" decimals="0" id="Tc_vJmlSUNWgEi55YtSysgGuw_5_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 5834808 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_LBZNo3Q_F02YKbhbmUqy2Q" decimals="2" id="Tc_kMG-Uj8ugkG_ncs0cj8X7w_5_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 3.01 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_LBZNo3Q_F02YKbhbmUqy2Q" decimals="0" id="Tc_mAxCAiCzz0KmHOd9Dk5h5A_6_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 7090 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_LBZNo3Q_F02YKbhbmUqy2Q" decimals="2" id="Tc_4jhmBc-EnUi30emPthOn0w_6_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 3.69 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Tc_1OokoU8nykyWkczqN9LgqQ_7_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 1389652 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="2" id="Tc_gDW1zCQGJkesA0sM3EB62g_7_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.17 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_LBZNo3Q_F02YKbhbmUqy2Q" decimals="0" id="Tc_B76SCeW-ukykG94cQd7dzw_8_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 4000000 </casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod>
<casi:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_LBZNo3Q_F02YKbhbmUqy2Q" decimals="2" id="Tc_OWKUON5QskeP6SZLGeAfvQ_8_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 3.22 </casi:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_E4cfEhslmEqaqXUgTa95tg" decimals="0" id="Tc_Wbx2bNOuAEKnwVWTmNkgkQ_9_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 18268372 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2019_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_E4cfEhslmEqaqXUgTa95tg" decimals="2" id="Tc_ubrWokfHDEuKYdmYiKRW3g_9_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.58 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" decimals="0" id="Tc_3CkLj4eiB0Gc49_U9mOaNg_10_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 2789473 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" decimals="2" id="Tc_r0yMSDiyUkCPc24okg5l6g_10_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.39 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" decimals="0" id="Tc_WV2TmgTnRUi5o5crwopVFA_10_11" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1856978 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" decimals="0" id="Tc_Ksbju-ETrUWTqvYfKjzKKw_11_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 2380686 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" decimals="2" id="Tc_2sunI0IX4Ue5N8wii2rCXg_11_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.71 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" decimals="0" id="Tc_6AwJINZ2PU2pGXkTKfbwOQ_12_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 117722 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" decimals="2" id="Tc_2jmXuoKfWk20EXh1HlVMPA_12_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 5.06 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" decimals="0" id="Tc_Ih9YqTaMo0Cw1lammBHZCw_13_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 995625 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_4ajNVWZi3UW7xE51RjyTYQ" decimals="2" id="Tc_0QyfP3LiHkK7GSUSE3cVlw_13_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 3.78 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_C_0f2_vSWk2_tFzDxKI0oA" decimals="0" id="Tc_q2_LCL3JukWFZmfR04He5A_15_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 16746238 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_C_0f2_vSWk2_tFzDxKI0oA" decimals="2" id="Tc_WPjYYyQdRUmMy6TdZECKrg_15_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.71 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_C_0f2_vSWk2_tFzDxKI0oA" decimals="0" id="Tc_CxSTxUUsoUSWMX6rrACw7Q_15_11" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 10866320 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="As_Of_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_C_0f2_vSWk2_tFzDxKI0oA" decimals="0" id="Tc_pDtw6COP7ECzyn6yCBgtdg_16_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 16746238 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_C_0f2_vSWk2_tFzDxKI0oA" decimals="2" id="Tc_czVE_1QvKUmiHa8Fh_5oMw_16_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.71 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="As_Of_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_C_0f2_vSWk2_tFzDxKI0oA" decimals="0" id="Tc_QXbKqC8p0kWIaQEQYZ-Asw_16_11" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 10866320 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="As_Of_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_C_0f2_vSWk2_tFzDxKI0oA" decimals="0" id="Tc_T23WDBRY60yzWx2KFpXD4w_17_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 9381854 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="As_Of_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_C_0f2_vSWk2_tFzDxKI0oA" decimals="2" id="Tc__OhLuE1BuE2gAV0rSMnl-g_17_5" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.35 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="As_Of_12_31_2020_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_C_0f2_vSWk2_tFzDxKI0oA" decimals="0" id="Tc_bCxLl8Lh0EWHLPjt0eXrDQ_17_11" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 9964551 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<casi:ShareBasedPaymentCashReceivedFromStockOptionExercises contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-5" id="Narr_MAbWC4S2NUOK1uuDhrcpSQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3900000 </casi:ShareBasedPaymentCashReceivedFromStockOptionExercises>
<casi:ShareBasedPaymentCashReceivedFromStockOptionExercises contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_lPMlM5-fxUqS73erzwRzBQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 854000 </casi:ShareBasedPaymentCashReceivedFromStockOptionExercises>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="As_Of_3_31_2018_srt_TitleOfIndividualAxis_casi_ExecutiveChairmanMember_r_Ljw9-FZEqemo-QQC7_uw" decimals="-5" id="Narr_o4njSNwqcEK19quaIDVHow" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 1000000.0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="As_Of_3_31_2018_srt_TitleOfIndividualAxis_casi_ExecutiveChairmanMember_us-gaap_AwardTypeAxis_casi_PerformanceBasedOptionMember_8h5yyrni5ku0vijspvPyqw" decimals="-5" id="Narr__riM1llLiku8dISWMehv8g" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 4000000.0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<casi:PeriodRequiredWhichSpecificOperationalAndStrategicMilestonesAchievedForSharesToVest contextRef="Duration_3_1_2018_To_3_31_2018_srt_TitleOfIndividualAxis_casi_ExecutiveChairmanMember_us-gaap_AwardTypeAxis_casi_PerformanceBasedOptionMember_5fDUkVDRlk-o3h5saWY3CQ" id="Narr_Lv3QfS64qE-D6AZ8gnxH8A"> P18M </casi:PeriodRequiredWhichSpecificOperationalAndStrategicMilestonesAchievedForSharesToVest>
<casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod contextRef="Duration_4_1_2019_To_4_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_casi_PerformanceBasedOptionMember_om11DpwZb0WH7U8GVWznOQ" decimals="-6" id="Narr_arXXn60WkUqqSfH-eJrNfA" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 4000000 </casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_4_1_2019_To_4_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_casi_PerformanceBasedOptionMember_om11DpwZb0WH7U8GVWznOQ" decimals="-6" id="Narr_GYkABsD_p02o8VjmFa4fCQ" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 4000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_4_1_2019_To_4_30_2019_srt_TitleOfIndividualAxis_casi_ExecutiveChairmanMember_us-gaap_AwardTypeAxis_casi_PerformanceBasedOptionMember_mc9xaL__jkWZVm7ErigaVw" decimals="2" id="Narr_tqZbd9fyW0yscyAvqflrWA" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.85 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_ct320nGp-0yvg7NbpCf5Jg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following summarizes information about stock options that are outstanding at December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:35.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life in Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$0.00 - $1.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,273,853</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.19</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,273,853</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.87</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.01 - $2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,982,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4.39</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,912,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.50</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$2.01 - $4.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,955,456</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.25</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.94</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,231,072</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.10</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$4.01 - $7.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,329,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6.40</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 759,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.50</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$7.01 - $9.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 205,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7.50</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8.23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 205,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8.23</p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,746,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">6.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,381,854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.35</p></td></tr></table>
</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeOneMember_jz-DLgUYvkea5mzhIVS8vQ" decimals="2" id="Narr_OiUcuF2W8EO4to1Eqep2dA" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 0.00 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeOneMember_jz-DLgUYvkea5mzhIVS8vQ" decimals="2" id="Narr_FZmVvXxz5ky72s07x_ZVkA" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.00 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeOneMember_U3C-XK9iPU6d4Mb42TVotQ" decimals="0" id="Tc_zy-9uFcrxEWExEgL1G4Uuw_7_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 1273853 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeOneMember_jz-DLgUYvkea5mzhIVS8vQ" id="Tc_KbUCW43H6kOjVqks4ZTWlg_7_4"> P5Y2M8D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeOneMember_U3C-XK9iPU6d4Mb42TVotQ" decimals="2" id="Tc_XJGmofPyT0Cgwb414dM74g_7_7" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 0.87 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeOneMember_U3C-XK9iPU6d4Mb42TVotQ" decimals="0" id="Tc_StEihkzFIEOaFiKBdVLtyw_7_10" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 1273853 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeOneMember_U3C-XK9iPU6d4Mb42TVotQ" decimals="2" id="Tc_PO7JoQ_pUkaRVd7GZhdlMw_7_13" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 0.87 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeTwoMember_AXo4Bu7yeEuIiC49yDETsw" decimals="2" id="Narr_iIDdt8F9XEGH9hhQ8jFaBw" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.01 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeTwoMember_AXo4Bu7yeEuIiC49yDETsw" decimals="2" id="Narr_Z4rEopbgdkaGz1cBNxa4Xw" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.00 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeTwoMember_fSS5z4uSU06hy24wGORyxg" decimals="0" id="Tc_ltDaOihuSUmDcaFoauMgbQ_8_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 4982929 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeTwoMember_AXo4Bu7yeEuIiC49yDETsw" id="Tc_u1Bsr224HEqDERDPdctbcA_8_4"> P4Y4M20D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeTwoMember_fSS5z4uSU06hy24wGORyxg" decimals="2" id="Tc_rtya8u1FnkuTjxwwCye_yA_8_7" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.50 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeTwoMember_fSS5z4uSU06hy24wGORyxg" decimals="0" id="Tc_iYiccHZqLEynXDEz_RjlfQ_8_10" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 4912929 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeTwoMember_fSS5z4uSU06hy24wGORyxg" decimals="2" id="Tc_COeiB9RrhkGSLUnJ70uVSg_8_13" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 1.50 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeThreeMember_isBWHts9jEy7FMfInj8KWg" decimals="2" id="Narr_Dv5yI2d-y0qJhe_qkooTLg" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.01 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeThreeMember_isBWHts9jEy7FMfInj8KWg" decimals="2" id="Narr_Yhc2-tgPJUCUqHOm-c43Cg" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 4.00 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeThreeMember_0X-YDMCZQUuLCmzP98c9CA" decimals="0" id="Tc_zgnydhtqdEiY726ZVj5pBQ_9_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 8955456 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeThreeMember_isBWHts9jEy7FMfInj8KWg" id="Tc_ueCeHXvf4E-NkpggJ327IA_9_4"> P8Y3M </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeThreeMember_0X-YDMCZQUuLCmzP98c9CA" decimals="2" id="Tc_aNX2MTptbky1sGfPVzxkAA_9_7" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.94 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeThreeMember_0X-YDMCZQUuLCmzP98c9CA" decimals="0" id="Tc_Gk3VPcdS_UaKr1T5aMgijA_9_10" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 2231072 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeThreeMember_0X-YDMCZQUuLCmzP98c9CA" decimals="2" id="Tc_xGRtSjEDOEyBWgA9mxBHGw_9_13" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 3.10 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFourMember_aXWWbqTDPE6E4RElYazC6w" decimals="2" id="Narr_R0V3AuEpxECKNKUVEDUcIA" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 4.01 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFourMember_aXWWbqTDPE6E4RElYazC6w" decimals="2" id="Narr__3uhyzpGZk-QqNSN_P69RQ" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 7.00 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFourMember_OSvGz7C22EK6BN2w9Fyv-g" decimals="0" id="Tc_6lF0E86zkUy7W0XPm60fRQ_10_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 1329000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFourMember_aXWWbqTDPE6E4RElYazC6w" id="Tc_3rUvorltmESvnVml8kLRDA_10_4"> P6Y4M24D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFourMember_OSvGz7C22EK6BN2w9Fyv-g" decimals="2" id="Tc_aCUO7EPAVUi8dMDSv7eBQQ_10_7" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 6.61 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFourMember_OSvGz7C22EK6BN2w9Fyv-g" decimals="0" id="Tc_o9UkT8KxR0GJ54BMKVaQ0A_10_10" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 759000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFourMember_OSvGz7C22EK6BN2w9Fyv-g" decimals="2" id="Tc_VvkbLiymckKyRX91qoityw_10_13" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 6.50 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFiveMember_766M2vim9Eq48qlcX4EQpQ" decimals="2" id="Narr_X53Fdrn1d0yLVP-PKhTyMA" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 7.01 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFiveMember_766M2vim9Eq48qlcX4EQpQ" decimals="2" id="Narr_Q48CFB6yeUaNzQz8BAZG_g" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 9.00 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFiveMember_wuGB45EeWUy7VxJsr6PHTA" decimals="0" id="Tc_ERdFg4Jwr0uQO5-Pi4T4Jw_11_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 205000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFiveMember_766M2vim9Eq48qlcX4EQpQ" id="Tc_afK9mSNoGUm4M-JXLZmt_g_11_4"> P7Y6M </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFiveMember_wuGB45EeWUy7VxJsr6PHTA" decimals="2" id="Tc_tfRU_Tzxfk6IqnxMUfiGbg_11_7" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 8.23 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFiveMember_wuGB45EeWUy7VxJsr6PHTA" decimals="0" id="Tc_CUVQbOgOnk28ti3hCY1IwA_11_10" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 205000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_casi_RangeFiveMember_wuGB45EeWUy7VxJsr6PHTA" decimals="2" id="Tc_NIISwIGpZ0WFYwFlxG3yiw_11_13" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 8.23 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Tc_vuSCGYDSA0inrCAPhyv6bg_12_2" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 16746238 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tc_Q9zhri3E20GpvTjP1bSjgQ_12_4"> P6Y8M15D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="2" id="Tc_PajhI4zN10yh9J1wK_JB5g_12_7" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.71 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Tc_XKxYBO3DqEKyBYXwVGh1EQ_12_10" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 9381854 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="2" id="Tc_TZdqAYSLt0SkcCHkqAHOeQ_12_13" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.35 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<casi:UnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriod contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_oINxWJVIe02NtsNIFYOXEg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 8208000 </casi:UnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriod>
<casi:UnrecognizedShareBasedCompensationCostExpectedToRecognizeOverWeightedAveragePeriod contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Narr_hsoVCdu5aUC9PC-hwNwYCw"> P1Y8M26D </casi:UnrecognizedShareBasedCompensationCostExpectedToRecognizeOverWeightedAveragePeriod>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_37iwcz5tKUa24LQ0_P8iLw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">17.      INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For financial reporting purposes, loss before income taxes includes the following components:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40,626)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,957)</p></td></tr><tr><td style="vertical-align:bottom;width:60.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">PRC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,885)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,405)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47,511)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (45,362)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Significant components of the Company’s deferred income tax assets and liabilities as of December 31, 2020 and 2019 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income tax assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 78,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 94,828</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development credit carryforward</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,244</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,740</p></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,733</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,436</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,423</p></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,533)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 396</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Valuation allowance for deferred income tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (94,986)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (114,120)</p></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has U.S. federal and state net operating loss (NOL) carryforwards of $324,707,000 at December 31, 2020.  The Company also has People’s Republic of China (“PRC”) NOL carryforwards of $13,464,000 at December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company’s U.S. federal NOL carryforwards generated prior to 2018 begin to expire in 2021. The Company also has research and experimentation (“R&E”) tax credit carryforwards of $6,244,000 as of December 31, 2020 that begin to expire in 2021. Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. For financial reporting purposes, a 100% valuation allowance has been recognized to reduce the net deferred tax assets to zero because it is more likely than not that the Company could not generate sufficient taxable income in the future to realize the benefit of deferred income tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A reconciliation of the provision for income taxes to the federal statutory rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax benefit at statutory rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,977)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,526)</p></td></tr><tr><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,701)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Attribute expiration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,707</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,461</p></td></tr><tr><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nondeductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 453</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deemed royalty</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,220</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (54)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (608)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in applicable tax rates</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,612</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td></tr><tr><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,134)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,072)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company had $2,581,000 of unrecognized tax benefits as of December 31, 2019 related to net R&E tax credit carryforwards. For the year ended December 31, 2020, there was a net reduction of unrecognized tax benefits of $499,000 related to R&E tax credits. The Company has a full valuation allowance at December 31, 2020 and 2019 against the full amount of its net deferred tax assets and, therefore, there was no impact on the Company’s financial position. The Company does not expect significant changes to the unrecognized benefit during 2020. As of December 31, 2020 and 2019, the Company did not accrue any interest related to uncertain tax positions. To date, there have been no interest or penalties charged to the Company related to income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrecognized tax benefits balance at January 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,581</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,986</p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions for tax positions of prior periods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (405)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions for tax positions of current period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrecognized tax benefits balance at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,581</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company and each of its PRC subsidiaries file income tax returns in the United States and the PRC, respectively. Due to the existence of tax attribute carryforwards (which are currently offset by a full valuation allowance), all of the Company’s tax returns since 1999 are open to examination by the taxing authorities. According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational errors made by the taxpayer or the withholding agent. The statute of limitations is extended to five years under special circumstances where the underpayment of taxes is more than RMB100,000 ($14,334). In the case of transfer pricing issues, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. The PRC tax returns for the Company’s PRC subsidiaries are open to examination by the PRC tax authorities for the tax years beginning in 2014.</p>
</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_nz8oo4NYM0mpIVaieb44mw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For financial reporting purposes, loss before income taxes includes the following components:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40,626)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,957)</p></td></tr><tr><td style="vertical-align:bottom;width:60.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">PRC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,885)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,405)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47,511)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (45,362)</p></td></tr></table>
</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_y0HVs_iJW0WQuu4C5YIQjg_2_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -40626000 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_D1kqe9fPJkuWhXUqKMkDpQ_2_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -28957000 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_Q3o9t1vb0Eiz-QmI5jrjzg_3_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -6885000 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_gt6I43xtnkGtq2lL2cNXSQ_3_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -16405000 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_9hsMn2S3UEGfdfGBDM7Ifw_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -47511000 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_Qm9zcgOqgka5Q1-DyXiv1A_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -45362000 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_xy5Pl6ZxW0ynl4ERzJxNVg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Significant components of the Company’s deferred income tax assets and liabilities as of December 31, 2020 and 2019 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income tax assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 78,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 94,828</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development credit carryforward</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,244</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,740</p></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,733</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,436</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,423</p></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,533)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 396</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Valuation allowance for deferred income tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (94,986)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (114,120)</p></td></tr><tr><td style="vertical-align:bottom;width:60.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr></table>
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_xGSlqSI3vUmxjIbaNcMEQA_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 78790000 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_rg9K0RIOdECeqz5pbcy5Cg_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 94828000 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_oCFSKbCHl0yt3wUO35F8Kg_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6244000 </us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_XZ2GffE9yECgMfclR6vwSw_5_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7740000 </us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_NQkppetCDkWZz0_D5g3yMg_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 8049000 </us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_1MQeOzggQEun0Fq93OtW2g_6_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5733000 </us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_9oaK_2jkL0OajfO8uD90tw_7_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4436000 </us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_0SyCLj73nEuG_v49woYEbQ_7_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5423000 </us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsOther contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_7q7KHYGtp0yxvnieBCQqPA_8_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -2533000 </us-gaap:DeferredTaxAssetsOther>
<us-gaap:DeferredTaxAssetsOther contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_td6d1e8Y2EiQrTdhXyvlSA_8_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 396000 </us-gaap:DeferredTaxAssetsOther>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_yGiLYdt3n0yDc1adk9N6Wg_9_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 94986000 </us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_WgAG_LYrqkeQh9TcrwdK2w_9_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 114120000 </us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsNet contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_CVMUc4_L6kmmdgj2e8HOfQ_10_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:DeferredTaxAssetsNet>
<us-gaap:DeferredTaxAssetsNet contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_ph6LzfsCg0mbyT912KdP1A_10_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:DeferredTaxAssetsNet>
<us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_9VK1qleIH0eKTZhq9GInBQ" decimals="0" id="Narr_5OkVt7fmAkyKw4HtP6CA8Q" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 324707000 </us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_bhXg5qk6QU6mkt_SVdxqhQ" decimals="0" id="Narr_vMI9cKrT5EOnkGQuBRUnsA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 13464000 </us-gaap:OperatingLossCarryforwards>
<us-gaap:TaxCreditCarryforwardAmount contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="0" id="Narr_kS0ffLqplkGYu7skXIl7eg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 6244000 </us-gaap:TaxCreditCarryforwardAmount>
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_Vqm9yTpom0WRfELmI0-APw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A reconciliation of the provision for income taxes to the federal statutory rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax benefit at statutory rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,977)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,526)</p></td></tr><tr><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,701)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Attribute expiration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,707</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,461</p></td></tr><tr><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nondeductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 453</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deemed royalty</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,220</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (54)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (608)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in applicable tax rates</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,612</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td></tr><tr><td style="vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,134)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,072)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr></table>
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_sKds52XtLEC39tMQse4cbQ_2_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -9977000 </us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_0rEJdbpx20Ky8jWiisXJaw_2_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -9526000 </us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc__cnnIcvqGE2sA4nx8dJ1Tg_3_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -732000 </us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_FXL5jbG-O0G6ah2h0aDqfg_3_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1701000 </us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
<casi:IncomeTaxReconciliationAttributeExpirationAmount contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_9Pxp2nARBEuskYHnfSTVHQ_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 13707000 </casi:IncomeTaxReconciliationAttributeExpirationAmount>
<casi:IncomeTaxReconciliationAttributeExpirationAmount contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_WRAm1Flv00OMk5uzf2YURw_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 12461000 </casi:IncomeTaxReconciliationAttributeExpirationAmount>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_rYB0qH2BmEOMcGITzesjbw_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 358000 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_WrBOOc7XOk2NI9qqbj3dKQ_5_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 453000 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<casi:EffectiveIncomeTaxRateReconciliationDeemedRoyalty contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_CEGeAHFgEE2igFR7dpnpKA_6_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 4220000 </casi:EffectiveIncomeTaxRateReconciliationDeemedRoyalty>
<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_BkjPY7C4MkKzq8KmTvZgpg_7_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -54000 </us-gaap:IncomeTaxReconciliationOtherAdjustments>
<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_DyJJWkI-qUaN-E_LRLjf6Q_7_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -608000 </us-gaap:IncomeTaxReconciliationOtherAdjustments>
<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_WoA5njvTRkexZkMzUZEFHw_8_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 11612000 </us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_cH3630TAvU-gTVVBWY_FEQ_8_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -7000 </us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_PIzpf4vSL0ykiEHyE7NNbQ_9_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -19134000 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_z0pfnytclUC-OnefrFOhPw_9_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> -1072000 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_C3Ts4ggLGUC-ejV_xJ5npw_10_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_sqoG4CZSX0WkP4XTzZREPg_10_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="0" id="Narr_omuJ0zymUkqN98Z6GUCEbg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2581000 </us-gaap:UnrecognizedTaxBenefits>
<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="0" id="Narr_6QaOKdzWiU63feMpD0ffFg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 499000 </us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_ezPptfyHpEicDnowjJwfVw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrecognized tax benefits balance at January 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,581</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,986</p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions for tax positions of prior periods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (405)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions for tax positions of current period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrecognized tax benefits balance at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,581</p></td></tr></table>
</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
<us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_J9K_f1XRZ0Gw_HxwzTmFfw_2_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2581000 </us-gaap:UnrecognizedTaxBenefits>
<us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2018_Qx1IVz1wIUe3rkaVNstInA" decimals="-3" id="Tc_kXZZuHegF0qeLhq0FcfOAg_2_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2986000 </us-gaap:UnrecognizedTaxBenefits>
<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_ogLyg_fFjkKBVi1OilWnBg_3_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 499000 </us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="-3" id="Tc_Jq6z32n-AkOumaEodgoGFA_3_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 405000 </us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Tc_qikkVPyWoUCuVgKAYZpqFA_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
<us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" decimals="-3" id="Tc_3U1nkH5qwkGoNHp0QbzYfw_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2082000 </us-gaap:UnrecognizedTaxBenefits>
<us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2019_2Fouv-NqqU-7AV7y6UXI1w" decimals="-3" id="Tc_XB2UN7KS7k28gusiOf4XUA_5_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2581000 </us-gaap:UnrecognizedTaxBenefits>
<us-gaap:FairValueDisclosuresTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_I241oYix-UW2fIW6aoySXw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">18.      FAIR VALUE MEASUREMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The majority of the Company’s financial instruments (consisting of cash and cash equivalents, account receivable, accounts payable, accrued liabilities, notes payable and bank borrowings) are carried at cost which approximates their fair values due to the short-term nature of the instruments. The Company’s investment in equity securities is carried at fair value, and investment in convertible loan-AFS are carried at fair value (see Note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level 1—Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level 2—Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level 3—Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has equity investments in the common stock of two publicly traded companies. The Company’s investments in these equity securities are carried at their estimated fair value, with changes in fair value reported in the consolidated statement of operations and comprehensive loss each reporting period (see Note 3). The fair value of the common stock is based on quoted market price for the investees’ common stock, a Level 1 input.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has an equity investment in the warrants of a publicly traded company. The Company’s investment is carried at its estimated fair value, with changes in fair value reported in the consolidated statement of operations and comprehensive loss each reporting period (see Note 3). The fair value of the warrants was measured using observable market-based inputs other than quoted prices in active markets for identical assets or liabilities, level 2 inputs.  The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of warrants. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the fair value determination of a warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables presents the Company’s financial assets and liabilities accounted for at fair value on a recurring basis as of December 31, 2020 and December 31, 2019, by level within the fair value hierarchy:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Investments in Current Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investments in common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investment in convertible loan-AFS</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 83</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Investments in Current Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investment in common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company measures equity investments without readily determinable fair values at its cost, minus impairment, if any, plus or minus changes resulting from observable transactions of identical or similar securities of the same issuer. On September 29, 2020, the Company remeasured the investments in equity securities in Juventas (see Note 3) to the fair value. The Company estimated the fair value of these securities based on the transaction price of similar securities issued by the investee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:31.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:66.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quantitative Information about Level 3 Fair Value Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In Thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> September 29, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (remeasurement date)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Valuation Techniques</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable Input</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average/Median</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:31.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment in equity securities using measurement alternative</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 12,872</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:middle;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Market comparable companies</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:middle;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Multiples of selected comparable companies</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.3/1.1</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has no non-financial assets and liabilities that are measured at fair value on a recurring basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2020, the intangible assets and assets held for sale with a total carrying amount of $3,087,000 were written down to their fair value of $1,550,000, resulting in an impairment charge of $1,537,000, which represents the difference between the carrying </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">value of the intangible asset and assets held for sale and its fair value. The Company estimated the fair value using Level 2 inputs based on quoted price</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2019, equipment leased to Juventas with a total carrying amount of $673,000 were written down to their fair value of $287,000, resulting in an impairment charge of $386,000, representing the difference between total carrying amount and fair value of these long-lived assets, which was calculated based on Level 3 Inputs. No impairment was recorded for the year ended December 31, 2020.</p>
</us-gaap:FairValueDisclosuresTextBlock>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wFvJ_UnaCEy70JZGiqlGhQ" id="Tb_A-vk_cphh0Sev6sC03KCaw">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Investments in Current Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investments in common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investment in convertible loan-AFS</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 83</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Investments in Current Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investment in common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr></table>
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
<us-gaap:InvestmentsFairValueDisclosure contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bhHRbIu-z0WM2EpLhHYUOg" decimals="-3" id="Tc_nX7ubnmbrEi0udkY5tH20Q_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 9309000 </us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:InvestmentsFairValueDisclosure contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jwd5pOG3-ke1GFqFizM3_Q" decimals="-3" id="Tc_akoLjzuwfUO7jxskHYJ7gQ_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 9309000 </us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:InvestmentsFairValueDisclosure contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_oEffp5rJ5EOhLowH14qfHA" decimals="-3" id="Tc_zaMfW5HWwU-Tviq3meEvog_4_9" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:InvestmentsFairValueDisclosure contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lBPlUswpVUGDYjz54-i3Tw" decimals="-3" id="Tc_hI76K_VtP0agZzH8hYb9yQ_4_12" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:InvestmentsFairValueDisclosure>
<casi:InvestmentsFairValueDisclosureConvertibleLoan contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bhHRbIu-z0WM2EpLhHYUOg" decimals="-3" id="Tc_9DRfoQAG506bDp_32PBfCg_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 83000 </casi:InvestmentsFairValueDisclosureConvertibleLoan>
<casi:InvestmentsFairValueDisclosureConvertibleLoan contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jwd5pOG3-ke1GFqFizM3_Q" decimals="-3" id="Tc_Oc_FFkv3WU2nuycJrGvDKA_5_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:InvestmentsFairValueDisclosureConvertibleLoan>
<casi:InvestmentsFairValueDisclosureConvertibleLoan contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_oEffp5rJ5EOhLowH14qfHA" decimals="-3" id="Tc_ZHxuJedf9E2fFIxq06d4oQ_5_9" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:InvestmentsFairValueDisclosureConvertibleLoan>
<casi:InvestmentsFairValueDisclosureConvertibleLoan contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lBPlUswpVUGDYjz54-i3Tw" decimals="-3" id="Tc_XLClrGor1EGYC3EU4pfwaw_5_12" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 83000 </casi:InvestmentsFairValueDisclosureConvertibleLoan>
<us-gaap:InvestmentsFairValueDisclosure contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9VLLZcGICUSzanFc4ARWfA" decimals="-3" id="Tc_DNXzO_2drk6LFbgdppPCww_4_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 625000 </us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:InvestmentsFairValueDisclosure contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nrp8PsrLdEGJKj6Whl5zvA" decimals="-3" id="Tc_P1YZV7PhjkK25G1WuOvBrA_4_6" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 625000 </us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:InvestmentsFairValueDisclosure contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NDecUyJtSU6AmNXpdhMMxA" decimals="-3" id="Tc_cnUkAywgEE2zZdYqPAUxnw_4_9" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:InvestmentsFairValueDisclosure contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_j-S5AVLOs0Ge_cTfFPPGEA" decimals="-3" id="Tc_30V96d_hnEae1420uWC_NQ_4_12" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Mnr_9uqx_kuKq1MlMD3I_g" id="Tb_ENYXOUYPbEagFTycsFE-AQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:31.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:66.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quantitative Information about Level 3 Fair Value Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In Thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> September 29, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (remeasurement date)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Valuation Techniques</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable Input</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average/Median</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:31.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment in equity securities using measurement alternative</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 12,872</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:middle;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Market comparable companies</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:middle;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Multiples of selected comparable companies</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.3/1.1</p></td></tr></table>
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
<us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="As_Of_9_29_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_MarketApproachValuationTechniqueMember_dpL9Vj2wlkqRA9BE5CcICQ" decimals="-3" id="Tc_Lx8DEBzM7UScb1YLRrAfxQ_5_3" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 12872000 </us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
<casi:EquitySecuritiesWithoutReadilyDeterminableFairValueMeasurementInput contextRef="Duration_9_29_2020_To_9_29_2020_srt_RangeAxis_srt_ArithmeticAverageMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_MarketApproachValuationTechniqueMember_-A6lzXG_GkGIg64-1pBm8Q" decimals="1" id="Narr_pYXQlMZMYkScn4qQJEqp1w" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 5.3 </casi:EquitySecuritiesWithoutReadilyDeterminableFairValueMeasurementInput>
<casi:EquitySecuritiesWithoutReadilyDeterminableFairValueMeasurementInput contextRef="Duration_9_29_2020_To_9_29_2020_srt_RangeAxis_srt_MedianMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_MarketApproachValuationTechniqueMember_0NVrfv0jlU6sH7i1LqgFjw" decimals="1" id="Narr_RQgSoZSSaE-GSGADVZMOZQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 1.1 </casi:EquitySecuritiesWithoutReadilyDeterminableFairValueMeasurementInput>
<casi:NonFinancialAssetsFairValueDisclosure contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9VLLZcGICUSzanFc4ARWfA" decimals="0" id="Narr_f25YNjw7d0Ghk-iwjroJsA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:NonFinancialAssetsFairValueDisclosure>
<casi:NonFinancialAssetsFairValueDisclosure contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bhHRbIu-z0WM2EpLhHYUOg" decimals="0" id="Narr_VfA4vQT12keYhrPQDD3CKA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </casi:NonFinancialAssetsFairValueDisclosure>
<casi:FairValueCarryingAmount contextRef="As_Of_6_30_2020_24wLKU2tYEGtsPPwep1fFw" decimals="0" id="Narr_ZrUDYiA_SEiXyk6chyJ7vQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 3087000 </casi:FairValueCarryingAmount>
<us-gaap:PropertyPlantAndEquipmentFairValueDisclosure contextRef="As_Of_6_30_2020_24wLKU2tYEGtsPPwep1fFw" decimals="0" id="Narr_-WjtbX_-EU61U7xlb83Zcg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1550000 </us-gaap:PropertyPlantAndEquipmentFairValueDisclosure>
<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" decimals="-3" id="Narr_UHebGXIMFkK-q5zctN6T8A" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1537000 </us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
<casi:FairValueCarryingAmount contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentLeasedToOtherPartyMember_Ty8_PndE_EaI4ks32NxmNQ" decimals="0" id="Narr__zqP-otTwkuLVJLVmeYLgw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 673000 </casi:FairValueCarryingAmount>
<us-gaap:PropertyPlantAndEquipmentFairValueDisclosure contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_ohbJmyu-WkOXhEgYfW8_vg" decimals="0" id="Narr_2hvslflGhkqKsLAHDuoDfg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 287000 </us-gaap:PropertyPlantAndEquipmentFairValueDisclosure>
<us-gaap:TangibleAssetImpairmentCharges contextRef="Duration_1_1_2019_To_12_31_2019_oz5D5hgZF0Os7ZPkGDnixw" decimals="0" id="Narr_MPjrHLoJoEyba3i9RKJHcA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 386000 </us-gaap:TangibleAssetImpairmentCharges>
<us-gaap:TangibleAssetImpairmentCharges contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentLeasedToOtherPartyMember_ynW65pwr1U-NW4BqvIvEFg" decimals="-3" id="Narr_HYwXWqyk70CJ7xZ2q08r3Q" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:TangibleAssetImpairmentCharges>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_48oSe5tIu0mhOqjdqxv8wA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">19.      RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Juventas.</span> On July 1, 2019, the Company entered into a one-year equipment lease with Juventas in the amount of RMB 80,000 ($15,000) a month, which is classified as an operating lease. Transactions with Juventas are considered to be related party transactions as the Company’s CEO and Chairman is the chairman and one of the founding shareholders of Juventas. In August 2020, the lease was renewed for another year with the same monthly lease income. During the year ended December 31, 2020, the Company recognized lease income of $140,000 and expects to recognize $70,000 of additional lease income in 2021 related to this lease. The lease can be extended after one year. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For license, investment and loan transactions with Juventas, refer to Note 1 and Note 3.  Transactions with Juventas are considered to be related party transactions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:22.5pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">he Company’s CEO and Chairman is the chairman and a founding shareholder of Juventas </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:22.5pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The Company’s Chairman of the Audit Committee, is a founding partner of Panacea Venture, which is a current shareholder of Juventas.  Panacea Venture is a global venture fund focusing on investments in healthcare and life science companies. </span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In June 2019 and September 2020, a committee of independent directors of CASI negotiated the terms of the investment and license agreements and recommended that the board of directors approve the transactions. The Company’s CEO did not participate in the committee’s deliberations or the board of directors’ approval of the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Spectrum/Acrotech.</span>  The Company had certain product rights and perpetual exclusive licenses from Spectrum Pharmaceuticals, Inc. (“Spectrum”) to develop and commercialize EVOMELA (Melphalan Hydrochloride For Injection) (“EVOMELA”), ZEVALIN (Ibritumomab Tiuxetan) (“ZEVALIN”) and MARQIBO (Vincristine Sulfate Liposome Injection) (“MARQIBO”) in the greater China region. Spectrum is a greater than a 6.8% shareholder of the Company as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Based on the original licenses, the Company had supply agreements with Spectrum for the purchase of EVOMELA, ZEVALIN, and MARQIBO in China for quality testing purposes to support the Company’s application for import drug registration and for commercialization purposes. On March 1, 2019, Spectrum completed the sale of its portfolio of seven FDA-approved hematology/oncology products including EVOMELA, MARQIBO, and ZEVALIN to Acrotech. The original supply agreements with Spectrum for EVOMELA, MARQIBO, and ZEVALIN were assumed by Acrotech; Spectrum agreed to continue with a short-term supply agreement for EVOMELA for the initial commercial product supply for the greater China region.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As part of the license arrangements with Spectrum, the Company issued to Spectrum a secured promissory note originally due March 17, 2016, which was subsequently amended and extended to September 17, 2019. The principal of the secured promissory note was $1.5 million and the coupon interest rate was 0.5%. The Company paid this note, including accrued interest in full during the year ended December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In 2018, the Company entered into commercial purchase obligation commitments for EVOMELA from Spectrum totaling $9.2 million under the short-term supply agreement for EVOMELA. All of these EVOMELA purchase commitments have been delivered as of October 2019. There were no transactions with Spectrum during the year ended December 31, 2020. For the year ended December 31, 2019, the transactions relating to the manufacturing and purchase of the EVOMELA commercial product supply amounted to $7.8 million. The amount due to Spectrum was $0.2 million as of December 31, 2019.  The Company also accrued $2.6 million for material costs related to EVOMELA during the year ended December 31, 2019 which are included in accrued expenses. As of December 31, 2020, all amounts due to Spectrum have been settled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">BioCheck.</span>  In June 2019, the Company entered into a one-year agreement primarily for the sublease of certain office and lab space with BioCheck Inc. (“BioCheck”) in the amount of $60,000 ($5,000 a month), which is classified as an operating lease. Transactions with BioCheck are considered to be related party transactions as Dr. Wei-Wu He, the Company’s CEO and Chairman is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">also the Chairman of BioCheck.  Transactions with ETP, parent of BioCheck, and a more than 5% shareholder of the Company, are also considered to be related party transactions as Dr. Wei-Wu He, the Company’s CEO and Chairman is also the chairman of ETP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Since the Company required additional office space, in January 2020, the agreement was amended for annualized rents in the amount of $144,000 ($12,000 a month) with a stipulation that the new rent was retroactive to October 1, 2019. During the year ended December 31, 2020, the Company recognized rent expense of $144,000 and expects to recognize $63,000 of additional rent expense in 2021 related to this lease. </p>
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:LessorOperatingLeaseTermOfContract contextRef="As_Of_7_1_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_JuventasCellTherapyLtdMember_F_-BCLgjvUy82LzmDiQyTw" id="Narr_fEploBRhzUeHa9araOvdgg"> P1Y </us-gaap:LessorOperatingLeaseTermOfContract>
<us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="Duration_7_1_2019_To_7_1_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_JuventasCellTherapyLtdMember_94l2cxCc4UiyeonD5c7v1Q" decimals="0" id="Narr_BB8Dy8fq_0ig6EWz-ZFpPA" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 80000 </us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
<us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="Duration_7_1_2019_To_7_1_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_JuventasCellTherapyLtdMember_94l2cxCc4UiyeonD5c7v1Q" decimals="0" id="Narr_1Zdu8y7fqUOJIJOjeqTHfw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 15000 </us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
<us-gaap:OperatingLeaseLeaseIncome contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_JuventasCellTherapyLtdMember_2ZY7ASMV40aQ7OayhfEwcQ" decimals="0" id="Narr_wgqRTfe7UkKUdAuEnzisGg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 140000 </us-gaap:OperatingLeaseLeaseIncome>
<us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_JuventasCellTherapyLtdMember_A4z5U9Prh0Cl6vHsWQwbPQ" decimals="0" id="Narr_8TPvZ1BTx0-JF2DiwvJoEA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 70000 </us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
<us-gaap:LessorOperatingLeaseTermOfContract contextRef="As_Of_12_31_2020_gIBy8tKxtU-Firg24uJ1CA" id="Narr_agdgHqe6CUyylrcE5vYMhw"> P1Y </us-gaap:LessorOperatingLeaseTermOfContract>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_WoRB8h-TokKoYkiKFGziHw" decimals="3" id="Narr_8uIUsrf7NEC_3xJx3QgQCg" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.068 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_eQLemJk6F0WbMAniqK5XdQ" decimals="-5" id="Narr_LqbR1z6OWkukHXB6JqybjA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1500000 </us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_eQLemJk6F0WbMAniqK5XdQ" decimals="3" id="Narr_ic6msilBdEqqZW0nhN_Y0w" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.005 </us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:PurchaseObligation contextRef="As_Of_12_31_2018_srt_ProductOrServiceAxis_casi_EVOMELAMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_Y8Xhm8SazU6Djq-ZzFHZ0g" decimals="-5" id="Narr_b6QKAZB_cUG_e-jQJLKHfw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 9200000 </us-gaap:PurchaseObligation>
<us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_casi_EVOMELAMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_TvgWYLCS-EmKadKELzLe8g" decimals="0" id="Narr_zcnGj5wuzkS5B1Qxq1KnDg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 0 </us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
<us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_casi_EVOMELAMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_uUR2cfDBL0CuT6877Yyc3g" decimals="-5" id="Narr_jiXPobkwO0qSeTjMJqPj6A" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 7800000 </us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_eQLemJk6F0WbMAniqK5XdQ" decimals="-5" id="Narr_hN9KIZKhRUyGi1cUnuqxFw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 200000 </us-gaap:AccountsPayableRelatedPartiesCurrent>
<casi:AmountOfExpenseIncurred contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_SpectrumMember_cL1Z9OiRlE2fr4NzaW5PTQ" decimals="-5" id="Narr_4nU_RgGm80aGoi2ubfdb5w" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 2600000 </casi:AmountOfExpenseIncurred>
<us-gaap:LessorOperatingLeaseTermOfContract contextRef="As_Of_6_30_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_g7mShfaPTUiOxv4vMu5DqA" id="Narr_HXlw5H9Xx0G6Yf7B4fcn-g"> P1Y </us-gaap:LessorOperatingLeaseTermOfContract>
<us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_c80qokpBP0aQFWTdXRvZ8w" decimals="0" id="Narr_BbEjy0pkgEK1GSnCxebjgg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 60000 </us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
<us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="Duration_6_1_2019_To_6_30_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_lJ1ywRFD2EiAOQLrvRKjMA" decimals="0" id="Narr_JNDm3iDo002mX_VMUzdAlQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5000 </us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_EmergingTechnologyPartnersLLCMember_uXDEWmJ6m0qAVRYQ0UGZ-Q" decimals="2" id="Narr_RkfQjy7i3UOAnfMjzGH42A" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.05 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_Z0SeyPstdkmDCloI1Gk3og" decimals="0" id="Narr_FHM6MmRBrkSumNiexIcw1Q" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 144000 </us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
<us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_MJOVgO3c8kyvCYvnCsQarw" decimals="0" id="Narr_XxQYh8pCWkKwkFI9tTMXtg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 12000 </us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
<us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_Z0SeyPstdkmDCloI1Gk3og" decimals="0" id="Narr_lfQtnDZ3nEKV48AZp4FLBA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 144000 </us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
<us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_casi_BiocheckInc.Member_dTedlgmNdUCWA_VCw7YlqQ" decimals="0" id="Narr_gAChfozLLUic7fVkjzh-Ow" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 63000 </us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
<casi:LicenseArrangementsDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_uwtbD13700yEzb-CvejhjA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">20.      ACROTECH LICENSE ARRANGEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has product rights and perpetual exclusive licenses from Acrotech Biopharma L.L.C. (“Acrotech”) to develop and commercialize its commercial product EVOMELA® (Melphalan Hydrochloride For Injection) in the greater China region (which includes China, Taiwan, Hong Kong and Macau), as well as similar rights to assets ZEVALIN® (Ibritumomab Tiuxetan) and MARQIBO® (Vincristine Sulfate Liposome Injection). The exclusive licenses held by the Company were originally licensed from Spectrum Pharmaceuticals, which they later transferred to Acrotech.  On December 3, 2018, the Company received NMPA’s approval for importation, marketing and sales in China and in August 2019 the Company launched EVOMELA in China.  The NMPA required post-marketing study is ongoing and actively recruiting.   </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company is currently evaluating future development options for ZEVALIN and MARQIBO due to the evolving standard of care environment, the rare and niche indications for these products, and its commitment to prioritize resources.</p>
</casi:LicenseArrangementsDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_outcgwNYAEWTng6ZgZM5Mg">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">21.      COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In conjunction with the BioInvent agreement entered into during 2020 (see Note 1), the Company is responsible for certain milestone and royalty payments. As of December 31, 2020, no milestones have been achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In conjunction with the Black Belt agreement entered into during 2019 (see Note 1), the Company is responsible for certain milestone and royalty payments. As of December 31, 2020, no milestones have been achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In conjunction with the Pharmathen agreement entered into during 2019 (see Note 1), the Company is responsible for one remaining milestone payment. As of December 31, 2020, the remaining milestone has not been met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In conjunction with the Laurus Labs agreement entered into during 2018, the Company is responsible for certain remaining milestone payments. As of December 31, 2020, the remaining milestones have not been met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In November 2019, CASI Wuxi entered into a lease agreement for the right to use state-owned land in China for the construction of a manufacturing facility. Pursuant to the agreement, CASI Wuxi commits to invest land use right and property, plant and equipment of RMB1 billion (equivalent to $143 million) within three years from the date of establishment of CASI Wuxi. On August 27, 2020, CASI Wuxi entered into a Construction Project Contract (the "Construction Contract") with China Electronic System Engineering No. 2 Construction Co., Ltd. ("China Engineering"). Pursuant to the Construction Contract, CASI Wuxi will pay a contract price of RMB 74,588,000 (equivalent to $10,923,000) to retain China Engineering to complete the phase 1 project of CASI Wuxi's research and development production base, consisting of construction and installation of a combined factory building, warehouse, guard house and public works. The estimated completion date is October 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company is subject in the normal course of business to various legal proceedings in which claims for monetary or other damages may be asserted.  Management does not believe such legal proceedings, unless otherwise disclosed herein, are material.</p>
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<casi:NumberMilestonesAchieved contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BioinventInternationalAbMember_Qqp3IKhp4EiuKj2iNZ3R_A" decimals="INF" id="Narr_AoMDwSyMm0yy5EVLUR8OIg" unitRef="Unit_Standard_Milestone__O5I2ENfv0G4abijkh4HOA"> 0 </casi:NumberMilestonesAchieved>
<casi:NumberMilestonesAchieved contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_BlackBeltTxLimitedMember_WkfBlGbnmUS5NuDaWNcn0A" decimals="INF" id="Narr_q76V46DQ4ky9cjcDY3P_XQ" unitRef="Unit_Standard_Milestone__O5I2ENfv0G4abijkh4HOA"> 0 </casi:NumberMilestonesAchieved>
<casi:NumberMilestonesPaymentsOutstanding contextRef="Duration_1_1_2020_To_12_31_2020_casi_InvestmentsContractCounterpartyAxis_casi_PharmathenGlobalBvMember_kc-NooqXmE2NjmxJx3QuNA" decimals="0" id="Narr_nl9oKk6fdkqZru-heny9dA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 1 </casi:NumberMilestonesPaymentsOutstanding>
<casi:LandUseRightAndPropertyPlantAndEquipmentCommitmentAmount contextRef="Duration_11_1_2019_To_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_dYsiMUDgcEaYApPduIKx9Q" decimals="-9" id="Narr_z9tZ8gmOf0mETtIe-E5nrg" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 1000000000 </casi:LandUseRightAndPropertyPlantAndEquipmentCommitmentAmount>
<casi:LandUseRightAndPropertyPlantAndEquipmentCommitmentAmount contextRef="Duration_11_1_2019_To_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_dYsiMUDgcEaYApPduIKx9Q" decimals="-6" id="Narr_XCYQJDAjxEG2iMaBn3l_1A" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 143000000 </casi:LandUseRightAndPropertyPlantAndEquipmentCommitmentAmount>
<casi:FixedAssetsInvestmentThresholdPeriod contextRef="Duration_11_1_2019_To_11_30_2019_dei_LegalEntityAxis_casi_CASIWuxiMember_dYsiMUDgcEaYApPduIKx9Q" id="Narr_w5Cc7GMxh02krehSBVeFoQ"> P3Y </casi:FixedAssetsInvestmentThresholdPeriod>
<casi:ConstructionProjectContractContractPrice contextRef="As_Of_8_27_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_hXZDZBgK3EqZJeFfmlyPRw" decimals="0" id="Narr_nUhSQRXefk2AJJaqJIXqyQ" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 74588000 </casi:ConstructionProjectContractContractPrice>
<casi:ConstructionProjectContractContractPrice contextRef="As_Of_8_27_2020_dei_LegalEntityAxis_casi_CASIWuxiMember_hXZDZBgK3EqZJeFfmlyPRw" decimals="0" id="Narr_S67JbsKsVE22V34WAucx1w" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 10923000 </casi:ConstructionProjectContractContractPrice>
<us-gaap:SubsequentEventsTextBlock contextRef="Duration_1_1_2020_To_12_31_2020_RmTD2HQEx0Gfj1OiqAXFaQ" id="Tb_AIpbdtQ40EyyA74yuUUEQA">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">22.      SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Cleave Investment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In March 2021, the Company entered into an exclusive license agreement with Cleave Therapeutics, Inc. (“Cleave”)for the development and commercialization of CB-5339, a novel VCP/p97 inhibitor, in mainland China, Taiwan, Hong Kong and Macau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">CB-5339, an oral second-generation, small molecule VCP/p97 inhibitor, is being evaluated in a Phase 1 clinical trial in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), while the National Cancer Institute (NCI) is sponsoring and evaluating CB-5339 in a Phase 1 clinical trial of patients with solid tumors and lymphomas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the agreement, Cleave and CASI will develop CB-5339 in both hematological malignancies and solid tumors, with CASI responsible for development and commercialization in China and associated markets. Cleave received a $5.5 million upfront payment and is eligible to receive up to $74 million in development and commercial milestone payments plus tiered royalties in the high-single to mid-double-digit range on net sales of CB-5339. In addition to the upfront cash payment, CASI made a $5.5 million investment in Cleave through a convertible note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Bank Borrowings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under the guaranteed line of Credit approved by Beijing Branch of China CITIC Bank Corporation Limited on November 3, 2020 (See Note 10), the Company had additional bank borrowings of RMB 4.6 million ($0.7 million) on February 3, 2021, of which RMB 3.0 million ($0.5 million) matures on September 2, 2021 and the remainder balance matures on November 7, 2021.  These additional bank borrowings bear interest at a fixed rate of 3.72% per annum. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">March 2021 Underwritten Public Offering </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 24, 2021, the Company closed an underwriting agreement (the “Underwriting Agreement”) <span style="color:#212529;">with Oppenheimer & Co. Inc., as representative of the several underwriters named therein (the “Underwriters”), providing for the offer and sale of </span><span style="color:#212529;">15,853,658</span><span style="color:#212529;"> shares of the Company’s common stock (the “Offering”) at a price to the public of </span><span style="color:#212529;">$2.05</span><span style="color:#212529;"> per share. In addition, the Company granted the Underwriters an option to purchase up to an additional </span><span style="color:#212529;">2,378,048</span><span style="color:#212529;"> shares of common stock, which terminates on the earlier of </span><span style="color:#212529;">30 days</span><span style="color:#212529;"> and the day before the Company files to the Securities and Exchange Commission (“SEC”) the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The Offering closed on March 26, 2021.  The gross proceeds to CASI from the Offering are approximately </span><span style="color:#212529;">$32.5</span><span style="color:#212529;"> million, excluding the over-allotment option and before deducting the underwriting discounts and commissions and offering expenses payable by CASI.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;">Certain insiders, including CASI’s Chairman and Chief Executive Officer, purchased shares of common stock in the Offering at the public offering price and on the same terms as the other purchasers in this Offering. The Company has agreed to pay the underwriters a commission of </span><span style="color:#212529;">1%</span><span style="color:#212529;"> of the gross proceeds raised from certain such insiders, and </span><span style="color:#212529;">6%</span><span style="color:#212529;"> of the gross proceeds raised in the offering from other investors. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;">The Offering is being made by means of a written prospectus supplement and accompanying prospectus forming part of a shelf registration statement on Form S-3 (Registration Statement No. 333-250801), previously filed with the SEC on November 20, 2020, which was declared effective on December 2, 2020. The Company filed a final prospectus supplement, dated March 24, 2021, with the SEC relating to the Offering.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#212529;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">Pursuant to the Underwriting Agreement, the Company’s directors and executive officers entered into agreements in substantially the form agreed to by the Underwriters providing for a </span><span style="-sec-ix-hidden:Hidden_XEr4M1yPWEqkn00183lPug;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">90-day</span></span><span style="color:#212529;"> “lock-up” period with respect to sales of specified securities, subject to certain exceptions.</span></p>
</us-gaap:SubsequentEventsTextBlock>
<casi:UpfrontPayment contextRef="Duration_3_1_2021_To_3_31_2021_casi_InvestmentsContractCounterpartyAxis_casi_CleaveTherapeuticsIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0v_ILorLUUKRQvssDQlmUw" decimals="-5" id="Narr_xyXNMhMEbE-_LF8MA--GCg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5500000 </casi:UpfrontPayment>
<casi:MilestoneAmountPayable contextRef="As_Of_3_31_2021_casi_InvestmentsContractCounterpartyAxis_casi_CleaveTherapeuticsIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_x6JKr8mi90iz9vrSPXy4xw" decimals="-6" id="Narr_oeCHIYHN3EenDtAXCDO0cA" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 74000000 </casi:MilestoneAmountPayable>
<casi:InvestmentInConvertibleNote contextRef="As_Of_3_31_2021_casi_InvestmentsContractCounterpartyAxis_casi_CleaveTherapeuticsIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_x6JKr8mi90iz9vrSPXy4xw" decimals="-5" id="Narr_Jxd4YalLE0qxcOp-2fMfKw" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 5500000 </casi:InvestmentInConvertibleNote>
<us-gaap:ProceedsFromLinesOfCredit contextRef="Duration_2_3_2021_To_2_3_2021_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3OV_uj7nQUeF6LjQRXSEAw" decimals="-5" id="Narr_ItAIqOgsb0CpIkqUKGUIVw" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 4600000 </us-gaap:ProceedsFromLinesOfCredit>
<us-gaap:ProceedsFromLinesOfCredit contextRef="Duration_2_3_2021_To_2_3_2021_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3OV_uj7nQUeF6LjQRXSEAw" decimals="-5" id="Narr_BULT1lhGDky6yflFa2mNNQ" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 700000 </us-gaap:ProceedsFromLinesOfCredit>
<us-gaap:ProceedsFromLinesOfCredit contextRef="Duration_11_7_2021_To_11_7_2021_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2ieeOhbi2kC-vNgbWmoAww" decimals="-5" id="Narr_qyW4kFPX50WHnZ4Zbfv82Q" unitRef="Unit_Standard_CNY_PUfT8E6phUCB0tg_XCxlaw"> 3000000.0 </us-gaap:ProceedsFromLinesOfCredit>
<us-gaap:ProceedsFromLinesOfCredit contextRef="Duration_11_7_2021_To_11_7_2021_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2ieeOhbi2kC-vNgbWmoAww" decimals="-5" id="Narr_fr5-jrxmKk-KQ_R6eY4xvg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 500000 </us-gaap:ProceedsFromLinesOfCredit>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_2_3_2021_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4-xaoyvvokiPt4Qcp-WTww" decimals="INF" id="Narr_UBkowGNbeka46OQ07EI9bQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.0372 </us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_11_7_2021_us-gaap_LineOfCreditFacilityAxis_casi_ChinaCiticBankCorporationLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CutzzCQ8EkG_GH0imLe7UQ" decimals="INF" id="Narr_hXrAZjjqcU2L4hyUOxo9Dw" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.0372 </us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:ExcessStockSharesAuthorized contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_m6l7tJZXbESjwZOx5NIjhA" decimals="INF" id="Narr_2db-OJ5MikudXNyO9Y71Zw" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 15853658 </us-gaap:ExcessStockSharesAuthorized>
<us-gaap:SharePrice contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_m6l7tJZXbESjwZOx5NIjhA" decimals="2" id="Narr_2T7ROSPPPUm5ZWHr9rNITA" unitRef="Unit_Divide_USD_shares_tKpAEIGoV0OCvBJ2oknsLg"> 2.05 </us-gaap:SharePrice>
<us-gaap:ExcessStockSharesAuthorized contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FOGLCtLtX0W7vhAYtY48Tw" decimals="INF" id="Narr_v-CEmqBwQEunMMN5LLhjdw" unitRef="Unit_Standard_shares_ygzjR1HfOEmiwXFo6IXJoA"> 2378048 </us-gaap:ExcessStockSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_3_24_2021_To_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f6dLbzT0Y0-fGMZpVgN2rw" id="Narr_Nu8ZoiP3m0ishXgUTsGTPQ"> P30D </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_3_26_2021_To_3_26_2021_ktqqJoYxs0CevRHoPfKp5g" decimals="-5" id="Narr__irOaKr0i0iXL1YqzgEYCg" unitRef="Unit_Standard_USD_s8uAkRb8IUWakZExzO9xNQ"> 32500000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<casi:PercentageOfUnderwritersCommission contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_srt_TitleOfIndividualAxis_casi_BoardOfDirectorsChairmanAndChiefExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_O2Fp4rasTECUr6UjLSJjfQ" decimals="4" id="Narr_MY1YABDFNk-UrW_gMH8QjQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.01 </casi:PercentageOfUnderwritersCommission>
<casi:PercentageOfUnderwritersCommission contextRef="As_Of_3_24_2021_srt_CounterpartyNameAxis_casi_OppenheimerAndCo.IncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mLDF7BJ3akakLuxfMK7juA" decimals="4" id="Narr_AI9WrkHnL0G6O70Y_e-RkQ" unitRef="Unit_Standard_pure_qA9wcVostkqlie0pE4Pq3w"> 0.06 </casi:PercentageOfUnderwritersCommission>
</xbrl>

10 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/28/24  CASI Pharmaceuticals, Inc.        20-F       12/31/23  142:21M                                    Toppan Merrill Bridge/FA
 4/26/23  CASI Pharmaceuticals, Inc.        20-F       12/31/22  129:16M                                    Toppan Merrill Bridge/FA
 4/26/23  CASI Pharmaceuticals, Inc. (DE)   20-F       12/31/22  129:16M                                    Toppan Merrill Bridge/FA
 3/28/22  CASI Pharmaceuticals, Inc. (DE)   10-K       12/31/21  104:11M                                    Toppan Merrill Bridge/FA
10/29/21  CASI Pharmaceuticals, Inc. (DE)   424B5                  1:316K                                   Toppan Merrill/FA
 8/13/21  CASI Pharmaceuticals, Inc. (DE)   S-8         8/13/21    3:78K                                    Toppan Merrill/FA
 8/13/21  CASI Pharmaceuticals, Inc. (DE)   S-8 POS     8/13/21    3:77K                                    Toppan Merrill/FA
 8/13/21  CASI Pharmaceuticals, Inc. (DE)   S-8 POS     8/13/21    3:77K                                    Toppan Merrill/FA
 8/13/21  CASI Pharmaceuticals, Inc. (DE)   S-8 POS     8/13/21    3:77K                                    Toppan Merrill/FA
 4/29/21  CASI Pharmaceuticals, Inc. (DE)   10-K/A     12/31/20   12:513K                                   Toppan Merrill/FA

16 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/10/21  CASI Pharmaceuticals, Inc. (DE)   10-Q/A      9/30/20   13:304K                                   Toppan Merrill/FA
11/09/20  CASI Pharmaceuticals, Inc. (DE)   10-Q        9/30/20   91:7.2M                                   Toppan Merrill/FA
 7/24/20  CASI Pharmaceuticals, Inc. (DE)   8-K:1,8,9   7/21/20    5:274K                                   Toppan Merrill/FA
 3/16/20  CASI Pharmaceuticals, Inc. (DE)   10-K       12/31/19   98:6.9M                                   Toppan Merrill/FA
 8/09/19  CASI Pharmaceuticals, Inc. (DE)   10-Q        6/30/19   75:16M                                    Toppan Merrill/FA
 7/19/19  CASI Pharmaceuticals, Inc. (DE)   8-K:1,9     7/19/19    4:312K                                   Toppan Merrill/FA
 5/15/19  CASI Pharmaceuticals, Inc. (DE)   10-Q        3/31/19   78:5.6M                                   Toppan Merrill/FA
 4/30/19  CASI Pharmaceuticals, Inc. (DE)   DEF 14A     6/20/19    1:699K                                   Toppan Merrill/FA
 3/29/19  CASI Pharmaceuticals, Inc. (DE)   10-K       12/31/18   91:7.7M                                   Toppan Merrill/FA
 9/14/18  CASI Pharmaceuticals, Inc. (DE)   8-K:1,3,9   9/11/18    4:373K                                   Toppan Merrill/FA
 3/23/18  CASI Pharmaceuticals, Inc. (DE)   8-K:1,3,9   3/19/18    4:214K                                   Toppan Merrill/FA
 2/23/18  CASI Pharmaceuticals, Inc. (DE)   8-K:1,9     2/23/18    3:251K                                   Toppan Merrill/FA
10/19/17  CASI Pharmaceuticals, Inc. (DE)   8-K:1,9    10/13/17    7:427K                                   Toppan Merrill/FA
 8/14/17  CASI Pharmaceuticals, Inc. (DE)   10-Q        6/30/17   40:1.7M                                   Toppan Merrill/FA
 4/17/07  CASI Pharmaceuticals, Inc.        8-K:5,8,9   4/16/07    9:152K                                   Bowne - DC/FA
 6/06/06  CASI Pharmaceuticals, Inc.        8-K:1,9     6/01/06    3:66K                                    Bowne - DC/FA
↑Top
Filing Submission 0001558370-21-003735   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., May 11, 2:26:14.2am ET